FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Mustafa, YM
   Meuren, LM
   Coelho, SVA
   de Arruda, LB
AF Mustafa, Yasmin Mucuna
   Meuren, Lana Monteiro
   Antunes Coelho, Sharton Vinicius
   de Arruda, Luciana Barros
TI Pathways Exploited by Flaviviruses to Counteract the Blood-Brain Barrier
   and Invade the Central Nervous System
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Review
DE blood-brain barrier; flavivirus; Japanese encephalitis virus; West Nile
   virus; Zika virus; dengue virus; yellow fever virus; brain microvascular
   endothelial cells
ID WEST-NILE-VIRUS; JAPANESE ENCEPHALITIS-VIRUS; YELLOW-FEVER VIRUS;
   MICROVASCULAR ENDOTHELIAL-CELLS; ZIKA-VIRUS; DENGUE VIRUS; IN-VITRO;
   HUMAN ASTROCYTES; VIRAL-INFECTION; IFN-ALPHA/BETA
AB Human infection by different flaviviruses may cause severe neurologic syndromes, through pathogenic mechanisms that are still largely unknown. Japanese encephalitis virus (JEV), West Nile virus (WNV), Zika virus (ZIKV), yellow fever virus (YFV), dengue virus (DENV), and tick-borne encephalitis virus (TBEV) are believed to reach the central nervous system by a hematogenous route, upon crossing the blood-brain barrier. Although the disruption of BBB during flavivirus infection has been largely evidenced in experimental models, the relevance of BBB breakdown for virus entering the brain was not completely elucidated. In vitro models of BBB had demonstrated that these viruses replicated in brain microvascular endothelial cells (BMECs), which induced downregulation of tight junction proteins and increased the permeability of the barrier. Other reports demonstrated that infection of BMECs allowed the basolateral release of infectious particles, without a remarkable cytopathic effect, what might be sufficient for virus invasion. Virus replication and activation of other cells associated to the BBB, mostly astrocytes and microglia, were also reported to affect the endothelial barrier permeability. This event might occur simultaneously or after BMECs infection, being a secondary effect leading to BBB disruption. Importantly, activation of BMECs, astrocytes, and microglia by flaviviruses was associated to the expression and secretion of inflammatory mediators, which are believed to recruit leukocytes to the CNS. The leukocyte infiltrate could further mediate viral invasion through a Trojan horse mechanism and might contribute to BBB breakdown and to neurological alterations. This review discussed the previous studies regarding in vitro and in vivo models of JEV, WNV, ZIKV, YFV, DENV, and TBEV infection and addressed the pathways for BBB overcome and invasion of the CNS described for each virus infection, aiming to increment the knowledge and stimulate further discussion about the role of BBB in the neuropathogenesis of flavivirus infection.
C1 [Mustafa, Yasmin Mucuna; Meuren, Lana Monteiro; Antunes Coelho, Sharton Vinicius; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio de Janeiro, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio de Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Arruda, Luciana B/N-9086-2013
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]; FINEPCiencia Tecnologia e Inovacao (FINEP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001. This work
   was also supported by FINEP, CNPq, and FAPERJ. LM, and SC are the
   recipients of a CNPq fellowship. YM is the recipient of a CAPES
   fellowship.
CR Agrawal T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069465
   Al-Obaidi MMJ, 2017, VIRUS RES, V233, P17, DOI 10.1016/j.virusres.2017.02.012
   Alimonti JB, 2018, FLUIDS BARRIERS CNS, V15, DOI 10.1186/s12987-018-0100-y
   Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575
   Araujo FMC, 2011, J VIROL METHODS, V177, P128, DOI 10.1016/j.jviromet.2011.07.003
   Argaw AT, 2012, J CLIN INVEST, V122, P2454, DOI 10.1172/JCI60842
   Ashour J, 2010, CELL HOST MICROBE, V8, P410, DOI 10.1016/j.chom.2010.10.007
   Vasconcelos BCB, 2016, NEUROPATHOLOGY, V36, P3, DOI 10.1111/neup.12229
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   BARRETT ADT, 1986, J GEN VIROL, V67, P631, DOI 10.1099/0022-1317-67-4-631
   Beck AS, 2015, EXPERT REV VACCINES, V14, P1479, DOI 10.1586/14760584.2015.1083430
   Bhatt RS, 2015, IMMUNOBIOLOGY, V220, P1170, DOI 10.1016/j.imbio.2015.06.002
   Bian PY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0486-5
   Bily T, 2015, SCI REP-UK, V5, DOI 10.1038/srep10745
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Bramley JC, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00206-17
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Chang CY, 2015, GLIA, V63, P1915, DOI 10.1002/glia.22857
   CHATURVEDI UC, 1991, J GEN VIROL, V72, P859, DOI 10.1099/0022-1317-72-4-859
   Chen CJ, 2014, J VIROL, V88, P1150, DOI 10.1128/JVI.02738-13
   Chen S, 2012, PHYS REV SPEC TOP-PH, V8, DOI 10.1103/PhysRevSTPER.8.020113
   Chow BW, 2015, TRENDS NEUROSCI, V38, P598, DOI 10.1016/j.tins.2015.08.003
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   da Conceicao TM, 2013, VIROLOGY, V435, P281, DOI 10.1016/j.virol.2012.09.038
   Vieira MADES, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170538
   Dai JF, 2008, J VIROL, V82, P4164, DOI 10.1128/JVI.02621-07
   Daniels BP, 2017, J CLIN INVEST, V127, P843, DOI 10.1172/JCI88720
   Daniels BP, 2014, MBIO, V5, DOI 10.1128/mBio.01476-14
   Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720
   Dhole P, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0658-4
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Domingues RB, 2008, J NEUROL SCI, V267, P36, DOI 10.1016/j.jns.2007.09.040
   Douam F, 2017, MBIO, V8, DOI [10.1128/mBio.00819-17, 10.1128/mbio.00819-17]
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   FABRY Z, 1995, J IMMUNOL, V155, P325
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Halstead SB, 2015, MICROBIOL MOL BIOL R, V79, P281, DOI 10.1128/MMBR.00009-15
   Hasebe R, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-165
   Heinemann U, 2012, GLIA, V60, P1251, DOI 10.1002/glia.22311
   Holzmann H, 2003, VACCINE, V21, pS36, DOI 10.1016/S0264-410X(02)00819-8
   Hussmann KL, 2013, J VIROL, V87, P2814, DOI 10.1128/JVI.02577-12
   Jain N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005329
   JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512
   JOHNSON RT, 1985, ANN NEUROL, V18, P567, DOI 10.1002/ana.410180510
   Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z
   Kellman EM, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060329
   Lai CY, 2012, J NEUROCHEM, V123, P250, DOI 10.1111/j.1471-4159.2012.07889.x
   Lazear HM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4304
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Li F, 2015, J VIROL, V89, P5602, DOI 10.1128/JVI.00143-15
   Li GH, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00449
   Lindquist L, 2008, LANCET, V371, P1861, DOI 10.1016/S0140-6736(08)60800-4
   Lindqvist R, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0748-7
   Liou ML, 1998, CELL TISSUE RES, V293, P389, DOI 10.1007/s004410051130
   Liu T, 2001, J VIROL, V75, P2107, DOI 10.1128/JVI.75.5.2107-2118.2001
   Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4
   Luethy LN, 2016, VIROLOGY, V487, P1, DOI 10.1016/j.virol.2015.09.019
   Lum LCS, 1996, AM J TROP MED HYG, V54, P256, DOI 10.4269/ajtmh.1996.54.256
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Miagostovich MP, 1997, CLIN NEUROPATHOL, V16, P204
   MIMS CA, 1957, BRIT J EXP PATHOL, V38, P329
   Miner JJ, 2015, NAT MED, V21, P1464, DOI 10.1038/nm.3974
   Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499
   Mladinich MC, 2017, MBIO, V8, DOI [10.1128/mBio.00952-17, 10.1128/mbio.00952-17]
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
   Morrey JD, 2008, J GEN VIROL, V89, P467, DOI 10.1099/vir.0.83345-0
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Myint KSA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002980
   Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407
   Orozco S, 2012, J GEN VIROL, V93, P2152, DOI 10.1099/vir.0.045088-0
   Palus M, 2017, VIROLOGY, V507, P110, DOI 10.1016/j.virol.2017.04.012
   Palus M, 2014, J GEN VIROL, V95, P2411, DOI 10.1099/vir.0.068411-0
   Papa MP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02557
   Patabendige A, 2018, MOL CELL NEUROSCI, V89, P60, DOI 10.1016/j.mcn.2018.04.002
   Paul AM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04839-7
   Potokar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086219
   Prestwood TR, 2012, J VIROL, V86, P12561, DOI 10.1128/JVI.06743-11
   Ramos C, 1998, J NEUROVIROL, V4, P465, DOI 10.3109/13550289809114548
   de Souza KPR, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-267
   Rochfort KD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101815
   Roe K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102598
   Roe K, 2012, J GEN VIROL, V93, P1193, DOI 10.1099/vir.0.040899-0
   Ruzek D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020472
   Ruzek D, 2009, J GEN VIROL, V90, P1649, DOI 10.1099/vir.0.010058-0
   Salimi H, 2016, NEUROTHERAPEUTICS, V13, P514, DOI 10.1007/s13311-016-0443-5
   Samuel MA, 2007, P NATL ACAD SCI USA, V104, P17140, DOI 10.1073/pnas.0705837104
   Samy AM, 2018, ACTA TROP, V188, P108, DOI 10.1016/j.actatropica.2018.08.014
   Sarathy VV, 2015, J GEN VIROL, V96, P3035, DOI 10.1099/jgv.0.000246
   Schreibelt G, 2007, FASEB J, V21, P3666, DOI 10.1096/fj.07-8329com
   Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916
   Sejvar JJ, 2003, JAMA-J AM MED ASSOC, V290, P511, DOI 10.1001/jama.290.4.511
   Shao Q, 2016, DEVELOPMENT, V143, P4127, DOI 10.1242/dev.143768
   Shresta S, 2004, J VIROL, V78, P2701, DOI 10.1128/JVI.78.6.2701-2710.2004
   Shresta S, 2006, J VIROL, V80, P10208, DOI 10.1128/JVI.00062-06
   Siegenthaler JA, 2013, CURR OPIN NEUROBIOL, V23, P1057, DOI 10.1016/j.conb.2013.06.006
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Soe HJ, 2017, J GEN VIROL, V98, P2993, DOI 10.1099/jgv.0.000981
   Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898
   Sucheston LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030950
   Suen WW, 2014, VIRUSES-BASEL, V6, P2796, DOI 10.3390/v6072796
   Thounaojam MC, 2014, J NEUROCHEM, V129, P143, DOI 10.1111/jnc.12609
   Velandia-Romero ML, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157786
   Velandia-Romero ML, 2012, J NEUROVIROL, V18, P374, DOI 10.1007/s13365-012-0117-y
   Verma S, 2009, VIROLOGY, V385, P425, DOI 10.1016/j.virol.2008.11.047
   Verma S, 2010, VIROLOGY, V397, P130, DOI 10.1016/j.virol.2009.10.036
   Wan WB, 2014, INT J NEUROSCI, V124, P75, DOI 10.3109/00207454.2013.825258
   Wang K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01148
   Wang PH, 2008, J VIROL, V82, P8978, DOI 10.1128/JVI.00314-08
   Wang SH, 2008, J IMMUNOL, V181, P2084, DOI 10.4049/jimmunol.181.3.2084
   Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140
   Yamada M, 2009, J COMP PATHOL, V141, P156, DOI 10.1016/j.jcpa.2009.04.006
   Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012
NR 117
TC 18
Z9 19
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD MAR 28
PY 2019
VL 10
AR 525
DI 10.3389/fmicb.2019.00525
PG 14
WC Microbiology
SC Microbiology
GA HQ8PU
UT WOS:000462687900001
PM 30984122
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Matassoli, FL
   Leao, IC
   Bezerra, BB
   Pollard, RB
   Lutjohann, D
   Hildreth, JEK
   de Arruda, LB
AF Matassoli, Flavio Lemos
   Leao, Ihid Carneiro
   Bezerra, Bruno Braz
   Pollard, Richard B.
   Lutjohann, Dieter
   Hildreth, James E. K.
   de Arruda, Luciana Barros
TI Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from
   Monocytes: Possible Implications for Suppression of HIV Chronic Immune
   Activation
SO MSPHERE
LA English
DT Article
DE HIV; beta-cyclodextrin; monocytes; inflammation; human immunodeficiency
   virus
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NECROSIS-FACTOR-ALPHA; T-CELL-ACTIVATION;
   VAGINAL TRANSMISSION; DISEASE PROGRESSION; DENDRITIC CELLS; LIPID RAFTS;
   CHOLESTEROL; INFECTION; EXPRESSION
AB Monocytes from HIV-infected patients produce increased levels of inflammatory cytokines, which are associated with chronic immune activation and AIDS progression. Chronic immune activation is often not restored even in patients showing viral suppression under ART. Therefore, new therapeutic strategies to control inflammation and modulate immune activation are required. Hydroxypropylbeta-cyclodextrin (HP-BCD) is a cholesterol-sequestering agent that has been reported to be safe for human use in numerous pharmaceutical applications and that has been shown to inactivate HIV in vitro and to control SIV infection in vivo. Since cellular cholesterol content or metabolism has been related to altered cellular activation, we evaluated whether HP-BCD treatment could modulate monocyte response to inflammatory stimuli. Treatment of monocytes isolated from HIV-positive and HIV-negative donors with HP-BCD inhibited the expression of CD36 and TNF-alpha after LPS stimulation, independent of raft disruption. Accordingly, HP-BCD-treated cells showed significant reduction of TNF-alpha and IL-10 secretion, which was associated with lower mRNA expression. LPS-induced p38MAPK phosphorylation was dampened by HP-BCD treatment, indicating this pathway as a target for HP-BCD-mediated anti-inflammatory response. The expression of HLA-DR was also reduced in monocytes and dendritic cells treated with HP-BCD, which could hinder T cell activation by these cells. Our data suggest that, besides its well-known antiviral activity, HP-BCD could have an immunomodulatory effect, leading to decreased inflammatory responses mediated by antigen-presenting cells, which may impact HIV pathogenesis and AIDS progression.
   IMPORTANCE Chronic immune activation is a hallmark of HIV infection and is often not controlled even in patients under antiretroviral therapy. Indeed, chronic diseases with inflammatory pathogenesis are being reported as major causes of death for HIV-infected persons. Hydroxypropyl-beta cyclodextrin (HP-BCD) is a cholesterol-sequestering drug that inhibits HIV replication and infectivity in vitro and in vivo. Recent studies have demonstrated the importance of cholesterol metabolism and content in different inflammatory conditions; therefore, we investigated the potential of HP-BCD as an immunomodulatory drug, regulating the activation of cells from HIV-infected patients. Treatment of monocytes with HP-BCD inhibited the expression and secretion of receptors and mediators that are usually enhanced in HIV patients. Furthermore, we investigated the molecular mechanisms associated with the immunomodulatory effect of HP-BCD. Our results indicate that, besides reducing viral replication, HP-BCD treatment may contribute to modulation of chronic immune activation associated with AIDS.
C1 [Matassoli, Flavio Lemos; Bezerra, Bruno Braz; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, RJ, Brazil.
   [Matassoli, Flavio Lemos; Leao, Ihid Carneiro; Hildreth, James E. K.] Univ Calif Davis, Dept Mol & Cellular Biol, Davis, CA 95616 USA.
   [Pollard, Richard B.] Univ Calif Davis, Sch Med, Dept Internal Med, Sacramento, CA 95817 USA.
   [Lutjohann, Dieter] Univ Clin Bonn, Inst Clin Chem & Clin Pharmacol, Bonn, Germany.
   [Hildreth, James E. K.] Meharry Med Coll, Dept Internal Med, Nashville, TN 37208 USA.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, RJ, Brazil.
EM arruda@micro.ufrj.br
RI Arruda, Luciana B/N-9086-2013
FU Coordination for the Improvement of Higher Education Personnel
   (CAPES)CAPES; CAPES-Science Without Borders program Special Visiting
   Researcher; Brazilian National Council for Scientific and Technological
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Carlos Chagas Filho Research Support Foundation
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Funding Authority for Studies and Projects
   (FINEP); National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA; University of
   California Los Angeles AIDS Institute (UCLA CFAR); NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [2013/21719-3]; UCLA CFAR grant [5P30 AI028697]; UCLA AIDS
   Institute; CNPqNational Council for Scientific and Technological
   Development (CNPq); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697, P30AI028697, P30AI028697, P30AI028697,
   P30AI028697, P30AI028697] Funding Source: NIH RePORTER
FX This work was supported by Coordination for the Improvement of Higher
   Education Personnel (CAPES), CAPES-Science Without Borders program
   Special Visiting Researcher, Brazilian National Council for Scientific
   and Technological Development (CNPq), Carlos Chagas Filho Research
   Support Foundation (FAPERJ), Funding Authority for Studies and Projects
   (FINEP), National Institutes of Health, and University of California Los
   Angeles AIDS Institute (UCLA CFAR).; J.E.K.H. is supported by NIH grant
   2013/21719-3, UCLA CFAR grant 5P30 AI028697, and the UCLA AIDS
   Institute. F.L.M. and B.B.B. were recipients of a CNPq fellowship.
CR Almeida CAM, 2002, AIDS RES HUM RETROV, V18, P1351, DOI 10.1089/088922202320935429
   Ambrose Z, 2008, J VIROL, V82, P6591, DOI 10.1128/JVI.02730-07
   Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516
   Angelovich TA, 2015, JAIDS-J ACQ IMM DEF, V69, P11, DOI 10.1097/QAI.0000000000000559
   Arima H, 2005, BIOCHEM PHARMACOL, V70, P1506, DOI 10.1016/j.bcp.2005.08.021
   Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495
   Aye ILMH, 2012, MOL HUM REPROD, V18, P341, DOI 10.1093/molehr/gas001
   Baranova IN, 2008, J IMMUNOL, V181, P7147, DOI 10.4049/jimmunol.181.10.7147
   Belge KU, 2002, J IMMUNOL, V168, P3536, DOI 10.4049/jimmunol.168.7.3536
   Berry-Kravis E, 2018, PEDIATR NEUROL, V80, P24, DOI 10.1016/j.pediatrneurol.2017.12.014
   Beyer M, 2016, NAT IMMUNOL, V17, P593, DOI 10.1038/ni.3399
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Brockman MA, 2009, BLOOD, V114, P346, DOI 10.1182/blood-2008-12-191296
   Carter GC, 2009, VIROLOGY, V386, P192, DOI 10.1016/j.virol.2008.12.031
   Dang EV, 2017, CELL, V171, P1057, DOI 10.1016/j.cell.2017.09.029
   Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576
   de Lima-Salgado TM, 2011, CELL BIOCHEM BIOPHYS, V59, P89, DOI 10.1007/s12013-010-9117-9
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   DeLucia DC, 2018, J VIROL, V92, DOI 10.1128/JVI.00092-18
   Donaghy H, 2003, BLOOD, V101, P4505, DOI 10.1182/blood-2002-10-3189
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Feeney ER, 2013, J INFECT DIS, V207, P628, DOI 10.1093/infdis/jis723
   Gascon RL, 2002, J ACQ IMMUN DEF SYND, V30, P146, DOI [10.1097/00042560-200206010-00002, 10.1097/01.QA1.0000017720.31903.6E]
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Graham DRM, 2003, J VIROL, V77, P8237, DOI 10.1128/JVI.77.15.8237-8248.2003
   Hunt PW, 2011, AIDS, V25, P2123, DOI 10.1097/QAD.0b013e32834c4ac1
   Khanna KV, 2002, J CLIN INVEST, V109, P205
   Lee MKS, 2016, BRIT J PHARMACOL, V173, P741, DOI 10.1111/bph.13319
   Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690
   Liao ZH, 2003, AIDS RES HUM RETROV, V19, P675, DOI 10.1089/088922203322280900
   Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200
   Meroni L, 2005, JAIDS-J ACQ IMM DEF, V38, P310
   Mir KD, 2012, J VIROL, V86, P7605, DOI 10.1128/JVI.06813-11
   Mujawar Z, 2006, PLOS BIOL, V4, P1970, DOI 10.1371/journal.pbio.0040365
   Orsilles MA, 2006, APMIS, V114, P55, DOI 10.1111/j.1600-0463.2006.apm_108.x
   Ory DS, 2017, LANCET, V390, P1758, DOI 10.1016/S0140-6736(17)31465-4
   Planes R, 2016, J VIROL, V90, P5886, DOI 10.1128/JVI.00262-16
   Plevin RE, 2016, SHOCK, V45, P22, DOI 10.1097/SHK.0000000000000470
   Rappocciolo G, 2014, MBIO, V5, DOI 10.1128/mBio.01031-13
   Reboldi A, 2014, SCIENCE, V345, P679, DOI 10.1126/science.1254790
   Renga B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035924
   Sabado RL, 2010, BLOOD, V116, P3839, DOI 10.1182/blood-2010-03-273763
   Said EA, 2010, NAT MED, V16, P452, DOI 10.1038/nm.2106
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Shi C, 2013, BBA-GEN SUBJECTS, V1830, P2538, DOI 10.1016/j.bbagen.2012.12.012
   Teigler JE, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98420
   Vaidya SA, 2014, J INFECT DIS, V210, P1042, DOI 10.1093/infdis/jiu206
   Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002
   Wada NI, 2015, AIDS, V29, P463, DOI 10.1097/QAD.0000000000000545
   Wilson EMP, 2014, J INFECT DIS, V210, P1396, DOI 10.1093/infdis/jiu275
   Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019
NR 52
TC 7
Z9 7
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD NOV-DEC
PY 2018
VL 3
IS 6
AR e00497-18
DI 10.1128/mSphere.00497-18
PG 13
WC Microbiology
SC Microbiology
GA HG1SQ
UT WOS:000454741100015
PM 30404938
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ribeiro, MR
   Moreli, JB
   Marques, RE
   Papa, MP
   Meuren, LM
   Rahal, P
   de Arruda, LB
   Oliani, AH
   Oliani, DCMV
   Oliani, SM
   Narayanan, A
   Nogueira, ML
AF Ribeiro, Milene Rocha
   Moreli, Jusciele Brogin
   Marques, Rafael Elias
   Papa, Michelle Premazzi
   Meuren, Lana Monteiro
   Rahal, Paula
   de Arruda, Luciana Barros
   Oliani, Antonio Helio
   Mos Vaz Oliani, Denise Cristina
   Oliani, Sonia Maria
   Narayanan, Aarthi
   Nogueira, Mauricio Lacerda
TI Zika-virus-infected human full-term placental explants display
   pro-inflammatory responses and undergo apoptosis
SO ARCHIVES OF VIROLOGY
LA English
DT Article
ID CHORIONIC-GONADOTROPIN; 1ST TRIMESTER; TROPHOBLAST; FETAL; INVASION;
   CELLS; COMPLICATIONS; TRANSMISSION; EXPRESSION; PROTECTION
AB Zika virus (ZIKV) is a flavivirus that has been highly correlated with the development of neurological disorders and other malformations in newborns and stillborn fetuses after congenital infection. This association is supported by the presence of ZIKV in the fetal brain and amniotic fluid, and findings suggest that infection of the placental barrier is a critical step for fetal ZIKV infection in utero. Therefore, relevant models to investigate the interaction between ZIKV and placental tissues are essential for understanding the pathogenesis of Zika syndrome. In this report, we demonstrate that explant tissue from full-term human placentas sustains a productive ZIKV infection, though the results depend on the strain. Viral infection was found to be associated with pro-inflammatory cytokine expression and apoptosis of the infected tissue, and these findings confirm that placental explants are targets of ZIKV replication. We propose that human placental explants are useful as a model for studying ZIKV infection ex vivo.
C1 [Ribeiro, Milene Rocha; Rahal, Paula; Oliani, Sonia Maria] Sao Paulo State Univ UNESP, Sch Biosci Humanities & Exact Sci, Dept Biol, Sao Jose Do Rio Preto, SP, Brazil.
   [Moreli, Jusciele Brogin] Fed Univ Sao Paulo UNIFESP, Sao Paulo, SP, Brazil.
   [Marques, Rafael Elias] Natl Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, Campinas, SP, Brazil.
   [Papa, Michelle Premazzi; Meuren, Lana Monteiro; de Arruda, Luciana Barros] Fed Univ Rio de Janeiro UFRJ, Paulo de Goes Dept Microbiol, Rio De Janeiro, Brazil.
   [Narayanan, Aarthi] George Mason Univ, Fairfax, VA 22030 USA.
   [Ribeiro, Milene Rocha; Oliani, Antonio Helio; Mos Vaz Oliani, Denise Cristina; Nogueira, Mauricio Lacerda] Sao Jose do Rio Preto Sch Med FAMERP, Dept Dermatol Infect & Parasit Dis, Virol Res Lab, Sao Jose Do Rio Preto, SP, Brazil.
RP Nogueira, ML (corresponding author), Sao Jose do Rio Preto Sch Med FAMERP, Dept Dermatol Infect & Parasit Dis, Virol Res Lab, Sao Jose Do Rio Preto, SP, Brazil.
EM mnogueira@famerp.br
RI OLIANI, ANTONIO/O-1673-2019; Marques, Rafael Elias/R-4890-2016; Arruda,
   Luciana B/N-9086-2013; Rahal, Paula/D-3871-2012; Nogueira, Mauricio
   L/B-7599-2012; Oliani, Sonia Maria/E-3476-2012
OI Marques, Rafael Elias/0000-0002-6949-0947; Rahal,
   Paula/0000-0001-5693-6148; Nogueira, Mauricio L/0000-0003-1102-2419;
   Moreli, Jusciele/0000-0002-0945-9462; Oliani, Antonio
   Helio/0000-0003-1242-4364; Oliani, Sonia Maria/0000-0003-0918-2130
FU Brazilian National Institute of Science and Technology for Dengue
   Studies (INCT em Dengue); Sao Paulo Research Foundation (FAPESP)Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/21719-3];
   Brazilian National Research Council (CAPES)National Council for
   Scientific and Technological Development (CNPq)CAPES
FX The authors gratefully acknowledge the Brazilian National Institute of
   Science and Technology for Dengue Studies (INCT em Dengue), the Sao
   Paulo Research Foundation (FAPESP; Grant No. 2013/21719-3 to MLN) and
   the Brazilian National Research Council (CAPES) for their financial
   support.
CR Aliota M. T., 2016, PLOS NEGLECT TROP D, V10, DOI DOI 10.1371/JOURNAL.PNTD.0004750
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Beckham JD, 2016, JAMA NEUROL, V73, P875, DOI 10.1001/jamaneurol.2016.0800
   Bowen JR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006164
   Brey EM, 2003, J HISTOCHEM CYTOCHEM, V51, P575, DOI 10.1177/002215540305100503
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Carpentier PA, 2011, AM J PATHOL, V178, P2802, DOI 10.1016/j.ajpath.2011.02.042
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Chaudhary V, 2017, J VIROL, V91, DOI 10.1128/JVI.00163-17
   Chutinimitkul S, 2005, J VIROL METHODS, V129, P8, DOI 10.1016/j.jviromet.2005.05.006
   Corry J, 2017, P NATL ACAD SCI USA, V114, P9433, DOI 10.1073/pnas.1707513114
   Coyne CB, 2016, NAT REV MICROBIOL, V14, P707, DOI 10.1038/nrmicro.2016.125
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720
   Derricott H, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12725
   El Costa H, 2016, SCI REP-UK, V6, DOI 10.1038/srep35296
   El Ghouzzi V, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.266
   Elovitz MA, 2006, PEDIATR RES, V59, P50, DOI 10.1203/01.pdr.0000191141.21932.b6
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Fettke F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00495
   Frank C, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.23.30252
   Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254
   Garcia-Ruiz G, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958-015-0111-3
   Girard S, 2014, AM J REPROD IMMUNOL, V72, P422, DOI 10.1111/aji.12274
   Giugliano S, 2015, J IMMUNOL, V195, P3737, DOI 10.4049/jimmunol.1500409
   Gomes CP, 2013, AM J REPROD IMMUNOL, V69, P545, DOI 10.1111/aji.12088
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Hamilton ST, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052899
   Hamming OJ, 2013, EMBO J, V32, P3055, DOI 10.1038/emboj.2013.232
   Heazell AEP, 2008, REPROD SCI, V15, P1034, DOI 10.1177/1933719108322438
   Helige C, 2008, HUM REPROD, V23, P2282, DOI 10.1093/humrep/den198
   Itinteang T, 2011, J CLIN PATHOL, V64, P870, DOI 10.1136/jclinpath-2011-200191
   Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875
   KURMAN RJ, 1984, INT J GYNECOL PATHOL, V3, P101, DOI 10.1097/00004347-198403010-00009
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lash GE, 2006, FASEB J, V20, P2512, DOI 10.1096/fj.06-6616com
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lee HC, 2014, J BIOL CHEM, V289, P5310, DOI 10.1074/jbc.M113.536102
   Leisser C, 2006, MOL HUM REPROD, V12, P601, DOI 10.1093/molehr/gal066
   LIBRACH CL, 1994, J BIOL CHEM, V269, P17125
   Malkki H, 2016, NAT REV NEUROL, V12, DOI [10.1038/nrneurol.2016.139, 10.1038/nrneurol.2016.22, 10.1038/nrneurol.2016.117, 10.1038/nrneurol.2016.78, 10.1038/nrneurol.2016.58, 10.1038/nrneurol.2016.175, 10.1038/nrneurol.2016.79, 10.1038/nrneurol.2016.151, 10.1038/nrneurol.2016.30, 10.1038/nrneurol.2016.52]
   McEwan M, 2009, CYTOKINE GROWTH F R, V20, P241, DOI 10.1016/j.cytogfr.2009.05.004
   Meager A, 2005, CYTOKINE, V31, P109, DOI 10.1016/j.cyto.2005.04.003
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moser G, 2010, HUM REPROD, V25, P1127, DOI 10.1093/humrep/deq035
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Onoguchi K, 2007, J BIOL CHEM, V282, P7576, DOI 10.1074/jbc.M608618200
   Otun HA, 2011, J REPROD IMMUNOL, V88, P1, DOI 10.1016/j.jri.2010.10.003
   Pacanowski M, 2012, JAMA-J AM MED ASSOC, V307, P1921, DOI 10.1001/jama.2012.3516
   Panchaud A, 2016, CLIN MICROBIOL REV, V29, P659, DOI 10.1128/CMR.00014-16
   Pantoja P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15674
   Pontillo A, 2013, REPROD SCI, V20, P563, DOI 10.1177/1933719112459240
   Quicke KM, 2016, CELL HOST MICROBE, V20, P83, DOI 10.1016/j.chom.2016.05.015
   Rabaan AA, 2017, J INFECT PUBLIC HEAL, V10, P141, DOI 10.1016/j.jiph.2016.05.007
   Raghupathy R, 2008, FRONT BIOSCI-LANDMRK, V13, P985, DOI 10.2741/2737
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Roth I, 1996, J EXP MED, V184, P539, DOI 10.1084/jem.184.2.539
   Roth I, 1999, DEV BIOL, V205, P194, DOI 10.1006/dbio.1998.9122
   Siwetz M, 2016, LAB INVEST, V96, P428, DOI 10.1038/labinvest.2015.159
   Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Vargas-Rojas MI, 2016, J MATERN-FETAL NEO M, V29, P1642, DOI 10.3109/14767058.2015.1057811
   Vermillion MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14575
   VICOVAC L, 1995, PLACENTA, V16, P41, DOI 10.1016/0143-4004(95)90080-2
   Vorou R, 2016, INT J INFECT DIS, V48, P85, DOI 10.1016/j.ijid.2016.05.014
   Waldorf KMA, 2016, NAT MED, V22, P1256, DOI 10.1038/nm.4193
   Wikan N, 2016, LANCET INFECT DIS, V16, pE119, DOI 10.1016/S1473-3099(16)30010-X
   Wilczynski JR, 2003, EUR J OBSTET GYN R B, V109, P8, DOI 10.1016/S0301-2115(02)00350-0
   Winkler CW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07099-7
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
NR 72
TC 6
Z9 6
U1 0
U2 7
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0304-8608
EI 1432-8798
J9 ARCH VIROL
JI Arch. Virol.
PD OCT
PY 2018
VL 163
IS 10
BP 2687
EP 2699
DI 10.1007/s00705-018-3911-x
PG 13
WC Virology
SC Virology
GA GT7UM
UT WOS:000444735000006
PM 29876782
OA Green Published
DA 2020-12-08
ER

PT J
AU Lucas, CGO
   Kitoko, JZ
   Ferreira, FM
   Suzart, VG
   Papa, MP
   Coelho, SVA
   Cavazzoni, CB
   Paula-Neto, HA
   Olsen, PC
   Iwasaki, A
   Pereira, RM
   Pimentel-Coelho, PM
   Vale, AM
   de Arruda, LB
   Bozza, MT
AF Lucas, Carolina G. O.
   Kitoko, Jamil Z.
   Ferreira, Fabricio M.
   Suzart, Vinicius G.
   Papa, Michelle P.
   Coelho, Sharton V. A.
   Cavazzoni, Cecilia B.
   Paula-Neto, Heitor A.
   Olsen, Priscilla C.
   Iwasaki, Akiko
   Pereira, Renata M.
   Pimentel-Coelho, Pedro M.
   Vale, Andre M.
   de Arruda, Luciana B.
   Bozza, Marcelo T.
TI Critical role of CD4(+) T cells and IFN gamma signaling in
   antibody-mediated resistance to Zika virus infection
SO NATURE COMMUNICATIONS
LA English
DT Article
ID GUILLAIN-BARRE-SYNDROME; WEST-NILE-VIRUS; MOUSE MODEL; DENGUE;
   PROTECTION; VACCINE; RESPONSES; IMMUNITY; BRAIN; PATHOGENESIS
AB Protective adaptive immunity to Zika virus (ZIKV) has been mainly attributed to cytotoxic CD8(+) T cells and neutralizing antibodies, while the participation of CD4(+) T cells in resistance has remained largely uncharacterized. Here, we show a neutralizing antibody response, dependent on CD4(+) T cells and IFN gamma signaling, which we detected during the first week of infection and is associated with reduced viral load in the brain, prevention of rapid disease onset and survival. We demonstrate participation of these components in the resistance to ZIKV during primary infection and in murine adoptive transfer models of heterologous ZIKV infection in a background of IFNR deficiency. The protective effect of adoptively transferred CD4(+) T cells requires IFN gamma signaling, CD8(+) T cells and B lymphocytes in recipient mice. Together, this indicates the importance of CD4(+) T cell responses in future vaccine design for ZIKV.
C1 [Lucas, Carolina G. O.; Kitoko, Jamil Z.; Ferreira, Fabricio M.; Suzart, Vinicius G.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Kitoko, Jamil Z.; Olsen, Priscilla C.] Univ Fed Rio de Janeiro, Lab Bacteriol & Imunologia Clin, Fac Farm, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Papa, Michelle P.; Coelho, Sharton V. A.; de Arruda, Luciana B.] Univ Fed Rio de Janeiro, Dept Virol, Lab Genet & Imunol Infeccoes Virais, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Cavazzoni, Cecilia B.; Vale, Andre M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Sinalizacao & Imunoreceptores, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Paula-Neto, Heitor A.] Univ Fed Rio de Janeiro, Dept Biotecnol Farmaceut, Lab Alvos Mol, Fac Farm, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06519 USA.
   [Pereira, Renata M.] Univ Fed Rio de Janeiro, Dept Imunol, Lab Imunol Mol, BR-21941902 Rio De Janeiro, RJ, Brazil.
   [Pimentel-Coelho, Pedro M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Neurobiol Celular & Mol, BR-21941902 Rio De Janeiro, RJ, Brazil.
RP Bozza, MT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Lab Inflamacao & Imunidade, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM mbozza@micro.ufrj.br
RI Olsen, Priscilla C/I-8994-2012; Pimentel-Coelho, Pedro
   Moreno/AAM-9106-2020; Pimentel-Coelho, Pedro M/K-1994-2015; Arruda,
   Luciana B/N-9086-2013; Pereira, Renata/V-6194-2019; Iwasaki,
   Akiko/Z-1591-2019; Kitoko, Jamil/AAY-1595-2020; Kitoko, JZ/D-1694-2016
OI Olsen, Priscilla C/0000-0002-8795-037X; Pimentel-Coelho, Pedro
   Moreno/0000-0002-2414-3386; Pimentel-Coelho, Pedro
   M/0000-0002-2414-3386; Iwasaki, Akiko/0000-0002-7824-9856; Kitoko,
   Jamil/0000-0003-0973-5460; Kitoko, JZ/0000-0003-0973-5460
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); CAPESCAPES; FINEPCiencia Tecnologia e
   Inovacao (FINEP); ICGEB [CRP/ BRA16-05-EC]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R21AI131284] Funding
   Source: NIH RePORTER
FX We thank Dr. Amilcar Tanuri and Dr. Ernesto T.A. Marques Jr. for kindly
   donating the ZIKV strain MR766 and PE243, respectively. Zika EDIII
   recombinant protein was kindly provided by Dr. Michel Nussenzweig. We
   acknowledge Leda R. Castilho, Matheus O. Souza, Renata G. F. Alvim, and
   Tulio M. Lima from Cell Culture Engineering Lab at COPPE/UFRJ for
   providing the purified VLPs used in the ELISA assays. We thank the
   members of the Bozza lab for helpful discussions and suggestions. This
   work was supported by grants from CNPq, FAPERJ, CAPES, FINEP (M.T.B) and
   ICGEB (CRP/ BRA16-05-EC; to R.M.P). C.G.O.L., J.Z.K., F.M.F., and
   V.G.S.S. are supported by fellowships from CAPES, M.P.P., and C.B.C. by
   CNPq and S.V.A.C. by FAPERJ.
CR Abbasi J, 2016, JAMA-J AM MED ASSOC, V316, P2588, DOI [10.1001/jama.2016.19328, 10.1001/jama.2016.18655]
   Aid M, 2017, CELL, V169, P610, DOI 10.1016/j.cell.2017.04.008
   Aliota MT, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005168
   Coelho SVA, 2017, J VIROL METHODS, V246, P65, DOI 10.1016/j.jviromet.2017.04.011
   Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Barzon L, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.32.30316
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brien JD, 2008, J IMMUNOL, V181, P8568, DOI 10.4049/jimmunol.181.12.8568
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Diamond MS, 2003, J EXP MED, V198, P1853, DOI 10.1084/jem.20031223
   Diamond MS, 2003, J VIROL, V77, P2578, DOI 10.1128/JVI.77.4.2578-2586.2003
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   do Rosario MS, 2016, AM J TROP MED HYG, V95, P1157, DOI 10.4269/ajtmh.16-0306
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Dowall SD, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005704
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]
   Iijima N, 2016, NATURE, V533, P552, DOI 10.1038/nature17979
   Johnson AJ, 1999, J VIROL, V73, P783, DOI 10.1128/JVI.73.1.783-786.1999
   Jurado KA, 2018, NAT MICROBIOL, V3, P141, DOI 10.1038/s41564-017-0060-z
   Kumar A, 2016, EMBO REP, V17, P1766, DOI 10.15252/embr.201642627
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2009, J CLIN INVEST, V119, P3266, DOI 10.1172/JCI39387
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Lenth RV, 2007, J ANIM SCI, V85, pE24, DOI 10.2527/jas.2006-449
   Manangeeswaran M, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006004
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004
   MuraliKrishna K, 1996, J GEN VIROL, V77, P705, DOI 10.1099/0022-1317-77-4-705
   Nazerai L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00593
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Papa MP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02557
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Prestwood TR, 2012, J VIROL, V86, P12561, DOI 10.1128/JVI.06743-11
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040
   Rivino L, 2017, IMMUNOLOGY, V150, P146, DOI 10.1111/imm.12681
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Scott JM, 2018, J VIROL, V92, DOI 10.1128/JVI.00038-18
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Shresta S, 2004, J VIROL, V78, P2701, DOI 10.1128/JVI.78.6.2701-2710.2004
   Sitati EM, 2006, J VIROL, V80, P12060, DOI 10.1128/JVI.01650-06
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sumathy K, 2017, SCI REP-UK, V7, DOI 10.1038/srep46375
   Swanstrom JA, 2016, MBIO, V7, DOI 10.1128/mBio.01123-16
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   Aragao MDV, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1901
   Winkler CW, 2017, J IMMUNOL, V198, P3526, DOI 10.4049/jimmunol.1601949
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Zellweger RM, 2014, J IMMUNOL, V193, P4117, DOI 10.4049/jimmunol.1401597
NR 63
TC 23
Z9 23
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 7
PY 2018
VL 9
AR 3136
DI 10.1038/s41467-018-05519-4
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GP6IG
UT WOS:000440981600013
PM 30087337
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Pinheiro, TM
   Mota, MTD
   Watanabe, ASA
   Biselli-Perico, JM
   Drumond, BP
   Ribeiro, MR
   Vedovello, D
   Araujo, JP
   Pimenta, PFP
   Chaves, BA
   da Silva, MMC
   Batista, ICA
   Papa, MP
   Meuren, LM
   Lucas, CGD
   Matassoli, FL
   Gil, LHVG
   Bozzi, A
   Calzavara-Silva, CE
   de Arruda, LB
   de Souza, DD
   Teixeira, MM
   Vasilakis, N
   Nogueira, ML
AF Pinheiro, Tauyne Menegaldo
   de Oliveira Mota, Manlio Tasso
   Aranha Watanabe, Aripuana Sakurada
   Biselli-Perico, Joice Matos
   Drumond, Betania Paiva
   Ribeiro, Milene Rocha
   Vedovello, Danila
   Araujo, Joao Pessoa, Jr.
   Paolucci Pimenta, Paulo Filemon
   Chaves, Barbara Aparecida
   Carneiro da Silva, Mayara Marques
   Andrade Batista, Izabella Cristina
   Papa, Michelle Premazzi
   Meuren, Lana Monteiro
   de Oliveira Lucas, Carolina Goncalves
   Matassoli, Flavio Lemos
   Vega Gonzales Gil, Laura Helena
   Bozzi, Adriana
   Calzavara-Silva, Carlos Eduardo
   de Arruda, Luciana Barros
   de Souza, Danielle da Gloria
   Teixeira, Mauro Martins
   Vasilakis, Nikos
   Nogueira, Mauricio Lacerda
TI Viral immunogenicity determines epidemiological fitness in a cohort of
   DENV-1 infection in Brazil
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DENGUE VIRUS; POPULATION-DYNAMICS; CO-CIRCULATION; IDENTIFICATION;
   REPLACEMENT; MOSQUITOS; SEVERITY; DISEASE; CLADE; FEVER
AB The dynamics of dengue virus (DENV) circulation depends on serotype, genotype and lineage replacement and turnover. In Sao Jose do Rio Preto, Brazil, we observed that the L6 lineage of DENV-1 (genotype V) remained the dominant circulating lineage even after the introduction of the L1 lineage. We investigated viral fitness and immunogenicity of the L1 and L6 lineages and which factors interfered with the dynamics of DENV epidemics. The results showed a more efficient replicative fitness of L1 over L6 in mosquitoes and in human and non-human primate cell lines. Infections by the L6 lineage were associated with reduced antigenicity, weak B and T cell stimulation and weak host immune system interactions, which were associated with higher viremia. Our data, therefore, demonstrate that reduced viral immunogenicity and consequent greater viremia determined the increased epidemiological fitness of DENV-1 L6 lineage in Sao Jose do Rio Preto.
C1 [Pinheiro, Tauyne Menegaldo; de Oliveira Mota, Manlio Tasso; Aranha Watanabe, Aripuana Sakurada; Biselli-Perico, Joice Matos; Ribeiro, Milene Rocha; Vedovello, Danila; Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto, Lab Pesquisa Virol, Dept Doencas Dermatol Infecciosas & Parasitarias, Sao Jose Do Rio Preto, SP, Brazil.
   [Drumond, Betania Paiva] Univ Fed Minas Gerais, Lab Virus, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Araujo, Joao Pessoa, Jr.] Univ Estadual Paulista Julio de Mesquita, Inst Biociencias, Lab Virol, Dept Microbiol & Imunol, Botucatu, SP, Brazil.
   [Paolucci Pimenta, Paulo Filemon; Chaves, Barbara Aparecida] Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Entomol Med, Belo Horizonte, MG, Brazil.
   [Chaves, Barbara Aparecida] Univ Estado Amazonas, Programa Posgrad Med Trop, Manaus, AM, Brazil.
   [Chaves, Barbara Aparecida] Fundacao Med Trop Dr Heitor Vieira Dourado FMT HV, Manaus, AM, Brazil.
   [Carneiro da Silva, Mayara Marques; Vega Gonzales Gil, Laura Helena] Fiocruz MS, Dept Virol, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Andrade Batista, Izabella Cristina; Bozzi, Adriana; Calzavara-Silva, Carlos Eduardo] Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
   [Papa, Michelle Premazzi; Meuren, Lana Monteiro; de Oliveira Lucas, Carolina Goncalves; Matassoli, Flavio Lemos; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Virol, Lab Genet & Imunol Infeccoes Virais, Rio De Janeiro, RJ, Brazil.
   [de Souza, Danielle da Gloria] Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Teixeira, Mauro Martins] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Inst Ciencias Biol, Lab Imunofarmacol, Belo Horizonte, MG, Brazil.
   [Vasilakis, Nikos] Univ Texas Med Branch, Ctr Trop Dis, Inst Human Infect & Immun, Dept Pathol,Ctr Biodef & Emerging Infect Dis, Galveston, TX 77555 USA.
   [Aranha Watanabe, Aripuana Sakurada] Univ Fed Juiz de Fora, Lab Virol, Dept Parasitol Microbiol & Imunol, Juiz De Fora, MG, Brazil.
   [Biselli-Perico, Joice Matos] Univ Estadual Paulista, Dept Biol, Inst Biociencias Letras & Ciencias Exatas, Sao Jose Do Rio Preto, SP, Brazil.
RP Nogueira, ML (corresponding author), Fac Med Sao Jose do Rio Preto, Lab Pesquisa Virol, Dept Doencas Dermatol Infecciosas & Parasitarias, Sao Jose Do Rio Preto, SP, Brazil.
EM mauriciolnogueira@gmail.com
RI Bozzi, Adriana/M-6795-2013; Araujo, Joao Pessoa/C-2444-2012; Nogueira,
   Mauricio L/B-7599-2012; Bozzi, Adriana/ABE-3750-2020; Teixeira, Mauro
   M/A-4587-2008; Araujo, JP/Q-3043-2019; de Oliveira Mota, Manlio
   Tasso/E-2619-2013; Vasilakis, Nikos/ABE-7318-2020; Arruda, Luciana
   B/N-9086-2013; Biselli, Joice Matos/B-6913-2014; Pimenta,
   Paulo/AAH-1502-2020; Vedovello, Danila/M-5757-2014
OI Bozzi, Adriana/0000-0002-8242-5584; Araujo, Joao
   Pessoa/0000-0002-9153-1485; Nogueira, Mauricio L/0000-0003-1102-2419;
   Teixeira, Mauro M/0000-0002-6944-3008; Araujo, JP/0000-0002-9153-1485;
   CALZAVARA-SILVA, CARLOS/0000-0002-1406-6401; ,
   Aripuana/0000-0003-0875-2269; Matos Biselli, Joice/0000-0001-5105-9537;
   Vedovello, Danila/0000-0001-8585-8206; Chaves,
   Barbara/0000-0003-2079-6096
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/11733-6,
   2013/21719-3, 2015/22750-7]; INCT-Dengue/CNPq; NIH/NIAIDUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [U01 AI115577]
FX Viral This work is funded by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), Grants # 2012/11733-6 and 2013/21719-3 to MLN and
   2015/22750-7 to TMP and by INCT-Dengue/CNPq. MLN and MMT are CNPq
   Fellows. NV is supported by a NIH/NIAID Grant # U01 AI115577. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abu Choudhury M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107264
   Azeredo EL, 2010, IMMUNOLOGY, V130, P202, DOI 10.1111/j.1365-2567.2009.03224.x
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bidet K, 2014, BIOCHEM J, V462, P215, DOI 10.1042/BJ20140456
   Bronzoni RVD, 2005, J CLIN MICROBIOL, V43, P696, DOI 10.1128/JCM.43.2.696-702.2005
   Chapman EG, 2014, SCIENCE, V344, P307, DOI 10.1126/science.1250897
   Chaturvedi UC, 2000, FEMS IMMUNOL MED MIC, V28, P183, DOI 10.1111/j.1574-695X.2000.tb01474.x
   Chen RB, 2011, VIRUSES-BASEL, V3, P1562, DOI 10.3390/v3091562
   Christenbury JG, 2010, J VIROL METHODS, V169, P202, DOI 10.1016/j.jviromet.2010.06.013
   Chutinimitkul S, 2005, J VIROL METHODS, V129, P8, DOI 10.1016/j.jviromet.2005.05.006
   Cologna R, 2005, J VIROL, V79, P853, DOI 10.1128/JVI.79.2.853-859.2005
   Cunha MD, 2016, INFECT GENET EVOL, V43, P130, DOI 10.1016/j.meegid.2016.05.021
   dos Santos FB, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-387
   Drummond A.J., 2002, BEAST BAYESIAN EVOLU
   Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI 10.1093/molbev/msi103
   Drumond BP, 2012, ARCH VIROL, V157, P2061, DOI 10.1007/s00705-012-1393-9
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Goncalves CM, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-320
   Goncalvez AP, 2002, VIROLOGY, V303, P110, DOI 10.1006/viro.2002.1686
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Ho LJ, 2005, J IMMUNOL, V174, P8163, DOI 10.4049/jimmunol.174.12.8163
   Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI 10.1016/S1567-1348(03)00004-2
   Horstick O, 2015, PATHOG GLOB HEALTH, V109, P19, DOI 10.1179/2047773215Y.0000000003
   Jain A, 2013, J CLIN IMMUNOL, V33, P613, DOI 10.1007/s10875-012-9855-0
   Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113
   Lambeth CR, 2005, J CLIN MICROBIOL, V43, P3267, DOI 10.1128/JCM.43.7.3267-3272.2005
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Liu-Helmersson J, 2016, EBIOMEDICINE, V7, P267, DOI 10.1016/j.ebiom.2016.03.046
   Machado DC, 2012, INTERVIROLOGY, V55, P475, DOI 10.1159/000337166
   Manakkadan A, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-37
   Manokaran G, 2015, SCIENCE, V350, P217, DOI 10.1126/science.aab3369
   Mendez JA, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-226
   Messina JP, 2014, TRENDS MICROBIOL, V22, P138, DOI 10.1016/j.tim.2013.12.011
   OhAinle M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003084
   Quiner CA, 2014, J VIROL, V88, P13125, DOI 10.1128/JVI.01822-14
   Raghwani J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002064
   Rambaut A, 2002, TREEANOTATOR V1 8 1
   Rambaut A., 2003, TRACER MCMC TRACE AN
   Sariol CA, 2018, TRENDS MICROBIOL, V26, P186, DOI 10.1016/j.tim.2017.10.004
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Vedovello D, 2015, ARCH VIROL, V160, P1189, DOI 10.1007/s00705-015-2378-2
   Villabona-Arenas CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062649
   Wargo AR, 2012, CURR OPIN VIROL, V2, P538, DOI 10.1016/j.coviro.2012.07.007
   Zhang CL, 2005, J VIROL, V79, P15123, DOI 10.1128/JVI.79.24.15123-15130.2005
NR 44
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2018
VL 12
IS 5
AR e0006525
DI 10.1371/journal.pntd.0006525
PG 25
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA GH9WW
UT WOS:000434021900060
PM 29813061
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Papa, MP
   Meuren, LM
   Coelho, SVA
   Lucas, CGD
   Mustafa, YM
   Matassoli, FL
   Silveira, PP
   Frost, PS
   Pezzuto, P
   Ribeiro, MR
   Tanuri, A
   Nogueira, ML
   Campanati, L
   Bozza, MT
   Neto, HAP
   Pimentel-Coelho, PM
   Figueiredo, CP
   de Aguiar, RS
   de Arruda, LB
AF Papa, Michelle P.
   Meuren, Lana M.
   Coelho, Sharton V. A.
   de Oliveira Lucas, Carolina G.
   Mustafa, Yasmin M.
   Matassoli, Flavio Lemos
   Silveira, Paola P.
   Frost, Paula S.
   Pezzuto, Paula
   Ribeiro, Milene R.
   Tanuri, Amilcar
   Nogueira, Mauricio L.
   Campanati, Loraine
   Bozza, Marcelo T.
   Paula Neto, Heitor A.
   Pimentel-Coelho, Pedro M.
   Figueiredo, Claudia P.
   de Aguiar, Renato S.
   de Arruda, Luciana B.
TI Zika Virus Infects, Activates, and Crosses Brain Microvascular
   Endothelial Cells, without Barrier Disruption
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE Zika virus; endothelial cells; blood brain barrier; transcytosis; mouse
   experimental model
ID JAPANESE ENCEPHALITIS-VIRUS; IN-VITRO; NERVOUS-SYSTEM; MODEL;
   TRANSCYTOSIS; ENDOCYTOSIS; INTEGRITY; TRANSPORT; PROTEINS; COMPLEX
AB Zika virus (ZIKV) has been associated to central nervous system (CNS) harm, and virus was detected in the brain and cerebrospinal fluids of microcephaly and meningoencephalitis cases. However, the mechanism by which the virus reaches the CNS is unclear. Here, we addressed the effects of ZIKV replication in human brain microvascular endothelial cells (HBMECs), as an in vitro model of blood brain barrier (BBB), and evaluated virus extravasation and BBB integrity in an in vivo mouse experimental model. HBMECs were productively infected by African and Brazilian ZIKV strains (ZIKV(MR766) and ZIKV(PE243)), which induce increased production of type I and type III IFN, inflammatory cytokines and chemokines. Infection with ZIKV(MR766) promoted earlier cellular death, in comparison to ZIKV(PE243), but infection with either strain did not result in enhanced endothelial permeability. Despite the maintenance of endothelial integrity, infectious virus particles crossed the monolayer by endocytosis/exocytosis-dependent replication pathway or by transcytosis. Remarkably, both viruses' strains infected IFNAR deficient mice, with high viral load being detected in the brains, without BBB disruption, which was only detected at later time points after infection. These data suggest that ZIKV infects and activates endothelial cells, and might reach the CNS through basolateral release, transcytosis or transinfection processes. These findings further improve the current knowledge regarding ZIKV dissemination pathways.
C1 [Papa, Michelle P.; Meuren, Lana M.; Coelho, Sharton V. A.; de Oliveira Lucas, Carolina G.; Mustafa, Yasmin M.; Matassoli, Flavio Lemos; de Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Dept Virol, Rio De Janeiro, Brazil.
   [de Oliveira Lucas, Carolina G.; Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Dept Imunol, Rio De Janeiro, Brazil.
   [Silveira, Paola P.; Pezzuto, Paula; Tanuri, Amilcar; de Aguiar, Renato S.] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil.
   [Frost, Paula S.; Figueiredo, Claudia P.] Univ Fed Rio de Janeiro, Fac Farm, Nucleo Neurociencias, Rio De Janeiro, Brazil.
   [Ribeiro, Milene R.; Nogueira, Mauricio L.] Fac Med Sao Jose Do Rio Preto, Lab Pesquisas Virol, Sao Jose Do Rio Preto, Brazil.
   [Campanati, Loraine] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Rio De Janeiro, Brazil.
   [Paula Neto, Heitor A.] Univ Fed Rio de Janeiro, Fac Farm, Dept Biotecnol Farmaceut, Lab Alvos Mol, Rio De Janeiro, Brazil.
   [Pimentel-Coelho, Pedro M.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Rio De Janeiro, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Dept Virol, Rio De Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Pimentel-Coelho, Pedro M/K-1994-2015; Arruda, Luciana B/N-9086-2013;
   Pimentel-Coelho, Pedro Moreno/AAM-9106-2020; Figueiredo, Claudia
   P/F-8424-2012; Nogueira, Mauricio L/B-7599-2012; Aguiar, Renato
   S/G-3542-2015; Campanati, Loraine/V-2632-2018
OI Pimentel-Coelho, Pedro M/0000-0002-2414-3386; Pimentel-Coelho, Pedro
   Moreno/0000-0002-2414-3386; Nogueira, Mauricio L/0000-0003-1102-2419;
   Aguiar, Renato S/0000-0001-5180-3717; Campanati,
   Loraine/0000-0001-9172-1951; Figueiredo, Claudia/0000-0001-9467-9891; da
   Silva Frost, Paula/0000-0002-3814-999X
FU CAPESCAPES; CAPES/PVE-Program; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJ-Rede ZIKA; FINEPCiencia
   Tecnologia e Inovacao (FINEP); FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); FAPESPFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/21719-3]
FX This work was supported by CAPES, CAPES/PVE-Program, CNPq, FAPERJ-Rede
   ZIKA, and FINEP. MP was the recipient of a CNPq fellowship. LM and CL
   were the recipient of a CAPES fellowship. SC was the recipient of a
   FAPERJ fellowship. MN is supported by a FAPESP grant #2013/21719-3. MN
   and MB are a CNPq Fellowship recipient.
CR Coelho SVA, 2017, J VIROL METHODS, V246, P65, DOI 10.1016/j.jviromet.2017.04.011
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Bayer A, 2016, CELL HOST MICROBE, V19, P705, DOI 10.1016/j.chom.2016.03.008
   Bramley JC, 2017, MSPHERE, V2, DOI 10.1128/mSphere.00206-17
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Chang CY, 2015, GLIA, V63, P1915, DOI 10.1002/glia.22857
   Chanthick C, 2016, SCI REP-UK, V6, DOI 10.1038/srep31855
   Chen CJ, 2014, J VIROL, V88, P1150, DOI 10.1128/JVI.02738-13
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   da Conceicao TM, 2013, VIROLOGY, V435, P281, DOI 10.1016/j.virol.2012.09.038
   Daniels BP, 2015, CLIN PHARMACOL THER, V97, P372, DOI 10.1002/cpt.75
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Diefenbach RJ, 2008, REV MED VIROL, V18, P35, DOI 10.1002/rmv.560
   Dohgu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039565
   Dowall SD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004658
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Finke S, 2005, VIRUS RES, V111, P120, DOI 10.1016/j.virusres.2005.04.004
   FUJIWARA T, 1988, J BIOL CHEM, V263, P18545
   Galliez RM, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw203
   Harmon B, 2012, J VIROL, V86, P12954, DOI 10.1128/JVI.02242-12
   JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Liou ML, 1998, CELL TISSUE RES, V293, P389, DOI 10.1007/s004410051130
   Lucey D, 2017, JAMA-J AM MED ASSOC, V317, P1368, DOI 10.1001/jama.2017.1553
   Luethy LN, 2016, VIROLOGY, V487, P1, DOI 10.1016/j.virol.2015.09.019
   Mahad D, 2006, BRAIN, V129, P212, DOI 10.1093/brain/awh655
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Miner JJ, 2016, CURR OPIN IMMUNOL, V38, P18, DOI 10.1016/j.coi.2015.10.008
   Miranda DD, 2016, AM J PUBLIC HEALTH, V106, P598, DOI 10.2105/AJPH.2016.303115
   Mladinich MC, 2017, MBIO, V8, DOI [10.1128/mBio.00952-17, 10.1128/mbio.00952-17]
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Morrey JD, 2008, J GEN VIROL, V89, P467, DOI 10.1099/vir.0.83345-0
   Nikolskaia OV, 2006, J CLIN INVEST, V116, P2739, DOI [10.1172/JC127798, 10.1172/JCI27798.]
   Racaniello VR, 2006, VIROLOGY, V344, P9, DOI 10.1016/j.virol.2005.09.015
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reis PA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003099
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Roach T, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0824-7
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Salinas S, 2010, NAT REV MICROBIOL, V8, P645, DOI 10.1038/nrmicro2395
   Samuel MA, 2007, P NATL ACAD SCI USA, V104, P17140, DOI 10.1073/pnas.0705837104
   Saunders NR, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3339/fnins.2015.00385, 10.3389/fnins.2015.00385]
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Singh PK, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92340
   Srinivasan B, 2015, JALA-J LAB AUTOM, V20, P107, DOI 10.1177/2211068214561025
   Tripathi S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006258
   Tugizov SM, 2013, J VIROL, V87, P8179, DOI 10.1128/JVI.00443-13
   Velandia-Romero ML, 2012, J NEUROVIROL, V18, P374, DOI 10.1007/s13365-012-0117-y
   Verma S, 2009, VIROLOGY, V385, P425, DOI 10.1016/j.virol.2008.11.047
   Vermillion MS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14575
   Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
NR 62
TC 33
Z9 35
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD DEC 22
PY 2017
VL 8
AR 2557
DI 10.3389/fmicb.2017.02557
PG 17
WC Microbiology
SC Microbiology
GA FQ8DF
UT WOS:000418592400001
PM 29312238
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Marinho, FA
   Sangenito, LS
   Oliveira, SSC
   De Arruda, LB
   D'Avila-levy, CM
   Santos, ALS
   Branquinha, MH
AF Marinho, Fernanda A.
   Sangenito, Leandro S.
   Oliveira, Simone S. C.
   De Arruda, Luciana B.
   D'Avila-levy, Claudia M.
   Santos, Andre L. S.
   Branquinha, Marta H.
TI The potent cell permeable calpain inhibitor MDL28170 affects the
   interaction of Leishmania amazonensis with macrophages and shows
   anti-amastigote activity
SO PARASITOLOGY INTERNATIONAL
LA English
DT Article
DE Leishmaniasis; Leishmania amazonensis; Calpain inhibitor; Interaction
   process; Intracellular amastigotes
AB Since the discovery of the28 first drugs used in leishmaniasis treatment up to now, the search for compounds with anti-Leishmania activity without toxic effects and able to overcome the emergency of resistant strains remains a major goal to combat this neglected disease. With this in mind, in the present work, we evaluated the effects of the calpain inhibitor MDL28170 on the interaction process of Leishmania amazonensis promastigote forms with murine peritoneal macrophages and on the intracellular amastigotes. Our results showed that the calpain inhibitor MDL28170 at 15 and 30 mu M significantly reduced the interaction process of promastigotes with macrophages by 16% and 41%, respectively. The inhibitor was also able to drastically reduce the number of infected macrophages in a time- and dose-dependent manner: after only 24 h, MDL28170 was able to significantly diminish the infection rate, presenting an IC50 value of 18.2 mu M for amastigotes. The treatment with MDL28170 did not alter the nitric oxide production, but the production of TNF-alpha was significantly raised. Altogether, the results presented here contribute to the search of new proteolytic inhibitors able to act in a selective and effective manner against the diseases caused by trypanosomatids.
C1 [Marinho, Fernanda A.; Sangenito, Leandro S.; Oliveira, Simone S. C.; Santos, Andre L. S.; Branquinha, Marta H.] Univ Fed Rio de Janeiro, IMPG, Dept Microbiol Geral, Lab Invest Peptidases, Rio de Janeiro, Brazil.
   [De Arruda, Luciana B.] Univ Fed Rio de Janeiro, IMPG, Dept Virol, Lab Genet & Imunol Infeccoes Virais, Rio de Janeiro, Brazil.
   [D'Avila-levy, Claudia M.] Fundacao Oswaldo Cruz FIOCRUZ, Colecao Protozoarios, Lab Estudos Integrados Protozool, Rio De Janeiro, Brazil.
   [Santos, Andre L. S.] Univ Fed Rio de Janeiro, Inst Quim, Programa Posgrad Bioquim, Rio de Janeiro, Brazil.
RP Branquinha, MH (corresponding author), Univ Fed Rio de Janeiro, IMPG, Dept Microbiol Geral, Lab Invest Peptidases, Rio de Janeiro, Brazil.
EM mbranquinha@micro.ufrj.br
RI Arruda, Luciana B/N-9086-2013; Santos, Andre/Z-5853-2019; Branquinha,
   Marta/AAA-3084-2019; d'Avila-Levy, Claudia M/O-7192-2014
OI Santos, Andre/0000-0003-0821-8592; d'Avila-Levy, Claudia
   M/0000-0001-8042-4695
FU Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnolegico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Coordenacao de
   Aperfeicoamento de Pessoal de NIvel Superior (CAPES)CAPES; Fundacao
   Oswaldo Cruz (FIOCRUZ); CNPq fellowshipNational Council for Scientific
   and Technological Development (CNPq); FAPERJ fellowshipCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ)
FX This work was supported by grants from Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho
   Nacional de Desenvolvimento Cientifico e Tecnolegico (CNPq), Coordenacao
   de Aperfeicoamento de Pessoal de NIvel Superior (CAPES) and Fundacao
   Oswaldo Cruz (FIOCRUZ). Andre L.S. Santos, Marta H. Branquinha and
   Claudia M. d'Avila-Levy were supported by CNPq and FAPERJ fellowships.
CR Awasthi A, 2004, INDIAN J MED RES, V119, P238
   Branquinha MH, 2013, CURR MED CHEM, V20, P3174
   d'Avila-Levy C. M., 2009, PARASITOLOGY, V136, P433
   d'Avila-Levy C. M., 2015, CURR MED CHEM, V22, P2225
   d'Avila-Levy CM, 2006, INT J ANTIMICROB AG, V28, P138, DOI 10.1016/j.ijantimicag.2006.03.021
   Donkor IO, 2015, EXPERT OPIN THER PAT, V25, P17, DOI 10.1517/13543776.2014.982534
   Ennes-Vidal V., 2010, ANTIMICROB CHEMOTHER, V66, P1395
   Ennes-Vidal V, 2017, PARASITOLOGY, V144, P117, DOI 10.1017/S003118201600189X
   Ennes-Vidal V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018371
   Ersfeld K, 2005, J MOL EVOL, V61, P742, DOI 10.1007/s00239-004-0272-8
   Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308
   Huang Q, 2014, CELL MOL LIFE SCI, V71, P3151, DOI 10.1007/s00018-013-1533-8
   Levy, 2014, PLOS ONE, V9
   Mottram JC, 2004, CURR OPIN MICROBIOL, V7, P375, DOI 10.1016/j.mib.2004.06.010
   No JH, 2016, ACTA TROP, V155, P113, DOI 10.1016/j.actatropica.2015.12.016
   Ono Y, 2016, NAT REV DRUG DISCOV, V15, P854, DOI 10.1038/nrd.2016.212
   Savoia D, 2015, J INFECT DEV COUNTR, V9, P588, DOI 10.3855/jidc.6833
   Soares DC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001787
   Souza AS, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-209
   Thompson J, 2016, AM J PHYSIOL-HEART C, V310, pH376, DOI 10.1152/ajpheart.00748.2015
   Tsikas D, 2007, J CHROMATOGR B, V851, P51, DOI 10.1016/j.jchromb.2006.07.054
   Undrovinas A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054436
NR 22
TC 3
Z9 3
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1383-5769
J9 PARASITOL INT
JI Parasitol. Int.
PD OCT
PY 2017
VL 66
IS 5
BP 579
EP 583
DI 10.1016/j.parint.2017.06.010
PG 5
WC Parasitology
SC Parasitology
GA FF6VB
UT WOS:000409154000011
PM 28663009
DA 2020-12-08
ER

PT J
AU Coelho, SVA
   Neris, RLS
   Papa, MP
   Schnellrath, LC
   Meuren, LM
   Tschoeke, DA
   Leomil, L
   Vercoza, BRF
   Miranda, M
   Thompson, FL
   Da Poian, AT
   Souza, TML
   Carneiro, FA
   Damaso, CR
   Assuncao-Miranda, I
   de Arruda, LB
AF Antunes Coelho, Sharton Vinicius
   Silva Neris, Romulo Leao
   Papa, Michelle Premazzi
   Schnellrath, Laila Castro
   Meuren, Lana Monteiro
   Tschoeke, Diogo A.
   Leomil, Luciana
   Farias Vercoza, Brunno Renato
   Miranda, Milene
   Thompson, Fabiano L.
   Da Poian, Andrea Thompson
   Souza, Thiago Moreno L.
   Carneiro, Fabiana Avila
   Damaso, Clarissa R.
   Assuncao-Miranda, Iranaia
   de Arruda, Luciana Barros
TI Development of standard methods for Zika virus propagation, titration,
   and purification
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE Zika virus; Virus propagation; Virus purification; Standard protocols
ID SEXUAL TRANSMISSION; BRAZIL
AB The emergence of Zika virus (ZIKV) infection has stimulated several research groups to study and collaborate to understand virus biology and pathogenesis. These efforts may assist with the development of antiviral drugs, vaccines and diagnostic tests, as well as to promote advancements in public health policies. Here, we aim to develop standard protocols for propagation, titration, and purification of ZIKV strains, by systematically testing different cell types, kinetics, multiplicity of infection and centrifugation protocols. ZIKV produces a productive infection in human, non-human primate, and rodents-derived cell lines, with different efficacies. The highest yield of ZIKV-AFR and ZIKV-BR infectious progeny was obtained at 7 days post infection in C6/36 cells (7 x 10(7) and 2 x 10(8) PFU/ml, respectively). However, high titers of ZIKV-AFR could be obtained at earlier time points in Vero cells (2.5 x 10(7) PFU/ml at 72 hpi), whereas ZIKV-BR titers reached 108 PFU/ml at 4dpi in C6/36 cells. High yield of purified virus was obtained by purification through a discontinuous sucrose gradient. This optimized procedure will certainly contribute to future studies of virus structure and vaccine development. Beyond the achievement of efficient virus propagation, the normalization of these protocols will also allow different laboratories around the world to better compare and discuss data regarding different features of ZIKV biology and disease, contributing to more efficient collaborations and progression in ZIKV research.
C1 [Antunes Coelho, Sharton Vinicius; Silva Neris, Romulo Leao; Papa, Michelle Premazzi; Meuren, Lana Monteiro; Assuncao-Miranda, Iranaia; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio de Janeiro, RJ, Brazil.
   [Schnellrath, Laila Castro; Damaso, Clarissa R.] Univ Fed Rio de Janeiro, IBCCF, Rio de Janeiro, RJ, Brazil.
   [Tschoeke, Diogo A.; Leomil, Luciana; Thompson, Fabiano L.] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio de Janeiro, RJ, Brazil.
   [Farias Vercoza, Brunno Renato; Carneiro, Fabiana Avila] UFRJ, Polo Avancado Xerem, NUMPEX Nucleo Multidisciplinar Pesquisas, Duque De Caxias, RJ, Brazil.
   [Miranda, Milene; Souza, Thiago Moreno L.] Fundacao Oswaldo Cruz, FIOCRUZ, IOC, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.
   [Da Poian, Andrea Thompson] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Rio de Janeiro, RJ, Brazil.
   [Souza, Thiago Moreno L.] Fiocruz MS, Ctr Technol Dev Hlth CDTS, Natl Inst Sci & Technol Innovat Neglected Dis INC, Rio De Janeiro, RJ, Brazil.
RP Assuncao-Miranda, I; de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, CCS, Bloco 1,Lab 1-SS-048,Lab 1-SS-055, Rio De Janeiro, RJ, Brazil.
EM iranaiamiranda@micro.ufrj.br; arruda@micro.ufrj.br
RI Da Poian, Andrea T./V-1699-2019; Vercoza, Brunno Renato
   Farias/AAB-4725-2019; Leomil, Luciana/O-4860-2019; Tschoeke, Diogo
   A/F-9913-2019; Souza, Thiago Moreno L./G-2900-2012; CARNEIRO, FABIANA
   A/S-4525-2018; Arruda, Luciana B/N-9086-2013; Damaso, Clarissa
   R/F-7737-2012
OI Vercoza, Brunno Renato Farias/0000-0001-6117-7879; Tschoeke, Diogo
   A/0000-0001-8134-4259; Souza, Thiago Moreno L./0000-0003-2212-3899;
   Damaso, Clarissa R/0000-0001-6299-2816; Thompson,
   Fabiano/0000-0002-7562-1683; Carneiro, Fabiana/0000-0002-6584-4875; Da
   Poian, Andrea/0000-0002-3969-704X
FU CAPESCAPES; CAPES/PVE-Program; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJ-Rede ZIKA; FINEPCiencia
   Tecnologia e Inovacao (FINEP); FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
FX This work was supported by CAPES, CAPES/PVE-Program, CNPq, FAPERJ-Rede
   ZIKA, and FINEP. SVAC was the recipient of a FAPERJ fellowship. RLSN and
   MPP were recipients of CNPq fellowships. LCS was the recipient of a
   CAPES fellowship. CD and ATP are recipients of CNPq research
   fellowships.
CR Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1960, DOI 10.3201/eid2011.141380
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Chen SX, 2004, VIROLOGY, V318, P123, DOI 10.1016/j.virol.2003.09.013
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Melo ASD, 2016, JAMA NEUROL, V73, P1407, DOI 10.1001/jamaneurol.2016.3720
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Donald CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005048
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Freshney R. I., 2005, CULTURE ANIMAL CELLS, P315
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868
   Kostyuchenko VA, 2016, NATURE, V533, P425, DOI 10.1038/nature17994
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Maramorosch K., 1994, ARTHROPOD CELL CULTU
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Nikolskaia OV, 2006, J CLIN INVEST, V116, P2739, DOI [10.1172/JC127798, 10.1172/JCI27798.]
   Nogueira ML, 2017, AM J TRANSPLANT, V17, DOI 10.1111/ajt.14047
   Nurk S, 2013, J COMPUT BIOL, V20, P714, DOI 10.1089/cmb.2013.0084
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Schmieder R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017288
   Schmieder R, 2011, BIOINFORMATICS, V27, P863, DOI 10.1093/bioinformatics/btr026
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Swaminathan S, 2016, NEW ENGL J MED, V375, P1907, DOI 10.1056/NEJMc1610613
   Tang WW, 2016, CELL REP, V17, P3091, DOI 10.1016/j.celrep.2016.11.070
   WAY HJ, 1976, J GEN VIROL, V30, P123, DOI 10.1099/0022-1317-30-1-123
   Weaver SC, 2016, ANTIVIR RES, V130, P69, DOI 10.1016/j.antiviral.2016.03.010
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zhang JJ, 2014, BIOINFORMATICS, V30, P614, DOI 10.1093/bioinformatics/btt593
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
NR 39
TC 25
Z9 25
U1 2
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD AUG
PY 2017
VL 246
BP 65
EP 74
DI 10.1016/j.jviromet.2017.04.011
PG 10
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA EY1PJ
UT WOS:000403737500011
PM 28445704
DA 2020-12-08
ER

PT J
AU Ribeiro, MR
   Moreli, JB
   Marques, RE
   Papa, MP
   Meuren, LM
   Rahal, P
   Arruda, LB
   Oliani, AH
   Oliani, DCMV
   Oliani, SM
   Narayanan, A
   Nogueira, ML
AF Ribeiro, M. R.
   Moreli, J. B.
   Marques, R. E.
   Papa, M. P.
   Meuren, L. M.
   Rahal, P.
   Arruda, L. B.
   Oliani, A. H.
   Oliani, D. C. M. V.
   Oliani, S. M.
   Narayanan, A.
   Nogueira, M. L.
TI STUDY OF ZIKA VIRUS INFECTION IN HUMAN PLACENTA EXPLANTS
SO PLACENTA
LA English
DT Meeting Abstract
CT Meeting of the
   Latin-American-Society-for-Maternal-Fetal-Interaction-and-Placenta
   (SLIMP)
CY APR 11-13, 2017
CL Puerto Varas, CHILE
SP Latin Amer Soc Maternal Fetal Interact & Placenta
C1 [Ribeiro, M. R.; Rahal, P.; Oliani, S. M.] Sao Paulo State Univ UNESP, Inst Biosci Letters & Exact Sci, Dept Biol, Sao Jose Do Rio Preto, SP, Brazil.
   [Moreli, J. B.] Univ Fed Sao Paulo UNIFESP, Sao Paulo, SP, Brazil.
   [Marques, R. E.] Natl Ctr Res Energy & Mat CNPEM, Brazilian Biosci Natl Lab LNBio, Campinas, SP, Brazil.
   [Papa, M. P.; Meuren, L. M.; Arruda, L. B.] Univ Fed Rio de Janeiro, Inst Microbiol, BR-21941 Rio De Janeiro, Brazil.
   [Narayanan, A.] George Mason Univ, Fairfax, VA 22030 USA.
   [Ribeiro, M. R.; Oliani, A. H.; Oliani, D. C. M. V.; Nogueira, M. L.] Fac Med Sao Jose do Rio Preto FAMERP, Lab Virol Res, Sao Jose Do Rio Preto, SP, Brazil.
RI Arruda, Luciana B/N-9086-2013; Nogueira, Mauricio L/B-7599-2012;
   Marques, Rafael Elias/R-4890-2016; OLIANI, ANTONIO/O-1673-2019
OI Nogueira, Mauricio L/0000-0003-1102-2419; Marques, Rafael
   Elias/0000-0002-6949-0947; 
NR 0
TC 0
Z9 0
U1 0
U2 7
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0143-4004
EI 1532-3102
J9 PLACENTA
JI Placenta
PD MAR
PY 2017
VL 51
BP 119
EP 120
DI 10.1016/j.placenta.2017.01.074
PG 2
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA ER2SZ
UT WOS:000398645400080
DA 2020-12-08
ER

PT J
AU Valadao, ALC
   Aguiar, RS
   de Arruda, LB
AF Valadao, Ana L. C.
   Aguiar, Renato S.
   de Arruda, Luciana B.
TI Interplay between Inflammation and Cellular Stress Triggered by
   Flaviviridae Viruses
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Review
DE flavivirus; innate immune response; ER stress; reactive oxygen species;
   stress granules
ID HEPATITIS-C VIRUS; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN
   RESPONSE; PATTERN-RECOGNITION RECEPTORS; IRF3 TRANSCRIPTION FACTOR;
   INNATE IMMUNE-RESPONSES; BETA GENE-EXPRESSION; TOLL-LIKE RECEPTOR-3;
   SPECK-LIKE PROTEIN; FACTOR-KAPPA-B
AB The Flaviviridae family comprises several human pathogens, including Dengue, Zika, Yellow Fever, West Nile, Japanese Encephalitis viruses, and Hepatitis C Virus. Those are enveloped, single-stranded positive sense RNA viruses, which replicate mostly in intracellular compartments associated to endoplasmic reticulum (ER) and Golgi complex. Virus replication results in abundant viral RNAs and proteins, which are recognized by cellular mechanisms evolved to prevent virus infection, resulting in inflammation and stress responses. Virus RNA molecules are sensed by Toll-like receptors (TLRs), RIG-I-like receptors (RIG-I and MDA5) and RNA-dependent protein kinases (PKR), inducing the production of inflammatory mediators and interferons. Simultaneously, the synthesis of virus RNA and proteins are distinguished in different compartments such as mitochondria, ER and cytoplasmic granules, triggering intracellular stress pathways, including oxidative stress, unfolded protein response pathway, and stress granules assembly. Here, we review the new findings that connect the inflammatory pathways to cellular stress sensors and the strategies of Flaviviridae members to counteract these cellular mechanisms and escape immune response.
C1 [Valadao, Ana L. C.; Aguiar, Renato S.] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil.
   [de Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Arruda, Luciana B/N-9086-2013; Aguiar, Renato S/G-3542-2015
OI Aguiar, Renato S/0000-0001-5180-3717
FU CAPESCAPES; CAPES/PVE-Program; CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX This work was supported by CAPES, CAPES/PVE-Program, CNPq, and FAPERJ.
   AV is the recipient of a FAPERJ fellowship.
CR Aguirre S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002934
   Albornoz A, 2014, J VIROL, V88, P6611, DOI 10.1128/JVI.03736-13
   Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082
   Anderson P, 2009, NAT REV MOL CELL BIO, V10, P430, DOI 10.1038/nrm2694
   Ariumi Y, 2011, J VIROL, V85, P6882, DOI 10.1128/JVI.02418-10
   Asdonk T, 2012, BIOCHEM BIOPH RES CO, V420, P66, DOI 10.1016/j.bbrc.2012.02.116
   Asehnoune K, 2004, J IMMUNOL, V172, P2522, DOI 10.4049/jimmunol.172.4.2522
   Ashour J, 2010, CELL HOST MICROBE, V8, P410, DOI 10.1016/j.chom.2010.10.007
   Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888
   Balagopal V, 2009, CURR OPIN CELL BIOL, V21, P403, DOI 10.1016/j.ceb.2009.03.005
   Banerjee S, 2014, MBIO, V5, DOI 10.1128/mBio.00856-14
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613
   Beckham CJ, 2008, CELL HOST MICROBE, V3, P206, DOI 10.1016/j.chom.2008.03.004
   Benali-Furet NL, 2005, ONCOGENE, V24, P4921, DOI 10.1038/sj.onc.1208673
   Bergqvist A, 2003, J BIOL CHEM, V278, P18877, DOI 10.1074/jbc.M300185200
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326
   Bidet K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004242
   Blazquez AB, 2014, FRONT MICROBIOL, V5, DOI [10.3389/fmicb.2014.00266, 10.3389/fmicb.2014.00797]
   Boo KH, 2010, YONSEI MED J, V51, P9, DOI 10.3349/ymj.2010.51.1.9
   Buchan JR, 2009, MOL CELL, V36, P932, DOI 10.1016/j.molcel.2009.11.020
   Chakrabarti A, 2012, J VIROL, V86, P11311, DOI 10.1128/JVI.00270-12
   Chan YK, 2015, CURR OPIN VIROL, V12, P7, DOI 10.1016/j.coviro.2015.01.004
   Chang TH, 2006, MICROBES INFECT, V8, P157, DOI 10.1016/j.micinf.2005.06.014
   Chattergoon MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004082
   Chattopadhyay S, 2010, EMBO J, V29, P1762, DOI 10.1038/emboj.2010.50
   Chen W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084953
   Choi JN, 2004, HEPATOLOGY, V39, P81, DOI 10.1002/hep.20001
   da Conceicao TM, 2013, VIROLOGY, V435, P281, DOI 10.1016/j.virol.2012.09.038
   Daffis S, 2008, J VIROL, V82, P10349, DOI 10.1128/JVI.00935-08
   Daito T, 2014, GASTROENTEROLOGY, V147, P463, DOI 10.1053/j.gastro.2014.04.035
   Dang SS, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-424
   Decembre E, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004434
   Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004
   Eckard SC, 2014, NAT IMMUNOL, V15, P839, DOI 10.1038/ni.2948
   Eksioglu EA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021186
   Emara MM, 2007, P NATL ACAD SCI USA, V104, P9041, DOI 10.1073/pnas.0703348104
   Fernandez-Garcia MD, 2009, CELL HOST MICROBE, V5, P318, DOI 10.1016/j.chom.2009.04.001
   Finnen RL, 2012, J VIROL, V86, P8119, DOI 10.1128/JVI.00313-12
   Fulda Simone, 2010, Int J Cell Biol, V2010, P214074, DOI 10.1155/2010/214074
   Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732
   Garaigorta U, 2012, J VIROL, V86, P11043, DOI 10.1128/JVI.07101-11
   Garaigorta U, 2009, CELL HOST MICROBE, V6, P513, DOI 10.1016/j.chom.2009.11.004
   Garcia-Mediavilla MV, 2005, J HEPATOL, V43, P606, DOI 10.1016/j.jhep.2005.04.019
   Garg AD, 2012, TRENDS MOL MED, V18, P589, DOI 10.1016/j.molmed.2012.06.010
   Gil L, 2004, AM J TROP MED HYG, V71, P652, DOI 10.4269/ajtmh.2004.71.652
   Gilfoy FD, 2007, J VIROL, V81, P11148, DOI 10.1128/JVI.00446-07
   Gillespie LK, 2010, J VIROL, V84, P10438, DOI 10.1128/JVI.00986-10
   Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023
   Gullberg RC, 2015, VIROLOGY, V475, P219, DOI 10.1016/j.virol.2014.10.037
   Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15
   Harijith A, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00352
   He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833
   He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108
   Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758
   Henao-Mejia J, 2012, NAT IMMUNOL, V13, P321, DOI 10.1038/ni.2257
   Hottz ED, 2013, BLOOD, V122, P3405, DOI 10.1182/blood-2013-05-504449
   Hsieh MJ, 2011, J CELL BIOCHEM, V112, P233, DOI 10.1002/jcb.22926
   Iglesias NG, 2009, VIRAL GENOME REPLICATION, P41, DOI 10.1007/b135974_3
   Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086
   Ishikawa H, 2008, NATURE, V456, P274, DOI 10.1038/nature07432
   Ivanov AV, 2015, VIRUSES-BASEL, V7, P2745, DOI 10.3390/v7062745
   Ivanov AV, 2013, VIRUSES-BASEL, V5, P439, DOI 10.3390/v5020439
   Ivanov AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024957
   Jain B, 2014, MICROB PATHOGENESIS, V69-70, P45, DOI 10.1016/j.micpath.2014.03.004
   Jiang X, 2013, IMMUNOL LETT, V152, P8, DOI 10.1016/j.imlet.2013.03.006
   Jiang XM, 2012, IMMUNITY, V36, P959, DOI 10.1016/j.immuni.2012.03.022
   Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734
   Katoh H, 2013, J VIROL, V87, P489, DOI 10.1128/JVI.02186-12
   Kaushik DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032270
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461
   Ke PY, 2012, VIRUSES-BASEL, V4, P2251, DOI 10.3390/v4102251
   Kedersha N, 2002, MOL BIOL CELL, V13, P195, DOI 10.1091/mbc.01-05-0221
   Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088
   Kedersha NL, 1999, J CELL BIOL, V147, P1431, DOI 10.1083/jcb.147.7.1431
   Kim HJ, 2015, AM J RESP CELL MOL, V53, P525, DOI 10.1165/rcmb.2014-0334OC
   Kim SK, 2015, PUBLIC MANAG REV, V17, P328, DOI 10.1080/14719037.2013.822530
   Klassen P, 2004, NUTRITION, V20, P542, DOI 10.1016/j.nut.2004.03.016
   Klomporn P, 2011, VIROLOGY, V409, P189, DOI 10.1016/j.virol.2010.10.010
   Kowalinski E, 2011, CELL, V147, P423, DOI 10.1016/j.cell.2011.09.039
   Kumar M, 2013, J VIROL, V87, P3655, DOI 10.1128/JVI.02667-12
   Labbe K, 2011, PROG INFLAMM RES SER, P17, DOI 10.1007/978-3-0348-0148-5_2
   Langereis MA, 2013, J VIROL, V87, P6314, DOI 10.1128/JVI.03213-12
   Lavut A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002527
   Lerner AG, 2012, CELL METAB, V16, P250, DOI 10.1016/j.cmet.2012.07.007
   Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200
   Li QS, 2013, NAT MED, V19, P722, DOI 10.1038/nm.3190
   Li W, 2002, J VIROL, V76, P11989, DOI 10.1128/JVI.76.23.11989-12000.2002
   Li YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070390
   Liao SL, 2002, NEUROSCI LETT, V324, P133, DOI 10.1016/S0304-3940(02)00236-7
   Lin SC, 2010, NATURE, V465, P885, DOI 10.1038/nature09121
   Lin YL, 2000, VIROLOGY, V276, P114, DOI 10.1006/viro.2000.0524
   Lipinski S, 2009, J CELL SCI, V122, P3522, DOI 10.1242/jcs.050690
   Liu JH, 2009, CELL HOST MICROBE, V5, P72, DOI 10.1016/j.chom.2008.11.008
   Liu YP, 2012, J IMMUNOL, V189, P4630, DOI 10.4049/jimmunol.1102737
   Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07
   Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7
   Lupfer C, 2015, CURR OPIN VIROL, V12, P38, DOI 10.1016/j.coviro.2015.02.007
   Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108
   Malathi K, 2010, RNA, V16, P2108, DOI 10.1261/rna.2244210
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Mazroui R, 2006, MOL BIOL CELL, V17, P4212, DOI 10.1091/mbc.E06-04-0318
   Medigeshi GR, 2007, J VIROL, V81, P10849, DOI 10.1128/JVI.01151-07
   Meier KC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000614
   Menu P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.132
   Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x
   Mittler R, 2011, TRENDS PLANT SCI, V16, P300, DOI 10.1016/j.tplants.2011.03.007
   Montero H, 2011, VIRUSES-BASEL, V3, P2328, DOI 10.3390/v3112328
   Motani K, 2011, J BIOL CHEM, V286, P33963, DOI 10.1074/jbc.M111.286823
   Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Munoz-Jordan JL, 2010, VIRUSES-BASEL, V2, P676, DOI 10.3390/v2020676
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nasirudeen AMA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000926
   Nazmi A, 2014, VIRUS RES, V185, P32, DOI 10.1016/j.virusres.2014.03.013
   Nazmi A, 2012, SCI REP-UK, V2, DOI 10.1038/srep00347
   Nazmi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021761
   Negash AA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003330
   O'Leary DP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044176
   Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983
   Olagnier D, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004566
   Olagnier D, 2014, J VIROL, V88, P4180, DOI 10.1128/JVI.03114-13
   Onomoto K, 2014, TRENDS IMMUNOL, V35, P420, DOI 10.1016/j.it.2014.07.006
   Onomoto K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043031
   Oshiumi H, 2010, CELL HOST MICROBE, V8, P496, DOI 10.1016/j.chom.2010.11.008
   Oshiumi H, 2009, J BIOL CHEM, V284, P807, DOI 10.1074/jbc.M804259200
   Pager CT, 2013, VIROLOGY, V435, P472, DOI 10.1016/j.virol.2012.10.027
   Pahl HL, 1997, TRENDS CELL BIOL, V7, P50, DOI 10.1016/S0962-8924(96)10050-7
   Pal S, 2010, J GASTROEN HEPATOL, V25, P627, DOI 10.1111/j.1440-1746.2009.06128.x
   Paracha UZ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-251
   Park HS, 2004, J IMMUNOL, V173, P3589, DOI 10.4049/jimmunol.173.6.3589
   Pena J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038202
   Perera-Lecoin Manuel, 2013, Viruses, V6, P69, DOI 10.3390/v6010069
   Pesne V, 2015, J VIROL, V89, P5462, DOI 10.1128/JVI.03197-14
   Pierson TC, 2013, CURR OPIN VIROL, V3, P3, DOI 10.1016/j.coviro.2012.12.001
   Pincus D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000415
   Piotrowska J, 2010, J VIROL, V84, P3654, DOI 10.1128/JVI.01320-09
   Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824
   Pothlichet J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003256
   Qin CF, 2011, MOL BIOL REP, V38, P3867, DOI 10.1007/s11033-010-0502-7
   Rahman MM, 2011, J VIROL, V85, P12505, DOI 10.1128/JVI.00410-11
   Rajput A, 2011, IMMUNITY, V34, P340, DOI 10.1016/j.immuni.2010.12.018
   Ramos HJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003039
   Reineke LC, 2013, VIROLOGY, V436, P255, DOI 10.1016/j.virol.2012.11.017
   Reshi Mohammad Latif, 2014, Int J Cell Biol, V2014, P467452, DOI 10.1155/2014/467452
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Ruggieri A, 2012, CELL HOST MICROBE, V12, P71, DOI 10.1016/j.chom.2012.05.013
   Saito T, 2008, NATURE, V454, P523, DOI 10.1038/nature07106
   Sakaguchi S, 2003, BIOCHEM BIOPH RES CO, V306, P860, DOI 10.1016/S0006-291X(03)01049-0
   SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994
   Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4
   Savic S, 2014, J AUTOIMMUN, V50, P59, DOI 10.1016/j.jaut.2013.11.002
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   Seet RCS, 2009, FREE RADICAL BIO MED, V47, P375, DOI 10.1016/j.freeradbiomed.2009.04.035
   Sen D, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00250
   Seronello S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027436
   Shen JS, 2005, MOL CELL BIOL, V25, P921, DOI 10.1128/MCB.25.3.921-932.2005
   Smit JM, 2011, VIRUSES-BASEL, V3, P160, DOI 10.3390/v3020160
   Smith JA, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00222
   Sou SN, 2012, BIOCHEM BIOPH RES CO, V420, P473, DOI 10.1016/j.bbrc.2012.03.030
   Soucy-Faulkner A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000930
   Soundravally R, 2008, ACTA TROP, V106, P156, DOI 10.1016/j.actatropica.2008.03.001
   Stawowczyk M, 2011, J BIOL CHEM, V286, P7257, DOI 10.1074/jbc.M110.207068
   Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005
   Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002
   Subramanian N, 2013, CELL, V153, P348, DOI 10.1016/j.cell.2013.02.054
   Sun PF, 2009, VIROLOGY, V383, P207, DOI 10.1016/j.virol.2008.10.022
   Sun WX, 2009, P NATL ACAD SCI USA, V106, P8653, DOI 10.1073/pnas.0900850106
   Szretter KJ, 2010, J VIROL, V84, P12125, DOI 10.1128/JVI.01026-10
   Takahashi K, 2006, J IMMUNOL, V176, P4520, DOI 10.4049/jimmunol.176.8.4520
   Takemura N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4492
   Tam AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045078
   Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002
   Thepparit Chutima, 2013, BMC Res Notes, V6, P372, DOI 10.1186/1756-0500-6-372
   Thoren F, 2004, J LEUKOCYTE BIOL, V76, P1180, DOI 10.1189/jlb.0704387
   Tsai WC, 2014, ANNU REV VIROL, V1, P147, DOI 10.1146/annurev-virology-031413-085505
   Tsai YT, 2009, CELL MICROBIOL, V11, P604, DOI 10.1111/j.1462-5822.2008.01277.x
   Umareddy I, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-91
   Valiente-Echeverria F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5819
   Valiente-Echeverria F, 2012, VIRUS RES, V169, P430, DOI 10.1016/j.virusres.2012.06.004
   Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009
   Vasallo C, 2015, VIRUS RES, V209, P100, DOI 10.1016/j.virusres.2015.03.013
   von Bernuth H, 2012, EUR J IMMUNOL, V42, P3126, DOI 10.1002/eji.201242683
   Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140
   Ward AM, 2011, RNA BIOL, V8, P1173, DOI 10.4161/rna.8.6.17836
   Weber C, 2008, PLANT J, V56, P517, DOI 10.1111/j.1365-313X.2008.03623.x
   White JP, 2012, TRENDS MICROBIOL, V20, P175, DOI 10.1016/j.tim.2012.02.001
   Williams KL, 2009, ANN NY ACAD SCI, V1171, pE12, DOI 10.1111/j.1749-6632.2009.05057.x
   Wu MF, 2013, BLOOD, V121, P95, DOI 10.1182/blood-2012-05-430090
   Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291
   Xu Z, 1998, J INTERF CYTOK RES, V18, P609, DOI 10.1089/jir.1998.18.609
   Yamaguchi A, 2005, DIGEST DIS SCI, V50, P1361, DOI 10.1007/s10620-005-2788-1
   Yang DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027552
   Yoo JS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004012
   Yoshida R, 2008, J BIOL CHEM, V283, P36211, DOI 10.1074/jbc.M806576200
   Yu CY, 2006, J VIROL, V80, P11868, DOI 10.1128/JVI.00879-06
   Yu CY, 2010, J VIROL, V84, P2421, DOI 10.1128/JVI.02174-09
   Zeng L, 2010, J IMMUNOL, V185, P2324, DOI 10.4049/jimmunol.0903052
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang LR, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00293
   Zhang PF, 2014, J CELL SCI, V127, P2471, DOI 10.1242/jcs.139626
   Zhong B, 2008, IMMUNITY, V29, P538, DOI 10.1016/j.immuni.2008.09.003
   Zhou H, 2013, EMBO J, V32, P583, DOI 10.1038/emboj.2013.2
   Zhou RB, 2011, NATURE, V475, DOI 10.1038/nature10156
   Zhu B, 2015, J IMMUNOL, V195, P2251, DOI 10.4049/jimmunol.1500370
   Zou J, 2013, IMMUNITY, V38, P717, DOI 10.1016/j.immuni.2012.12.007
NR 209
TC 25
Z9 26
U1 1
U2 24
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD AUG 25
PY 2016
VL 7
AR 1233
DI 10.3389/fmicb.2016.01233
PG 19
WC Microbiology
SC Microbiology
GA DT9VS
UT WOS:000381851000001
PM 27610098
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Lucas, CGDO
   Matassoli, FL
   Pecanha, LMT
   Santillo, BT
   Oliveira, LMD
   Oshiro, TM
   Marques, ETDA
   Oxenius, A
   de Arruda, LB
AF Lucas, Carolina G. D. O.
   Matassoli, Flavio L.
   Pecanha, Ligia M. T.
   Santillo, Bruna Tereso
   da Silva Oliveira, Luanda Mara
   Oshiro, Telma Miyuki
   Marques, Ernesto T. D. A., Jr.
   Oxenius, Annette
   de Arruda, Luciana B.
TI Dendritic cells primed with a chimeric plasmid containing HIV-1-gag
   associated with lysosomal-associated protein-1 (LAMP/gag) is a potential
   therapeutic vaccine against HIV
SO FASEB JOURNAL
LA English
DT Article
DE HIV immunotherapy; T-cell activation; dendritic cell vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REGULATORY T-CELLS; 1-INFECTED
   INDIVIDUALS; VIROLOGICAL RESPONSES; MEMBRANE PROTEIN-1; II COMPARTMENT;
   GAG; INFECTION; ELICITS; CD4(+)
AB The decline in number and function of T cells is a hallmark of HIV infection, and preservation or restoration of HIV-specific cellular immune response is a major goal of AIDS treatment. Dendritic cells (DCs) play a key role in the initiation and maintenance of the immune response, and their use as a vaccine vehicle is a promising strategy for enhancing vaccine efficacy. We evaluated the potential of DC-mediated immunization with a DNA vaccine consisting of HIV-1-p55gag (gag, group-specific antigen) associated to lysosomal associated protein (LAMP) sequence (LAMP/gag vaccine). Immunization of mice with mouse DCs transfected with LAMP/gag (Lg-mDCs) stimulated more potent B-and T-cell responses than naked DNA or DCs pulsed with inactivated HIV. Anti-Gag antibody levels were sustained for at least 3 mo after immunization, and recall T-cell responses were also strongly detected at this time point. Human DCs transfected with LAMP/gag (Lg-hDCs) were also activated and able to stimulate greater T-cell response than native gag-transfected DCs. Coculture between Lg-hDCs and T lymphocytes obtained from patients with HIV resulted in upregulation of CD38, CD69, HLA-DR, and granzyme B by CD4(+) and CD8(+) T cells, and increased IFN-gamma and TNF-alpha production. These results indicate that the use of LAMP/gag-DC may be an efficient strategy for enhancing immune function in patients with HIV.
C1 [Lucas, Carolina G. D. O.; Matassoli, Flavio L.; de Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Virol, Rio De Janeiro, Brazil.
   [Pecanha, Ligia M. T.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunol, Rio De Janeiro, Brazil.
   [Santillo, Bruna Tereso; da Silva Oliveira, Luanda Mara; Oshiro, Telma Miyuki] Univ Sao Paulo, Escola Med, Dept Dermatol, Lab Dermatol & Imunodeficiencias LIM 56, Sao Paulo, Brazil.
   [Santillo, Bruna Tereso; Oxenius, Annette] Swiss Fed Inst Technol, Inst Microbiol, Zurich, Switzerland.
   [Marques, Ernesto T. D. A., Jr.] Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [Marques, Ernesto T. D. A., Jr.] Fundacao Oswaldo Cruz Fiocruz Pernambuco, Ctr Pesquisas Aggeu Magalhaes CPqAM, Dept Virol, Recife, PE, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, CCS, Lab I SS 048, Bloco 1,Av Carlos Chagas Filho,377 Cidade Univ, BR-21941902 Rio De Janeiro, RJ, Brazil.
EM arruda@micro.ufrj.br
RI Marques, Ernesto T. A/L-4967-2013; Oshiro, Telma M/C-7152-2012; Arruda,
   Luciana B/N-9086-2013; Tereso Santillo, Bruna/P-6047-2016; da Silva
   Oliveira, Luanda Mara/E-7273-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Oshiro, Telma
   M/0000-0002-8791-9233; Tereso Santillo, Bruna/0000-0003-2851-1657; da
   Silva Oliveira, Luanda Mara/0000-0003-0903-8219; Lucas,
   Carolina/0000-0003-4590-2756
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES;
   Coordination for the Improvement of Higher Education Personnel)CAPES;
   CAPES/Programa Professor Visitante do Exterior-Ciencias sem Fronteiras
   (CAPES-Special Visiting Researcher, Science Without Borders program);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq;
   National Council for Scientific and Technological Development)National
   Council for Scientific and Technological Development (CNPq); Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ; Research Support Foundation of the State of Rio de Janeiro);
   Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [310030-113947]
FX The authors thank Dr. James K. Hildreth (University of California-Davis,
   Davis, CA, USA) and Dr. J. Thomas August (The Johns Hopkins School of
   Medicine, Baltimore, MD, USA) for kindly providing the anti-Gag M1 and
   anti-LAMP-2 antibodies, respectively; Dr. Helio Dutra [Instituto de
   Ciencias Biomedicas, Universidade Federal do Rio de Janeiro (UFRJ)] for
   helpful assistance with flow cytometry; and Joao Baltazar (Instituto de
   Microbiologia Paulo de Goes, UFRJ) for technical support. This work was
   supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES; Coordination for the Improvement of Higher Education Personnel),
   CAPES/Programa Professor Visitante do Exterior-Ciencias sem Fronteiras
   (CAPES-Special Visiting Researcher, Science Without Borders program),
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq;
   National Council for Scientific and Technological Development), Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   (FAPERJ; Research Support Foundation of the State of Rio de Janeiro),
   and the Swiss National Science Foundation Grant 310030-113947 (to A.O.).
   C.G.D.O.L. and F.L.M. were the recipients of FAPERJ and CAPES
   fellowships. The authors declare no conflicts of interest.
CR Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784
   Andres C, 2015, J VIROL, V89, P9189, DOI 10.1128/JVI.01062-15
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Ayinde D, 2015, J VIROL, V89, P6994, DOI 10.1128/JVI.00069-15
   Brandt L, 2011, JAIDS-J ACQ IMM DEF, V57, P101, DOI 10.1097/QAI.0b013e318215a991
   Breton G, 2013, J IMMUNOL, V191, P2194, DOI 10.4049/jimmunol.1200646
   Buisson S, 2009, J INFECT DIS, V199, P1862, DOI 10.1086/599122
   Chen Wei-Ti, 2013, J AIDS Clin Res, V4, P218
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Chun TW, 2010, AIDS, V24, P2803, DOI 10.1097/QAD.0b013e328340a239
   Connolly NC, 2008, CLIN VACCINE IMMUNOL, V15, P284, DOI 10.1128/CVI.00221-07
   Costiniuk CT, 2013, AIDS RES HUM RETROV, V29, P266, DOI [10.1089/aid.2011.0343, 10.1089/AID.2011.0343]
   Godinho RMD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099887
   Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115
   DCV2/MANON07-ORVACS Study Group, 2013, SCI TRANSL MED, V5
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Donaghy H, 2001, BLOOD, V98, P2574, DOI 10.1182/blood.V98.8.2574
   Erikstrup C, 2010, JAIDS-J ACQ IMM DEF, V53, P303, DOI 10.1097/QAI.0b013e3181ca3f7c
   Favre D, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000632
   Ferrando-Martinez S, 2012, J VIROL, V86, P3667, DOI 10.1128/JVI.07034-11
   Frank I, 2002, J VIROL, V76, P2936, DOI 10.1128/JVI.76.6.2936-2951.2002
   French MA, 2013, AIDS, V27, P519, DOI 10.1097/QAD.0b013e32835cb720
   Gandhi RT, 2002, ANNU REV MED, V53, P149, DOI 10.1146/annurev.med.53.082901.104011
   Garcia F, 1999, AIDS, V13, pF79, DOI 10.1097/00002030-199907300-00002
   Hel Z, 2002, J IMMUNOL, V169, P4778, DOI 10.4049/jimmunol.169.9.4778
   Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999
   Kalams SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029231
   Kaushik S, 2013, AIDS RES HUM RETROV, V29, P501, DOI [10.1089/aid.2012.0200, 10.1089/AID.2012.0200]
   Kim CJ, 2013, J IMMUNOL, V191, P2164, DOI 10.4049/jimmunol.1300829
   KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992
   Klatt NR, 2012, MUCOSAL IMMUNOL, V5, P646, DOI 10.1038/mi.2012.38
   Kovari H, 2013, CLIN INFECT DIS, V56, P870, DOI 10.1093/cid/cis919
   Krathwohl MD, 2006, J INFECT DIS, V193, P494, DOI 10.1086/499597
   Kulkarni V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111085
   Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117
   Levy Y, 2006, AIDS, V20, P405, DOI 10.1097/01.aids.0000206504.09159.d3
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Manel N, 2010, NATURE, V467, P214, DOI 10.1038/nature09337
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196
   Mishra S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097881
   Piketty C, 2001, J INFECT DIS, V183, P1328, DOI 10.1086/319861
   Presicce P, 2012, AIDS, V26, P263, DOI 10.1097/QAD.0b013e32834ed8df
   Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998
   Schenal M, 2005, AIDS, V19, P653, DOI 10.1097/01.aids.0000166088.85951.25
   Sciaranghella G, 2013, AIDS, V27, P175, DOI 10.1097/QAD.0b013e32835bd1f0
   Selvaraj A, 2013, PATHOG DIS, V69, P184, DOI 10.1111/2049-632X.12067
   Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
   Simon GG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008574
   Smed-Sorensen A, 2011, CURR OPIN HIV AIDS, V6, P405, DOI 10.1097/COH.0b013e328349b06b
   Tan RM, 2008, JAIDS-J ACQ IMM DEF, V47, P553, DOI 10.1097/QAI.0b013e31816856c5
   Turk G, 2013, J VIROL, V87, P7445, DOI 10.1128/JVI.00865-13
   Van Gulck E, 2012, AIDS, V26, pF1, DOI 10.1097/QAD.0b013e32834f33e8
   Wilgenhof S, 2011, J IMMUNOTHER, V34, P448, DOI 10.1097/CJI.0b013e31821dcb31
   Yonkers NL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023884
NR 55
TC 1
Z9 1
U1 0
U2 9
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2016
VL 30
IS 8
BP 2970
EP 2984
DI 10.1096/fj.201500059
PG 15
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA DS7WP
UT WOS:000380994000029
PM 27199296
DA 2020-12-08
ER

PT J
AU Correa, ARV
   Berbel, ACER
   Papa, MP
   de Morais, ATS
   Pecanha, LMT
   de Arruda, LB
AF Vargas Correa, Arturo Ramon
   Egypto Rosa Berbel, Ana Carolina
   Papa, Michelle Premazzi
   de Morais, Ana Theresa Silveira
   Torres Pecanha, Ligia Maria
   de Arruda, Luciana Barros
TI Dengue Virus Directly Stimulates Polyclonal B Cell Activation
SO PLOS ONE
LA English
DT Article
ID CROSS-REACTIVE ANTIBODIES; ORIGINAL ANTIGENIC SIN; PRINCIPAL
   TARGET-CELLS; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODIES;
   HEMORRHAGIC-FEVER; IMMUNE-RESPONSE; T-CELLS; INFECTION; PATHOGENESIS
AB Dengue infection is associated to vigorous inflammatory response, to a high frequency of activated B cells, and to increased levels of circulating cross-reactive antibodies. We investigated whether direct infection of B cells would promote activation by culturing primary human B lymphocytes from healthy donors with DENV in vitro. B cells were susceptible, but poorly permissive to infection. Even though, primary B cells cultured with DENV induced substantial IgM secretion, which is a hallmark of polyclonal B cell activation. Notably, DENV induced the activation of B cells obtained from either DENV immune or DENV naive donors, suggesting that it was not dependent on DENV-specific secondary/memory response. B cell stimulation was dependent on activation of MAPK and CD81. B cells cultured with DENV also secreted IL-6 and presented increased expression of CD86 and HLA-DR, which might contribute to B lymphocyte co-stimulatory function. Indeed, PBMCs, but not isolated B cells, secreted high amounts of IgG upon DENV culture, suggesting that interaction with other cell types in vivo might promote Ig isotype switching and IgG secretion from different B cell clones. These findings suggest that activation signaling pathways triggered by DENV interaction with non-specific receptors on B cells might contribute to the exacerbated response observed in dengue patients.
C1 [Vargas Correa, Arturo Ramon; Egypto Rosa Berbel, Ana Carolina; Papa, Michelle Premazzi; de Morais, Ana Theresa Silveira; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Paulo Goes, Rio De Janeiro, RJ, Brazil.
   [Torres Pecanha, Ligia Maria] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Paulo Goes, Rio De Janeiro, RJ, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Paulo Goes, Rio De Janeiro, RJ, Brazil.
EM arruda@micro.ufrj.br
RI Arruda, Luciana B/N-9086-2013
FU Brazilian Ministry of Health; CAPESCAPES; CNPqNational Council for
   Scientific and Technological Development (CNPq); FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); program INCT-Dengue; program Pronex-Rede Dengue; CAPES
   fellowshipCAPES; CNPq fellowshipNational Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by Brazilian Ministry of Health, CAPES, CNPq,
   FAPERJ, and by the programs INCT-Dengue and Pronex-Rede Dengue. A. C. E.
   R. Berbel was the recipient of a CAPES fellowship, A. R. V. Correa was
   the recipient of a FAPERJ and CAPES fellowship. A. T. S. Morais and M.
   P. Papa were the recipients of a CNPq fellowship. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Balakrishnan T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029430
   Beltramello M, 2010, CELL HOST MICROBE, V8, P271, DOI 10.1016/j.chom.2010.08.007
   Blackley S, 2007, J VIROL, V81, P13325, DOI 10.1128/JVI.01568-07
   BOONPUCKNAVIG S, 1976, AM J PATHOL, V85, P37
   Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9
   CHUNGUE E, 1994, J INFECT DIS, V170, P1304, DOI 10.1093/infdis/170.5.1304
   Conceicao TM, 2010, J VIROL METHODS, V163, P1, DOI 10.1016/j.jviromet.2009.10.001
   Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008
   de Alwis R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001188
   De Vita S, 2008, AUTOIMMUN REV, V8, P95, DOI 10.1016/j.autrev.2008.05.005
   DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X
   Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181
   DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0
   Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133
   Efremov DG, 2007, AUTOIMMUN REV, V7, P102, DOI 10.1016/j.autrev.2007.02.021
   Farquhar MJ, 2011, BIOCHEM SOC T, V39, P532, DOI 10.1042/BST0390532
   Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393
   FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.iy.13.040195.001015
   Friberg H, 2012, VIRAL IMMUNOL, V25, P348, DOI 10.1089/vim.2012.0010
   Garcia-Bates TM, 2013, J IMMUNOL, V190, P80, DOI 10.4049/jimmunol.1103350
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   HALSTEAD SB, 1977, NATURE, V265, P739, DOI 10.1038/265739a0
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P350
   Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kou Z, 2008, J MED VIROL, V80, P134, DOI 10.1002/jmv.21051
   Kurosaki T, 2002, NAT REV IMMUNOL, V2, P354, DOI 10.1038/nri801
   Kwissa M, 2014, CELL HOST MICROBE, V16, P115, DOI 10.1016/j.chom.2014.06.001
   Li XL, 2000, EUR J IMMUNOL, V30, P1576, DOI 10.1002/1521-4141(200006)30:6<1576::AID-IMMU1576>3.0.CO;2-0
   Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261
   Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt;143::AID-JMV1009&gt;3.0.CO;2-L
   Lin YS, 2004, CURR PHARM DESIGN, V10, P213, DOI 10.2174/1381612043453469
   Lin YW, 2002, J VIROL, V76, P12242, DOI 10.1128/JVI.76.23.12242-12249.2002
   Machida K, 2005, J VIROL, V79, P8079, DOI 10.1128/JVI.79.13.8079-8089.2005
   Machida K, 2008, J VIROL, V82, P6711, DOI 10.1128/JVI.02582-07
   Maddaly R, 2010, FEBS LETT, V584, P4883, DOI 10.1016/j.febslet.2010.08.022
   MARKOFF LJ, 1991, J INFECT DIS, V164, P294, DOI 10.1093/infdis/164.2.294
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407
   Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863
   Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453
   Rosa D, 2005, P NATL ACAD SCI USA, V102, P18544, DOI 10.1073/pnas.0509402102
   Rossbacher J, 2003, J EXP MED, V198, P591, DOI 10.1084/jem.20022042
   Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Schieffelin JS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-28
   Thai KTD, 2011, CLIN MICROBIOL INFEC, V17, P1823, DOI 10.1111/j.1469-0691.2010.03434.x
   THEOFILOPOULOS AN, 1976, J IMMUNOL, V117, P953
   Woods A, 2007, J VIROL, V81, P12525, DOI 10.1128/JVI.00839-07
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
NR 58
TC 10
Z9 11
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 10
PY 2015
VL 10
IS 12
AR e0143391
DI 10.1371/journal.pone.0143391
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CZ1YZ
UT WOS:000366903500003
PM 26656738
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Medaglia, MLG
   Moussatche, N
   Nitsche, A
   Dabrowski, PW
   Li, Y
   Damon, IK
   Lucas, CGO
   Arruda, LB
   Damaso, CR
AF Medaglia, Maria Luiza G.
   Moussatche, Nissin
   Nitsche, Andreas
   Dabrowski, Pjotr Wojtek
   Li, Yu
   Damon, Inger K.
   Lucas, Carolina G. O.
   Arruda, Luciana B.
   Damaso, Clarissa R.
TI Genomic Analysis, Phenotype, and Virulence of the Historical Brazilian
   Smallpox Vaccine Strain IOC: Implications for the Origins and
   Evolutionary Relationships of Vaccinia Virus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID COMPLEMENT-CONTROL PROTEIN; CANTAGALO VIRUS; PROTECTIVE EFFICACY;
   IMMUNE-RESPONSES; T-CELL; POXVIRUS; DRYVAX; IMMUNOGENICITY; INFECTION;
   ORTHOPOXVIRUS
AB Smallpox was declared eradicated in 1980 after an intensive vaccination program using different strains of vaccinia virus (VACV; Poxviridae). VACV strain IOC (VACV-IOC) was the seed strain of the smallpox vaccine manufactured by the major vaccine producer in Brazil during the smallpox eradication program. However, little is known about the biological and immunological features as well as the phylogenetic relationships of this first-generation vaccine. In this work, we present a comprehensive characterization of two clones of VACV-IOC. Both clones had low virulence in infected mice and induced a protective immune response against a lethal infection comparable to the response of the licensed vaccine ACAM2000 and the parental strain VACV-IOC. Full-genome sequencing revealed the presence of several fragmented virulence genes that probably are nonfunctional, e.g., F1L, B13R, C10L, K3L, and C3L. Most notably, phylogenetic inference supported by the structural analysis of the genome ends provides evidence of a novel, independent cluster in VACV phylogeny formed by VACV-IOC, the Brazilian field strains Cantagalo (CTGV) and Serro 2 viruses, and horsepox virus, a VACV-like virus supposedly related to an ancestor of the VACV lineage. Our data strongly support the hypothesis that CTGV-like viruses represent feral VACV that evolved in parallel with VACV-IOC after splitting from a most recent common ancestor, probably an ancient smallpox vaccine strain related to horsepox virus. Our data, together with an interesting historical investigation, revisit the origins of VACV and propose new evolutionary relationships between ancient and extant VACV strains, mainly horsepox virus, VACV-IOC/CTGV-like viruses, and Dryvax strain.
   IMPORTANCE
   First-generation vaccines used to eradicate smallpox had rates of adverse effects that are not acceptable by current health care standards. Moreover, these vaccines are genetically heterogeneous and consist of a pool of quasispecies of VACV. Therefore, the search for new-generation smallpox vaccines that combine low pathogenicity, immune protection, and genetic homogeneity is extremely important. In addition, the phylogenetic relationships and origins of VACV strains are quite nebulous. We show the characterization of two clones of VACV-IOC, a unique smallpox vaccine strain that contributed to smallpox eradication in Brazil. The immunogenicity and reduced virulence make the IOC clones good options for alternative second-generation smallpox vaccines. More importantly, this study reveals the phylogenetic relationship between VACV-IOC, feral VACV established in nature, and the ancestor-like horsepox virus. Our data expand the discussion on the origins and evolutionary connections of VACV lineages.
C1 [Medaglia, Maria Luiza G.; Damaso, Clarissa R.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Biol Mol Virus, Rio De Janeiro, Brazil.
   [Moussatche, Nissin] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA.
   [Nitsche, Andreas; Dabrowski, Pjotr Wojtek] Robert Koch Inst, Ctr Biol Threats & Special Pathogens, Berlin, Germany.
   [Li, Yu; Damon, Inger K.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot, Atlanta, GA USA.
   [Lucas, Carolina G. O.; Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, Brazil.
RP Damaso, CR (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Biol Mol Virus, Rio De Janeiro, Brazil.
EM damasoc@biof.ufrj.br
RI Arruda, Luciana B/N-9086-2013; Damaso, Clarissa R/F-7737-2012;
   Moussatche, Nissin/W-1024-2019; Dabrowski, Piotr Wojtek/L-1423-2015
OI Damaso, Clarissa R/0000-0001-6299-2816; Lucas,
   Carolina/0000-0003-4590-2756; Dabrowski, Piotr
   Wojtek/0000-0003-4893-805X
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FaperjCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ); CAPESCAPES; Ministerio da Defesa
FX This work was supported by grants from CNPq, Faperj, CAPES, and
   Ministerio da Defesa to C.R.D. M.L.G.M. was the recipient of a
   fellowship from CNPq and is the recipient of a fellowship from Faperj.
   C.G.O.L. is the recipient of a Faperj fellowship; C.R.D. is the
   recipient of a research fellowship from CNPq.
CR Afonso PP, 2012, J VIROL, V86, P5039, DOI 10.1128/JVI.07162-11
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Barbosa AV, 2014, J INFECT DEV COUNTR, V8, P1646, DOI 10.3855/jidc.5216
   Baxby D, 1996, SOC HIST MED, V9, P117, DOI 10.1093/shm/9.1.117
   BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8
   Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100
   Berhanu A, 2010, VACCINE, V29, P289, DOI 10.1016/j.vaccine.2010.10.039
   Copeman SM, 1899, VACCINATION ITS NATU
   Crookshank EM, 1889, HIST PATHOLOGY VACCI
   Damaso CRA, 2000, VIROLOGY, V277, P439, DOI 10.1006/viro.2000.0603
   Damon IK, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004108
   Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075
   Edwardes E.J., 1902, CONCISE HIST SMALL P
   Fenner F, 1988, SMALLPOX ITS ERADICA
   Fernandes TM., 1999, VACINA ANTIVARIOLICA
   Ferrier-Rembert A, 2007, VACCINE, V25, P8290, DOI 10.1016/j.vaccine.2007.09.050
   Foster FP., 1872, BOARD TRUST FP FOST
   Garcel A, 2009, VACCINE, V27, P708, DOI 10.1016/j.vaccine.2008.11.063
   Girgis NM, 2008, J VIROL, V82, P4205, DOI 10.1128/JVI.02426-07
   Gordon SN, 2011, J INFECT DIS, V203, P1043, DOI 10.1093/infdis/jiq162
   Grosenbach DW, 2008, VACCINE, V26, P933, DOI 10.1016/j.vaccine.2007.11.095
   Hochman G, 2009, MED HIST, V53, P229, DOI 10.1017/S002572730000020X
   ISAACS SN, 1992, P NATL ACAD SCI USA, V89, P628, DOI 10.1073/pnas.89.2.628
   Jacobs BL, 2009, ANTIVIR RES, V84, P1, DOI 10.1016/j.antiviral.2009.06.006
   Jentarra GM, 2008, VACCINE, V26, P2860, DOI 10.1016/j.vaccine.2008.03.044
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Leite JA, 2005, EMERG INFECT DIS, V11, P1935, DOI 10.3201/eid1112.050773
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Lindsley CA, 1882, VACCINATION THE CASE
   MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Medaglia MLG, 2009, EMERG INFECT DIS, V15, P1142, DOI 10.3201/eid1507.081702
   Meseda CA, 2005, VIROLOGY, V339, P164, DOI 10.1016/j.virol.2005.06.002
   Meseda CA, 2009, CLIN VACCINE IMMUNOL, V16, P1261, DOI 10.1128/CVI.00040-09
   Monath TP, 2004, INT J INFECT DIS, V8, pS31, DOI 10.1016/j.ijid.2004.09.002
   Moss B, 2011, IMMUNOL REV, V239, P8, DOI 10.1111/j.1600-065X.2010.00975.x
   MOUSSATCHE N, 1991, J VIROL, V65, P2555, DOI 10.1128/JVI.65.5.2555-2561.1991
   Moussatche N, 2008, J INFECT DEV COUNTR, V2, P156, DOI 10.3855/jidc.258
   National Research Council, 2011, GUIDE CARE USE LAB A
   NYCBH, 1876, 5 6 ANN REP BOARD HL, V1874/1875
   NYCBH, 1872, 2 ANN REP BOARD HLTH, V1871/1872
   Osborne JD, 2007, VACCINE, V25, P8807, DOI 10.1016/j.vaccine.2007.10.040
   Palmer S, 2010, HIST CIENC SAUDE-MAN, V17, P777, DOI 10.1590/S0104-59702010000300012
   Panchanathan V, 2010, IMMUNOL CELL BIOL, V88, P461, DOI 10.1038/icb.2009.110
   Perdiguero B, 2009, J INTERF CYTOK RES, V29, P581, DOI 10.1089/jir.2009.0073
   Peters NE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003649
   Precopio ML, 2007, J EXP MED, V204, P1405, DOI 10.1084/jem.20062363
   Puissant-Lubrano B, 2010, J CLIN INVEST, V120, P1636, DOI 10.1172/JCI38506
   Qin L, 2015, J VIROL, V89, P1809, DOI 10.1128/JVI.02797-14
   Qin L, 2013, VIROLOGY, V442, P59, DOI 10.1016/j.virol.2013.03.025
   Qin L, 2011, J VIROL, V85, P13049, DOI 10.1128/JVI.05779-11
   Quixabeira-Santos JC, 2011, EMERG INFECT DIS, V17, P726, DOI 10.3201/eid1704.101581
   Rice AD, 2011, J VIROL, V85, P550, DOI 10.1128/JVI.00254-10
   Rutty C., 2008, CRAFTING IMMUNITY WO, P280
   Sanchez-Sampedro L, 2015, VIRUSES-BASEL, V7, P1726, DOI 10.3390/v7041726
   Santos-Fernandes E, 2013, ANTIVIR RES, V97, P301, DOI 10.1016/j.antiviral.2012.11.010
   Sharon M, 2007, VACCINE, V25, P7743, DOI 10.1016/j.vaccine.2007.09.023
   Shchelkunov SN, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003756
   Ferreira JMS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003043
   Smith GL, 2004, VIRUS RES, V106, P189, DOI 10.1016/j.virusres.2004.08.015
   Smithson C, 2014, COMPUTATION, V2, P182, DOI 10.3390/computation2040182
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Taylor JM, 2006, J BIOL CHEM, V281, P39728, DOI 10.1074/jbc.M607465200
   Tcherepanov V, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-150
   Teixeira LA, 2003, HIST CIENC SAUDE-MAN, V10, P23
   Trindade GS, 2009, CLIN INFECT DIS, V48, pE37, DOI 10.1086/595856
   Tulman ER, 2006, J VIROL, V80, P9244, DOI 10.1128/JVI.00945-06
   VELLINI L L, 1953, Hospital (Rio J), V44, P247
   Willrich M., 2011, POX AM HIST
   Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265
   Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107
   Zhai DY, 2010, J BIOL CHEM, V285, P5569, DOI 10.1074/jbc.M109.078113
   Zhang Q, 2013, PLOS ONE, P8
NR 73
TC 16
Z9 17
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD DEC
PY 2015
VL 89
IS 23
BP 11909
EP 11925
DI 10.1128/JVI.01833-15
PG 17
WC Virology
SC Virology
GA CZ1WM
UT WOS:000366896600015
PM 26378174
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Godinho, RMD
   Matassoli, FL
   Lucas, CGD
   Rigato, PO
   Goncalves, JLS
   Sato, MN
   Maciel, M
   Pecanha, LMT
   August, JT
   Marques, ETA
   de Arruda, LB
AF da Costa Godinho, Rodrigo Maciel
   Matassoli, Flavio Lemos
   de Oliveira Lucas, Carolina Goncalves
   Rigato, Paula Ordonhez
   Santos Goncalves, Jorge Luiz
   Sato, Maria Notomi
   Maciel, Milton, Jr.
   Torres Pecanha, Ligia Maria
   Thomas August, J.
   de Azevedo Marques, Ernesto Torres, Jr.
   de Arruda, Luciana Barros
TI Regulation of HIV-Gag Expression and Targeting to the
   Endolysosomal/Secretory Pathway by the Luminal Domain of
   Lysosomal-Associated Membrane Protein (LAMP-1) Enhance Gag-Specific
   Immune Response
SO PLOS ONE
LA English
DT Article
ID T-CELL RESPONSES; VIRUS TYPE-1 GAG; CLASS-II COMPARTMENT; MHC CLASS-I;
   DNA VACCINATION; LYMPHOCYTE RESPONSES; ANTIGEN PRESENTATION; CODON
   USAGE; LONGITUDINAL ANALYSIS; ELITE CONTROLLERS
AB We have previously demonstrated that a DNA vaccine encoding HIV-p55gag in association with the lysosomal associated membrane protein-1 (LAMP-1) elicited a greater Gag-specific immune response, in comparison to a DNA encoding the native gag. In vitro studies have also demonstrated that LAMP/Gag was highly expressed and was present in MHCII containing compartments in transfected cells. In this study, the mechanisms involved in these processes and the relative contributions of the increased expression and altered traffic for the enhanced immune response were addressed. Cells transfected with plasmid DNA constructs containing p55gag attached to truncated sequences of LAMP-1 showed that the increased expression of gag mRNA required p55gag in frame with at least 741 bp of the LAMP-1 luminal domain. LAMP luminal domain also showed to be essential for Gag traffic through lysosomes and, in this case, the whole sequence was required. Further analysis of the trafficking pathway of the intact LAMP/Gag chimera demonstrated that it was secreted, at least in part, associated with exosome-like vesicles. Immunization of mice with LAMP/gag chimeric plasmids demonstrated that high expression level alone can induce a substantial transient antibody response, but targeting of the antigen to the endolysosomal/secretory pathways was required for establishment of cellular and memory response. The intact LAMP/gag construct induced polyfunctional CD4(+) T cell response, which presence at the time of immunization was required for CD8(+) T cell priming. LAMP-mediated targeting to endolysosomal/secretory pathway is an important new mechanistic element in LAMP-mediated enhanced immunity with applications to the development of novel anti-HIV vaccines and to general vaccinology field.
C1 [da Costa Godinho, Rodrigo Maciel; Matassoli, Flavio Lemos; de Oliveira Lucas, Carolina Goncalves; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, Brazil.
   [Rigato, Paula Ordonhez; Sato, Maria Notomi] Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Dermatol Imunodeficiencias,LIM 56, Sao Paulo, Brazil.
   [Santos Goncalves, Jorge Luiz; Torres Pecanha, Ligia Maria] Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Imunol, Rio De Janeiro, Brazil.
   [Maciel, Milton, Jr.] Naval Med Res Ctr, Infect Dis Directorate, Enter Dis Dept, Silver Spring, MD USA.
   [Maciel, Milton, Jr.; Thomas August, J.; de Azevedo Marques, Ernesto Torres, Jr.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD USA.
   [de Azevedo Marques, Ernesto Torres, Jr.] Ctr Vaccine Res, Dept Infect Dis & Microbiol, Pittsburgh, PA USA.
   [de Azevedo Marques, Ernesto Torres, Jr.] Fiocruz Pernambuco, Dept Virol, Recife, PE, Brazil.
RP de Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Dept Virol, Rio De Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Marques, Ernesto T. A/L-4967-2013; Ordonhez Rigato, Paula/J-3618-2012;
   Arruda, Luciana B/N-9086-2013; Godinho, Rodrigo/G-5135-2015; Sato, Maria
   N/C-1196-2012; iMed.ULisboa, M2B/B-5277-2014; Sato, Maria N/C-2853-2012
OI Marques, Ernesto T. A/0000-0003-3826-9358; Sato, Maria
   N/0000-0002-7911-1824; iMed.ULisboa, M2B/0000-0002-1245-3715; Lucas,
   Carolina/0000-0003-4590-2756
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R37-AI41908, R21-AI44317];
   Brazilian Ministry of Health; CAPESCAPES; CNPqNational Council for
   Scientific and Technological Development (CNPq); FAPERJCarlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); FINEPCiencia Tecnologia e Inovacao (FINEP); NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R21AI044317,
   R21AI044317] Funding Source: NIH RePORTER
FX This work was supported by Grants R37-AI41908 and R21-AI44317 from the
   National Institute of Allergy and Infectious Diseases, National
   Institutes of Health; and by Brazilian Ministry of Health, CAPES, CNPq,
   FAPERJ, and FINEP. R. M. C. Godinho and F. L. Matassoli were the
   recipients of a CNPq fellowship; C.G.O. Lucas was the recipient of a
   FAPERJ fellowship. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], MOL IMMUNOL, V47, P1507
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   Bazhan SI, 2010, MOL IMMUNOL, V47, P1507, DOI 10.1016/j.molimm.2010.01.020
   Bertoletti A, 1998, J VIROL, V72, P2439, DOI 10.1128/JVI.72.3.2439-2448.1998
   Bivas-Benita M, 2013, MUCOSAL IMMUNOL, V6, P156, DOI 10.1038/mi.2012.59
   Bockl K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034723
   Bojak A, 2002, INTERVIROLOGY, V45, P275, DOI 10.1159/000067919
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8
   Chikhlikar P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000135
   Clayton A, 2005, J CELL SCI, V118, P3631, DOI 10.1242/jcs.02494
   COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Delcayre A, 2005, BLOOD CELL MOL DIS, V35, P158, DOI 10.1016/j.bcmd.2005.07.003
   Deml L, 2001, J VIROL, V75, P10991, DOI 10.1128/JVI.75.22.10991-11001.2001
   Denzer K, 2000, J CELL SCI, V113, P3365
   DUBEY C, 1995, J IMMUNOL, V155, P45
   Durali D, 1998, J VIROL, V72, P3547, DOI 10.1128/JVI.72.5.3547-3553.1998
   Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121
   FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495
   Ferre AL, 2010, J VIROL, V84, P11020, DOI 10.1128/JVI.00980-10
   Ferre AL, 2010, J VIROL, V84, P10354, DOI 10.1128/JVI.00803-10
   Ferre AL, 2009, BLOOD, V113, P3978, DOI 10.1182/blood-2008-10-182709
   Fu TM, 1997, MOL MED, V3, P362, DOI 10.1007/BF03401683
   Fuller DH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033715
   Graf M, 2000, J VIROL, V74, P10822, DOI 10.1128/JVI.74.22.10822-10826.2000
   Hartman ZC, 2011, VACCINE, V29, P9361, DOI 10.1016/j.vaccine.2011.09.133
   Kaur M, 2009, VACCINE, V27, P2128, DOI 10.1016/j.vaccine.2009.01.128
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Langlade-Demoyen P, 2003, EUR J IMMUNOL, V33, P720, DOI 10.1002/eji.200323287
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   Midha S, 2009, EUR J IMMUNOL, V39, P159, DOI 10.1002/eji.200838058
   Nanjundappa RH, 2012, VACCINE, V30, P3519, DOI 10.1016/j.vaccine.2012.03.075
   Nanjundappa RH, 2011, VACCINE, V29, P3538, DOI 10.1016/j.vaccine.2011.02.095
   Ngumbela KC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002356
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Owen RE, 2010, AIDS, V24, P1095, DOI 10.1097/QAD.0b013e3283377a1e
   Pissani F, 2012, VACCINE, V30, P5519, DOI 10.1016/j.vaccine.2012.06.042
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491
   Pontesilli O, 1998, J INFECT DIS, V178, P1008, DOI 10.1086/515659
   Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075
   Qiu JT, 2000, J VIROL, V74, P5997, DOI 10.1128/JVI.74.13.5997-6005.2000
   Qiu JT, 1999, J VIROL, V73, P9145, DOI 10.1128/JVI.73.11.9145-9152.1999
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Schliehe C, 2012, J VIROL, V86, P9782, DOI 10.1128/JVI.00694-12
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   SCHWARTZ S, 1992, J VIROL, V66, P7176, DOI 10.1128/JVI.66.12.7176-7182.1992
   Shedlock DJ, 2000, J LEUKOCYTE BIOL, V68, P793
   Stober D, 2002, EUR J IMMUNOL, V32, P1099, DOI 10.1002/1521-4141(200204)32:4<1099::AID-IMMU1099>3.3.CO;2-#
   Sui YJ, 2010, P NATL ACAD SCI USA, V107, P9843, DOI 10.1073/pnas.0911932107
   Thakur A, 2012, VACCINE, V30, P4907, DOI 10.1016/j.vaccine.2012.05.049
   Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Vaccari M, 2005, J IMMUNOL, V175, P3502, DOI 10.4049/jimmunol.175.6.3502
   Vargas-Inchaustegui DA, 2012, J IMMUNOL, V189, P1878, DOI 10.4049/jimmunol.1201026
   Wang QM, 2012, DNA CELL BIOL, V31, P489, DOI 10.1089/dna.2011.1309
   Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438
   Zhang HF, 2011, CELL MOL IMMUNOL, V8, P23, DOI 10.1038/cmi.2010.59
   Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594
NR 67
TC 9
Z9 9
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 16
PY 2014
VL 9
IS 6
AR e99887
DI 10.1371/journal.pone.0099887
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AJ5PV
UT WOS:000337738600077
PM 24932692
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Lima, TFA
   Rocha, JDB
   Guimaraes-Costa, AB
   Barbosa, JM
   Decote-Ricardo, D
   Saraiva, EM
   Arruda, LB
   Piuvezam, MR
   Pecanha, LMT
AF Lima, Thaline F. A.
   Rocha, Juliana D. B.
   Guimaraes-Costa, Anderson B.
   Barbosa-Filho, Jose M.
   Decote-Ricardo, Debora
   Saraiva, Elvira M.
   Arruda, Luciana B.
   Piuvezam, Marcia R.
   Pecanha, Ligia M. T.
TI Warifteine, an Alkaloid Purified from Cissampelos sympodialis, Inhibits
   Neutrophil Migration In Vitro and In Vivo
SO JOURNAL OF IMMUNOLOGY RESEARCH
LA English
DT Article
ID B-LYMPHOCYTE FUNCTION; EXTRACELLULAR TRAPS; INFLAMMATORY CYTOKINES;
   TETRANDRINE; EICHL; MENISPERMACEAE; BERBAMINE; EXTRACT; PATHWAY; ASSAY
AB Cissampelos sympodialis Eichl is a plant fromthe Northeast and Southeast of Brazil. Its root infusion is popularly used for treatment of inflammatory and allergic diseases. We investigated whether warifteine, its main alkaloid, would have anti-inflammatory effect due to a blockage of neutrophil function. In vivo warifteine treatment inhibited casein-induced neutrophil migration to the peritoneal cavity but did not inhibit neutrophil mobilization from the bone marrow. Analysis of the direct effect of warifteine upon neutrophil adherence and migration in vitro demonstrated that the alkaloid decreased cell adhesion to P and E-selectin-transfected cells. In addition, fLMP-induced neutrophil migration in a transwell system was blocked by warifteine; this effect was mimicked by cAMP mimetic/inducing substances, and warifteine increased intracellular cAMP levels in neutrophils. The production of DNA extracellular traps (NETs) was also blocked by warifteine but there was no alteration on PMA-induced oxidative burst or LPS-stimulated TNF alpha secretion. Taken together, our data indicate that the alkaloid warifteine is a potent anti-inflammatory substance and that it has an effect on neutrophil migration through a decrease in both cell adhesion and migration.
C1 [Lima, Thaline F. A.; Rocha, Juliana D. B.; Guimaraes-Costa, Anderson B.; Saraiva, Elvira M.; Pecanha, Ligia M. T.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, CCS, BR-21944570 Rio De Janeiro, RJ, Brazil.
   [Barbosa-Filho, Jose M.; Piuvezam, Marcia R.] Univ Fed Paraiba, Dept Fisiol & Patol, BR-58051970 Joao Pessoa, PB, Brazil.
   [Decote-Ricardo, Debora] Univ Fed Rural Rio de Janeiro, Inst Vet, BR-23890000 Seropedica, RJ, Brazil.
   [Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Dept Virol, BR-21944570 Rio De Janeiro, RJ, Brazil.
RP Pecanha, LMT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, CCS, Bloco 1,Sala I2-062, BR-21944570 Rio De Janeiro, RJ, Brazil.
EM lpecanha@micro.ufrj.br
RI Filho, Jose Maria Barbosa/B-3951-2010; Decote-Ricardo,
   Debora/O-6480-2019; Costa, Anderson G. B./K-1059-2012; Arruda, Luciana
   B/N-9086-2013; Saraiva, Elvira M/L-2864-2017
OI Filho, Jose Maria Barbosa/0000-0002-9567-4096; Costa, Anderson G.
   B./0000-0003-4582-1980; Saraiva, Elvira M/0000-0002-6388-5286;
   Abdelwahab, Hanan/0000-0003-3995-164X
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); PRONEX-MCT; PUC/PETROBRAS; FAPERJCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ);
   CAPES/MECCAPES
FX This research was supported by CNPq, PRONEX-MCT, PUC/PETROBRAS, and
   FAPERJ. Thaline F. A. Lima and Juliana D. B. Rocha were recipients of
   the CNPq and CAPES/MEC fellowships, respectively. The authors are
   indebted to Mr. Sidney Gomes da Costa for the technical support. The
   authors thank Dr. Leonardo Nimrichter for providing the CHO-transfected
   cells, Dr. Adriana Bonomo for supplying the anti-Gr1 antibody, and Dr.
   Marcelo Bozza for providing the ROS detection probe.
CR Alexandre-Moreira MS, 2003, BRAZ J MED BIOL RES, V36, P1511, DOI 10.1590/S0100-879X2003001100010
   Alexandre-Moreira MS, 2003, BRAZ J MED BIOL RES, V36, P199, DOI 10.1590/S0100-879X2003000200006
   Anderson R, 1998, BRIT J PHARMACOL, V124, P547, DOI 10.1038/sj.bjp.0701849
   Barbosa-Filho Jose M., 1997, Ciencia e Cultura (Sao Paulo), V49, P386
   Batista-Lima Karla V., 2001, Acta Farmaceutica Bonaerense, V20, P275
   Bezerra-Santos CR, 2006, INT IMMUNOPHARMACOL, V6, P1152, DOI 10.1016/j.intimp.2006.02.007
   Bezerra-Santos CR, 2012, INT IMMUNOPHARMACOL, V13, P148, DOI 10.1016/j.intimp.2012.03.014
   Bezerra-Santos CR, 2004, J ETHNOPHARMACOL, V95, P191, DOI 10.1016/j.jep.2004.06.037
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Brinkmann V, 2012, J CELL BIOL, V198, P773, DOI 10.1083/jcb.201203170
   Correa M. P., 1984, DICIONARIO PLANTAS U
   Cortes SF, 1995, PHYTOTHER RES, V9, P579
   Costa HF, 2008, INT IMMUNOPHARMACOL, V8, P519, DOI 10.1016/j.intimp.2007.11.009
   Costa HF, 2013, INT IMMUNOPHARMACOL, V17, P300, DOI 10.1016/j.intimp.2013.05.024
   Cui BB, 2012, AUTOIMMUNITY, V45, P593, DOI 10.3109/08916934.2012.719952
   Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5
   de Lira GA, 2002, FITOTERAPIA, V73, P356, DOI 10.1016/S0367-326X(02)00089-8
   DeFreitas MR, 1996, J PHARM PHARMACOL, V48, P332, DOI 10.1111/j.2042-7158.1996.tb05928.x
   DEVI S, 1995, J IMMUNOL, V154, P5376
   Dworski R, 2011, J ALLERGY CLIN IMMUN, V127, P1260, DOI 10.1016/j.jaci.2010.12.1103
   Etzioni A, 2010, CLIN REV ALLERG IMMU, V38, P54, DOI 10.1007/s12016-009-8132-3
   Fang QZ, 2004, ACTA PHARMACOL SIN, V25, P327
   Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027
   Furie B, 1996, HAEMOSTASIS, V26, P60
   Furze RC, 2008, IMMUNOLOGY, V125, P281, DOI 10.1111/j.1365-2567.2008.02950.x
   GILMAN AG, 1970, P NATL ACAD SCI USA, V67, P305, DOI 10.1073/pnas.67.1.305
   Guimaraes-Costa Anderson B, 2012, J Parasitol Res, V2012, P929743, DOI 10.1155/2012/929743
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   He FQ, 2011, INT IMMUNOPHARMACOL, V11, P1220, DOI 10.1016/j.intimp.2011.03.023
   Herter J, 2013, J IMMUNOL, V190, P4451, DOI 10.4049/jimmunol.1203179
   Ho LJ, 2004, BRIT J PHARMACOL, V143, P919, DOI 10.1038/sj.bjp.0706000
   Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719
   Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301
   Lai JH, 2002, ACTA PHARMACOL SIN, V23, P1093
   LI SY, 1989, INT J IMMUNOPHARMACO, V11, P395
   Luo Y, 2001, CURRENT PROTOCOLS IM, V3, P20
   Melo PS, 2003, TOXICOL LETT, V142, P143, DOI 10.1016/S0378-4274(03)00064-X
   Neeli I, 2008, J IMMUNOL, V180, P1895, DOI 10.4049/jimmunol.180.3.1895
   Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052
   Piuvezam M. R., ALLERGIC DIS HIGHLIG, V51000
   Piuvezam MR, 1999, J ETHNOPHARMACOL, V67, P93, DOI 10.1016/S0378-8741(98)00235-9
   Ren YP, 2008, J IMMUNOL, V181, P1491, DOI 10.4049/jimmunol.181.2.1491
   Rocha JDB, 2010, PLANTA MED, V76, P325, DOI 10.1055/s-0029-1186165
   ROEHM NW, 1991, J IMMUNOL METHODS, V142, P257, DOI 10.1016/0022-1759(91)90114-U
   Saffarzadeh M, 2013, CURR OPIN HEMATOL, V20, P3, DOI 10.1097/MOH.0b013e32835a0025
   Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015
   SEOW WK, 1992, LIFE SCI, V50, pPL53, DOI 10.1016/0024-3205(92)90373-W
   SEOW WK, 1986, IMMUNOL LETT, V13, P83, DOI 10.1016/0165-2478(86)90131-8
   Simon D, 2013, ALLERGY, V68, P409, DOI 10.1111/all.12111
   Smith CW, 2008, J ALLERGY CLIN IMMUN, V121, pS375, DOI 10.1016/j.jaci.2007.07.030
   Tansho S, 1999, MICROBIOL IMMUNOL, V43, P235, DOI 10.1111/j.1348-0421.1999.tb02398.x
   Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639
   Van Epps D E, 1977, Inflammation, V2, P115, DOI 10.1007/BF00918673
   Varella MH, 1999, J NEUROCHEM, V73, P485, DOI 10.1046/j.1471-4159.1999.0730485.x
   Wang YM, 2009, J CELL BIOL, V184, P205, DOI 10.1083/jcb.200806072
   WILKINSON PC, 1981, IMMUNOLOGY, V42, P637
   Woodfin A, 2010, CURR OPIN HEMATOL, V17, P9, DOI 10.1097/MOH.0b013e3283333930
   Yang Y., 2013, INVEST OPHTHALMOL, V54, P2516
NR 58
TC 7
Z9 7
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-8861
EI 2314-7156
J9 J IMMUNOL RES
JI J Immunol. Res.
PY 2014
VL 2014
AR 752923
DI 10.1155/2014/752923
PG 12
WC Immunology
SC Immunology
GA AJ1UK
UT WOS:000337441200001
PM 24995347
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU da Costa, ECB
   Amorim, R
   da Silva, FC
   Rocha, DR
   Papa, MP
   de Arruda, LB
   Mohana-Borges, R
   Ferreira, VF
   Tanuri, A
   da Costa, LJ
   Ferreira, SB
AF da Costa, Emmerson C. B.
   Amorim, Raquel
   da Silva, Fernando C.
   Rocha, David R.
   Papa, Michelle P.
   de Arruda, Luciana B.
   Mohana-Borges, Ronaldo
   Ferreira, Vitor F.
   Tanuri, Amilcar
   da Costa, Luciana J.
   Ferreira, Sabrina B.
TI Synthetic 1,4-Pyran Naphthoquinones Are Potent Inhibitors of Dengue
   Virus Replication
SO PLOS ONE
LA English
DT Article
ID BETA-LAPACHONE; TRYPANOSOMA-CRUZI; NS3 PROTEASE; HELICASE ACTIVITY; NS2B
   COFACTOR; RNA HELICASE; DERIVATIVES; TRIPHOSPHATASE; RECOMBINANT;
   1,4-NAPHTHOQUINONE
AB Dengue virus infection is a serious public health problem in endemic areas of he world where 2,5 billion people live. Clinical manifestations of the Dengue infection range from a mild fever to fatal cases of hemorrhagic fever. Although being the most rapidly spreading mosquito-borne viral infection in the world, until now no strategies are available for effective prevention or control of Dengue infection. In this scenario, the development of compounds that specifically inhibit viral replication with minimal effects to the human hosts will have a substantial effect in minimizing the symptoms of the disease and help to prevent viral transmission in the affected population. The aim of this study was to screen compounds with potential activity against dengue virus from a library of synthetic naphthoquinones Several 1,2- and 1,4-pyran naphthoquinones were synthesized by a three-component reaction of lawsone, aldehyde (formaldehyde or arylaldehydes) and different dienophiles adequately substituted. These compounds were tested for he ability to inhibit the ATPase activity of the viral NS3 enzyme in in vitro assays and the replication of dengue virus in cultured cells. We have identified two 1,4-pyran naphthoquinones, which inhibited dengue virus replication in mammal cells by 99.0% and three others that reduced the dengue virus ATPase activity of NS3 by two-fold in in vitro assays
C1 [da Costa, Emmerson C. B.; Mohana-Borges, Ronaldo] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Genom Estrutural, Rio De Janeiro, Brazil.
   [Amorim, Raquel; Papa, Michelle P.; de Arruda, Luciana B.; da Costa, Luciana J.] Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.
   [da Silva, Fernando C.; Rocha, David R.; Ferreira, Vitor F.] Univ Fed Fluminense, Dept Quim Organ, Inst Quim, BR-24000 Niteroi, RJ, Brazil.
   [Tanuri, Amilcar] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil.
   [Ferreira, Sabrina B.] Univ Fed Rio de Janeiro, Dept Quim Organ, Inst Quim, Rio De Janeiro, Brazil.
RP da Costa, LJ (corresponding author), Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.
EM ljcosta@micro.ufrj.br; sabrinab@iq.ufrj.br
RI Costa, Luciana J/B-7878-2013; Borges, Ronaldo S Mohana/C-5575-2013; da
   Rocha, David R/J-9912-2012; Amorim, Raquel/M-8161-2013; Arruda,
   Luciana/B-5806-2014; de Carvalho da Silva, Fernando/E-3408-2014;
   ferreira, Vitor francisco/Y-4031-2019; Ferreira, Sabrina
   Baptista/AAC-9368-2019; Arruda, Luciana B/N-9086-2013
OI da Rocha, David R/0000-0002-7928-8646; Amorim,
   Raquel/0000-0002-1605-0702; de Carvalho da Silva,
   Fernando/0000-0002-2042-3778; ferreira, Vitor
   francisco/0000-0002-2166-766X; Ferreira, Sabrina
   Baptista/0000-0002-5363-0888; 
FU CNPq (Brazil)National Council for Scientific and Technological
   Development (CNPq); CAPES-FAPERJCAPESCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); CAPESCAPES;
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [471588/2009-1]; FAPERJ-PRONEXCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ) [110.574/2010];
   CNPq INCT-Dengue
FX Fellowships granted to VFF by CNPq (Brazil), DRR by CAPES-FAPERJ and SBF
   and RA by CAPES are gratefully acknowledged. This work was partially
   supported by CAPES; CNPq grant 471588/2009-1; FAPERJ-PRONEX grant number
   110.574/2010 and CNPq INCT-Dengue. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5
   Benarroch D, 2004, VIROLOGY, V328, P208, DOI 10.1016/j.virol.2004.07.004
   Boguszewska-Chachulska AM, 2004, FEBS LETT, V567, P253, DOI 10.1016/j.febslet.2004.04.072
   BOOTHMAN DA, 1989, CANCER RES, V49, P605
   Cui TA, 1998, VIROLOGY, V246, P409, DOI 10.1006/viro.1998.9213
   da Rocha DR, 2011, ORG BIOMOL CHEM, V9, P4315, DOI 10.1039/c1ob05209h
   da Silva AJM, 2009, J BRAZIL CHEM SOC, V20, P176, DOI 10.1590/S0103-50532009000100026
   da Silva EN, 2010, J MED CHEM, V53, P504, DOI 10.1021/jm900865m
   da Silva FD, 2009, J BRAZIL CHEM SOC, V20, P1478, DOI 10.1590/S0103-50532009000800014
   De Burghgraeve T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037244
   DRISCOLL JS, 1974, CANCER CHEMOTH REP 2, V4, P3
   Ertl P, 1999, BIOORG MED CHEM LETT, V9, P2863, DOI 10.1016/S0960-894X(99)00489-8
   Eyong KO, 2008, BIOORG MED CHEM LETT, V18, P5387, DOI 10.1016/j.bmcl.2008.09.053
   FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995
   Ferreira S, 2013, MEDCHEMCOMM UNPUB
   Ferreira SB, 2011, EUR J MED CHEM, V46, P3071, DOI 10.1016/j.ejmech.2011.03.012
   Ferreira VF, 2006, BIOORGAN MED CHEM, V14, P5459, DOI 10.1016/j.bmc.2006.04.046
   Ferreira VF, 2010, ORG BIOMOL CHEM, V8, P4793, DOI 10.1039/c0ob00277a
   Fiske CH, 1927, SCIENCE, V65, P401, DOI 10.1126/science.65.1686.401
   Francisco AI, 2010, J BRAZIL CHEM SOC, V21, P1293, DOI 10.1590/S0103-50532010000700017
   Gebhard LG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036244
   GUIRAUD P, 1994, PLANTA MED, V60, P373, DOI 10.1055/s-2006-959504
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Halstead Scott B, 2005, Vaccine, V23, P849, DOI 10.1016/j.vaccine.2004.03.069
   Hussain H, 2007, ARKIVOC, P145, DOI 10.3998/ark.5550190.0008.204
   Johnson BW, 2005, J CLIN MICROBIOL, V43, P4977, DOI 10.1128/JCM.43.10.4977-4983.2005
   Jorqueira A, 2006, PARASITOL RES, V99, P429, DOI 10.1007/s00436-006-0153-8
   Kwong AD, 2005, NAT REV DRUG DISCOV, V4, P845, DOI 10.1038/nrd1853
   Leung D, 2001, J BIOL CHEM, V276, P45762, DOI 10.1074/jbc.M107360200
   Levin MK, 2003, J BIOL CHEM, V278, P23311, DOI 10.1074/jbc.M301283200
   Li HT, 1999, J VIROL, V73, P3108, DOI 10.1128/JVI.73.4.3108-3116.1999
   Lima NMF, 2004, MEM I OSWALDO CRUZ, V99, P757, DOI 10.1590/S0074-02762004000700017
   Lima NMF, 2002, J BRAZIL CHEM SOC, V13, P822, DOI 10.1590/S0103-50532002000600015
   Liu KKC, 2004, MINI-REV MED CHEM, V4, P1105
   LOPES JN, 1978, ANN TROP MED PARASIT, V72, P523, DOI 10.1080/00034983.1978.11719356
   Luo D, 2008, J VIROL, V82, P173, DOI 10.1128/JVI.01788-07
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   Monks Terrence J, 2002, Curr Drug Metab, V3, P425, DOI 10.2174/1389200023337388
   Niyomrattanakit P, 2004, J VIROL, V78, P13708, DOI 10.1128/JVI.78.24.13708-13716.2004
   Perez-Sacau E, 2005, CHEM BIODIVERS, V2, P264, DOI 10.1002/cbdv.200590009
   Racloz V, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001648
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Sampath A, 2009, ANTIVIR RES, V81, P6, DOI 10.1016/j.antiviral.2008.08.004
   Silva TMS, 2005, BIOORGAN MED CHEM, V13, P193, DOI 10.1016/j.bmc.2004.09.043
   Teixeira MJ, 2005, INFECT IMMUN, V73, P1191, DOI 10.1128/IAI.73.2.1191-1195.2005
   WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587
   WHO, 2009, DENG GUID DIAGN TREA
   *WHO, 2006, SCI WORK GROUP REP D
   Xu T, 2005, J VIROL, V79, P10278, DOI 10.1128/JVI.79.16.10278-10288.2005
NR 50
TC 20
Z9 20
U1 0
U2 21
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2013
VL 8
IS 12
AR e82504
DI 10.1371/journal.pone.0082504
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276IX
UT WOS:000328745100035
PM 24376541
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Gonzalez, Y
   Doens, D
   Santamaria, R
   Ramos, M
   Restrepo, CM
   de Arruda, LB
   Lleonart, R
   Gutierrez, M
   Fernandez, PL
AF Gonzalez, Yisett
   Doens, Deborah
   Santamaria, Ricardo
   Ramos, Marla
   Restrepo, Carlos M.
   de Arruda, Luciana Barros
   Lleonart, Ricardo
   Gutierrez, Marcelino
   Fernandez, Patricia L.
TI A Pseudopterane Diterpene Isolated From the Octocoral Pseudopterogorgia
   acerosa Inhibits the Inflammatory Response Mediated by TLR-Ligands and
   TNF-Alpha in Macrophages
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; TOLL-LIKE RECEPTORS; BIOLOGICAL-ACTIVITY; NATURAL-PRODUCTS;
   ACTIVATION; EXPRESSION; TRIPTOLIDE; (+)-TOTAROL; MODULATORS; MOLECULE
AB Several diterpenoids isolated from terrestrial and marine environments have been identified as important anti-inflammatory agents. Although considerable progress has been made in the area of anti-inflammatory treatment, the search for more effective and safer compounds is a very active field of research. In this study we investigated the anti-inflammatory effects of a known pseudopterane diterpene (referred here as compound 1) isolated from the octocoral Pseudopterogorgia acerosa on the tumor necrosis factor-alpha (TNF-alpha) and TLRs- induced response in macrophages. Compound 1 inhibited the expression and secretion of the inflammatory mediators TNF-alpha, interleukin (IL)-6, IL-1 beta, nitric oxide (NO), interferon gamma-induced protein 10 (IP-10), ciclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS) and monocyte chemoattractant protein-1 (MCP-1) induced by LPS in primary murine macrophages. This effect was associated with the inhibition of I.Ba degradation and subsequent activation of NF kappa B. Compound 1 also inhibited the expression of the co-stimulatory molecules CD80 and CD86, which is a hallmark of macrophage activation and consequent initiation of an adaptive immune response. The anti-inflammatory effect was not exclusive to LPS because compound 1 also inhibited the response of macrophages to TNF-alpha and TLR2 and TLR3 ligands. Taken together, these results indicate that compound 1 is an anti-inflammatory molecule, which modulates a variety of processes occurring in macrophage activation.
C1 [Gonzalez, Yisett; Doens, Deborah; Ramos, Marla; Restrepo, Carlos M.; Lleonart, Ricardo; Fernandez, Patricia L.] Inst Invest Cient & Serv Alta Tecno, Ctr Biol Celular & Mol Enfermedades, Ciudad De Panama, Panama.
   [Gonzalez, Yisett; Doens, Deborah; Restrepo, Carlos M.] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur, India.
   [Santamaria, Ricardo; Gutierrez, Marcelino] Inst Invest Cient & Serv Alta Tecno, Ctr Descubrimiento Drogas & Biodiversidad, Ciudad De Panama, Panama.
   [de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol, Lab Genet & Imunol Infeccoes Virais, Rio De Janeiro, Brazil.
RP Fernandez, PL (corresponding author), Inst Invest Cient & Serv Alta Tecno, Ctr Biol Celular & Mol Enfermedades, Ciudad De Panama, Panama.
EM pllanes@indicasat.org.pa
RI Arruda, Luciana B/N-9086-2013; Gutierrez, Marcelino/V-8134-2019; Arruda,
   Luciana/B-5806-2014; Lleonart, Ricardo/Q-5372-2019
OI Gutierrez, Marcelino/0000-0003-1423-3772; Lleonart,
   Ricardo/0000-0002-5830-6315; Llanes Fernandez,
   Patricia/0000-0002-0762-0566; Gonzalez, Yisett/0000-0002-1623-9484
FU Secretar a Nacional de Ciencia Tecnolog a e Innovacion (SENACYT),
   Republic of Panama [FID11-082, COL08-064]; Fogarty International
   Center's International Cooperative Biodiversity Groups programUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [TW006634];
   FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Fogarty
   International Center (FIC) [U01TW006634, U01TW006634, U01TW006634,
   U01TW006634, U01TW006634, U01TW006634, U01TW006634, U01TW006634,
   U01TW006634, U01TW006634, U01TW006634, U01TW006634, U01TW006634,
   U01TW006634, U01TW006634, U01TW006634, U01TW006634, U01TW006634,
   U01TW006634] Funding Source: NIH RePORTER
FX This work was supported by the Secretar a Nacional de Ciencia Tecnolog a
   e Innovacion (SENACYT), Republic of Panama [Grants FID11-082,
   COL08-064]; and [in part] by the Fogarty International Center's
   International Cooperative Biodiversity Groups program [Grant TW006634].
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amigo M, 2008, LIFE SCI, V82, P256, DOI 10.1016/j.lfs.2007.11.017
   BANDURRAGA MM, 1982, J AM CHEM SOC, V104, P6463, DOI 10.1021/ja00387a059
   Berrue F, 2009, NAT PROD REP, V26, P681, DOI 10.1039/b821918b
   Blunt JW, 2013, NAT PROD REP, V30, P237, DOI 10.1039/c2np20112g
   Chung JY, 2002, J CELL SCI, V115, P679
   Crow MK, 2006, SPRINGER SEMIN IMMUN, V27, P409, DOI 10.1007/s00281-006-0018-3
   de las Heras B., 2009, Inflammation & Allergy Drug Targets, V8, P28
   Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010
   FENICAL W, 1987, J NAT PROD, V50, P1001, DOI 10.1021/np50054a001
   Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200
   Folmer F, 2008, BIOCHEM PHARMACOL, V75, P603, DOI 10.1016/j.bcp.2007.07.044
   Giron N, 2008, TOXICOL APPL PHARM, V228, P179, DOI 10.1016/j.taap.2007.12.006
   Gupta SC, 2011, MOL PHARMACOL, V80, P769, DOI 10.1124/mol.111.073122
   Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111
   Hughes CC, 2009, ANGEW CHEM INT EDIT, V48, P725, DOI 10.1002/anie.200804890
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1
   Kleinert H, 2004, EUR J PHARMACOL, V500, P255, DOI 10.1016/j.ejphar.2004.07.030
   Kondratyuk TP, 2012, MAR DRUGS, V10, P451, DOI 10.3390/md10020451
   Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200
   Liu J, 2005, ACTA PHARMACOL SIN, V26, P223, DOI 10.1111/j.1745-7254.2005.00035.x
   Lu L, 2011, ANTICANCER RES, V31, P1
   Lucas R, 2003, LIFE SCI, V72, P2543, DOI 10.1016/S0024-3205(03)00167-X
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Mateo CR, 2000, BBA-BIOMEMBRANES, V1509, P167, DOI 10.1016/S0005-2736(00)00291-1
   Medina RA, 2008, J AM CHEM SOC, V130, P6324, DOI 10.1021/ja801383f
   Micol V, 2001, BBA-BIOMEMBRANES, V1511, P281, DOI 10.1016/S0005-2736(01)00284-X
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   ODA T, 2011, INT J APP RES NAT PR, V4, P16
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Premkumar Vummidigiridhar, 2010, BMC Chemical Biology, V10, P3, DOI 10.1186/1472-6769-10-3
   Roethle PA, 2008, NAT PROD REP, V25, P298, DOI 10.1039/b705660p
   Singh M, 1999, PLANTA MED, V65, P2, DOI 10.1055/s-1999-13952
   TINTO WF, 1991, TETRAHEDRON, V47, P8679, DOI 10.1016/S0040-4020(01)96190-3
   Quang TH, 2011, BIOORGAN MED CHEM, V19, P2625, DOI 10.1016/j.bmc.2011.03.009
   Urzua A, 2008, MOLECULES, V13, P882, DOI 10.3390/molecules13040822
   VanGool SW, 1996, IMMUNOL REV, V153, P47
   Wang W, 2010, ACTA PHARMACOL SIN, V31, P191, DOI 10.1038/aps.2009.205
   Wei W, 2011, PARIS REV, P13
   Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529
NR 43
TC 5
Z9 6
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2013
VL 8
IS 12
AR e84107
DI 10.1371/journal.pone.0084107
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 276GD
UT WOS:000328735700150
PM 24358331
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Guabiraba, R
   Besnard, AG
   Marques, RE
   Maillet, I
   Fagundes, CT
   Conceicao, TM
   Rust, NM
   Charreau, S
   Paris, I
   Lecron, JC
   Renauld, JC
   Quesniaux, V
   Da Poian, AT
   Arruda, LB
   Souza, DG
   Ryffel, B
   Teixeira, MM
AF Guabiraba, Rodrigo
   Besnard, Anne-Gaelle
   Marques, Rafael E.
   Maillet, Isabelle
   Fagundes, Caio T.
   Conceicao, Thais M.
   Rust, Naiara M.
   Charreau, Sandrine
   Paris, Isabelle
   Lecron, Jean-Claude
   Renauld, Jean-Christophe
   Quesniaux, Valerie
   Da Poian, Andrea T.
   Arruda, Luciana B.
   Souza, Danielle G.
   Ryffel, Bernhard
   Teixeira, Mauro M.
TI IL-22 modulates IL-17A production and controls inflammation and tissue
   damage in experimental dengue infection
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Dengue virus; IL-17A; IL-22; Infection; Inflammation
ID DELTA-T-CELLS; INNATE IMMUNE-RESPONSE; ORIGINAL ANTIGENIC SIN;
   NATURAL-KILLER-CELLS; VIRUS-INFECTION; HEMORRHAGIC-FEVER;
   INTERLEUKIN-22; PATHOGENESIS; HEPATITIS; HEPATOCYTES
AB Dengue virus (DENV), a mosquito-borne flavivirus, is a public health problem in many tropical countries. IL-22 and IL-17A are key cytokines in several infectious and inflammatory diseases. We have assessed the contribution of IL-22 and IL-17A in the pathogenesis of experimental dengue infection using a mouse-adapted DENV serotype 2 strain (P23085) that causes a disease that resembles severe dengue in humans. We show that IL-22 and IL-17A are produced upon DENV-2 infection in immune-competentmice. Infected IL-22(-/-) mice had increased lethality, neutrophil accumulation and pro-inflammatory cytokines in tissues, notably IL-17A. Viral load was increased in spleen and liver of infected IL-22(-/-) mice. There was also more severe liver injury, as seen by increased transaminases levels and tissue histopathology. gamma delta T cells and NK cells are sources of IL-17A and IL-22, respectively, in liver and spleen. We also show that DENV-infected HepG2 cells treated with rhIL-22 had reduced cell death and decreased IL-6 production. IL-17RA(-/-) mice were protected upon infection and IL-17A-neutralizing-Ab-treatment partially reversed the phenotype observed in IL-22(-/-)-infected mice. We suggest that disrupting the balance between IL-22 and IL-17A levels may represent an important strategy to reduce inflammation and tissue injury associated with severe dengue infection.
C1 [Guabiraba, Rodrigo; Marques, Rafael E.; Fagundes, Caio T.; Teixeira, Mauro M.] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Guabiraba, Rodrigo; Besnard, Anne-Gaelle; Maillet, Isabelle; Ryffel, Bernhard] Univ Orleans, F-45071 Orleans, France.
   [Guabiraba, Rodrigo; Besnard, Anne-Gaelle; Maillet, Isabelle; Ryffel, Bernhard] CNRS, UMR 7355, F-45071 Orleans, France.
   [Guabiraba, Rodrigo; Besnard, Anne-Gaelle; Maillet, Isabelle; Ryffel, Bernhard] Univ Cape Town, IIDMM, ZA-7925 Cape Town, South Africa.
   [Fagundes, Caio T.; Souza, Danielle G.] Univ Fed Minas Gerais, Dept Microbiol, Inst Ciencias Biol, BR-31270901 Belo Horizonte, MG, Brazil.
   [Conceicao, Thais M.; Da Poian, Andrea T.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Ctr Ciencias Saude, Rio De Janeiro, RJ, Brazil.
   [Rust, Naiara M.; Arruda, Luciana B.] Univ Fed Rio de Janeiro, Inst Microbiol Paulo Goes, Ctr Ciencias Saude, Rio De Janeiro, RJ, Brazil.
   [Charreau, Sandrine; Paris, Isabelle; Lecron, Jean-Claude] Univ Poitiers, EA4331, Poitiers, France.
   [Charreau, Sandrine; Paris, Isabelle; Lecron, Jean-Claude] Ctr Hosp Univ Poitiers, Poitiers, France.
   [Renauld, Jean-Christophe] Catholic Univ Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium.
   [Renauld, Jean-Christophe] Catholic Univ Louvain, de Duve Inst, Expt Med Unit, B-1200 Brussels, Belgium.
RP Guabiraba, R (corresponding author), Univ Fed Minas Gerais, Dept Bioquim & Imunol, Inst Ciencias Biol, Av Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.
EM rguabiraba@gmail.com; bryffel@cnrs-orleans.fr
RI Arruda, Luciana/B-5806-2014; Teixeira, Mauro M/A-4587-2008; Fagundes,
   Caio/AAK-9336-2020; Da Poian, Andrea T./V-1699-2019; souza,
   danielle/D-3378-2014; Marques, Rafael Elias/R-4890-2016; R,
   Guabiraba/F-1396-2010; Arruda, Luciana B/N-9086-2013; Renauld,
   Jean-Christophe/B-7268-2012
OI Teixeira, Mauro M/0000-0002-6944-3008; Fagundes,
   Caio/0000-0002-6747-5233; Marques, Rafael Elias/0000-0002-6949-0947; R,
   Guabiraba/0000-0003-4005-1753; Miranda Rust, Naiara/0000-0002-5107-5745;
   Renauld, Jean-Christophe/0000-0003-1736-2131; Da Poian,
   Andrea/0000-0002-3969-704X
FU Centro de Microscopia Eletronica (CEMEL, UFMG); French National Research
   Agency (ANR)French National Research Agency (ANR); Fondation pour la
   Recherche Medicale (FRM)Fondation pour la Recherche Medicale; Fond
   Europeen de Developpement Regional (FEDER)European Union (EU); Centre
   Nationale de la Recherche Scientifique (CNRS/France); Le Studium
   (CNRS/France); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq/Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa de Minas
   Gerais (FAPEMIG/Brazil)Minas Gerais State Research Foundation (FAPEMIG);
   program INCT em Dengue (CNPq, Brazil)
FX We thank Mrs. Ana Luiza Queiroz (UFMG), Mrs. Jennifer Palomo, Mrs. Lea
   Brault and Mr. Louis Fauconnier (CNRS/Orleans) for their helpful
   technical assistance. We thank Dr. Andre G. Oliveira and the Centro de
   Microscopia Eletronica (CEMEL, UFMG) for their support. This work was
   supported by the French National Research Agency (ANR), Fondation pour
   la Recherche Medicale (FRM), Fond Europeen de Developpement Regional
   (FEDER), Centre Nationale de la Recherche Scientifique (CNRS/France), Le
   Studium (CNRS/France), Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq/Brazil) and Fundacao de Amparo a Pesquisa de Minas
   Gerais (FAPEMIG/Brazil). The work was done under the auspices of the
   program INCT em Dengue (CNPq, Brazil).
CR Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710
   Becquart P, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-356
   Beetz S, 2008, IMMUNOBIOLOGY, V213, P173, DOI 10.1016/j.imbio.2007.10.006
   Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC
   Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537
   Chen RF, 2005, FEMS IMMUNOL MED MIC, V44, P43, DOI 10.1016/j.femsim.2004.11.012
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Colonna M, 2009, IMMUNITY, V31, P15, DOI 10.1016/j.immuni.2009.06.008
   Conceicao TM, 2010, J INFECTION, V60, P65, DOI 10.1016/j.jinf.2009.10.003
   Couvelard A, 1999, HUM PATHOL, V30, P1106, DOI 10.1016/S0046-8177(99)90230-7
   Crowe CR, 2009, J IMMUNOL, V183, P5301, DOI 10.4049/jimmunol.0900995
   Dambacher J, 2008, CYTOKINE, V41, P209, DOI 10.1016/j.cyto.2007.11.016
   Dinh TT, 2010, AM J TROP MED HYG, V83, P774, DOI 10.4269/ajtmh.2010.10-0090
   Duangchinda T, 2010, P NATL ACAD SCI USA, V107, P16922, DOI 10.1073/pnas.1010867107
   Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004
   Fagundes CT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001449
   Goto M, 2009, CELL IMMUNOL, V254, P81, DOI 10.1016/j.cellimm.2008.10.002
   Green S, 2006, CURR OPIN INFECT DIS, V19, P429, DOI 10.1097/01.qco.0000244047.31135.fa
   Guabiraba R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015680
   Guo HL, 2010, J VIROL, V84, P7750, DOI 10.1128/JVI.00187-10
   Guzman M. G, 2002, LANCET INFECT DIS
   Guzmán María G., 2002, Rev Panam Salud Publica, V11, P223, DOI 10.1590/S1020-49892002000400003
   Hamada S, 2008, J IMMUNOL, V181, P3456, DOI 10.4049/jimmunol.181.5.3456
   Jain A, 2013, J CLIN IMMUNOL, V33, P613, DOI 10.1007/s10875-012-9855-0
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Juffrie M, 2000, INFECT IMMUN, V68, P702, DOI 10.1128/IAI.68.2.702-707.2000
   Kalayanarooj S, 1997, J INFECT DIS, V176, P313, DOI 10.1086/514047
   Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308
   Liu CC, 2002, J MED VIROL, V68, P241, DOI 10.1002/jmv.10198
   Liu ZX, 2006, HEPATOLOGY, V43, P1220, DOI 10.1002/hep.21175
   Malavige GN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050387
   Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887
   Pham TB, 2009, J CLIN VIROL, V45, P276, DOI 10.1016/j.jcv.2009.04.004
   Radaeva S, 2004, HEPATOLOGY, V39, P1332, DOI 10.1002/hep.20184
   Renneson J, 2011, AM J PATHOL, V179, P1872, DOI 10.1016/j.ajpath.2011.06.023
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Ryzhakov G, 2011, J IMMUNOL, V187, P5357, DOI 10.4049/jimmunol.1100917
   Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466
   Sonnenberg GF, 2011, NAT IMMUNOL, V12, P383, DOI 10.1038/ni.2025
   Sonnenberg GF, 2010, J EXP MED, V207, P1293, DOI 10.1084/jem.20092054
   Souza DG, 2009, P NATL ACAD SCI USA, V106, P14138, DOI 10.1073/pnas.0906467106
   Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Whittington HA, 2004, AM J RESP CELL MOL, V31, P220, DOI 10.1165/rcmb.2003-0285OC
   Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007
   Xing WW, 2011, CYTOKINE, V56, P174, DOI 10.1016/j.cyto.2011.07.022
   Zenewicz LA, 2007, IMMUNITY, V27, P647, DOI 10.1016/j.immuni.2007.07.023
   Zenewicz LA, 2008, EUR J IMMUNOL, V38, P3265, DOI 10.1002/eji.200838655
   Zhang Y, 2011, GASTROENTEROLOGY, V141, P1897, DOI 10.1053/j.gastro.2011.06.051
   Zheng Y, 2007, NATURE, V445, P648, DOI 10.1038/nature05505
NR 53
TC 30
Z9 32
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JUN
PY 2013
VL 43
IS 6
BP 1529
EP 1544
DI 10.1002/eji.201243229
PG 16
WC Immunology
SC Immunology
GA 169MZ
UT WOS:000320785700021
PM 23505056
DA 2020-12-08
ER

PT J
AU da Conceicao, TM
   Rust, NM
   Berbel, ACER
   Martins, NB
   Santos, CAD
   Da Poian, AT
   de Arruda, LB
AF da Conceicao, Thais Moraes
   Rust, Naiara Miranda
   Egypto Rosa Berbel, Ana Carolina
   Martins, Nathalia Balthazar
   do Nascimento Santos, Carlos Antonio
   Da Poian, Andrea Thompson
   de Arruda, Luciana Barros
TI Essential role of RIG-I in the activation of endothelial cells by dengue
   virus
SO VIROLOGY
LA English
DT Article
DE Dengue; Endothelial cells; RIG-I; Interferon; Proinflammatory cytokines
ID NECROSIS-FACTOR-ALPHA; TOLL-LIKE RECEPTORS; INDUCIBLE GENE-I; TNF-ALPHA;
   ADHESION MOLECULES; HEMORRHAGIC-FEVER; VASCULAR ENDOTHELIUM; CYTOKINE
   PRODUCTION; IMMUNE-RESPONSES; TIGHT JUNCTION
AB Dengue virus (DENV) infection is associated to exacerbated inflammatory response and structural and functional alterations in the vascular endothelium. However, the mechanisms underlying DENV-induced endothelial cell activation and their role in the inflammatory response were not investigated so far. We demonstrated that human brain microvascular endothelial cells (HBMECs) are susceptible to DENV infection, which induces the expression of the cytoplasmic pattern recognition receptor (PRR) RIG-I. Infection of HBMECs promoted an increase in the production of type I IFN and proinflammatory cytokines, which were abolished after RIG-I silencing. DEN V-infected HBMECs also presented a higher ICAM-1 expression dependent on RIG-I activation as well. On the other hand, ablation of RIG-I did not interfere with virus replication. Our data suggest that RIG-I activation by DENV may participate in the disease pathogenesis through the modulation of cytokine release and expression of adhesion molecules, probably contributing to leukocyte recruitment and amplification of the inflammatory response. (C) 2012 Elsevier Inc. All rights reserved.
C1 [da Conceicao, Thais Moraes; Da Poian, Andrea Thompson] Univ Fed Rio de Janeiro, CCS, Inst Bioquim Med, Bloco E,Lab E-018,Av Carlos Chagas Filho,373 Cida, Rio De Janeiro, RJ, Brazil.
   [Rust, Naiara Miranda; Egypto Rosa Berbel, Ana Carolina; de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, CCS, Inst Microbiol Paulo de Goes, Rio De Janeiro, RJ, Brazil.
   [Martins, Nathalia Balthazar; do Nascimento Santos, Carlos Antonio] Inst Nacl Metrol Qualidade & Tecnol Inmetro, Programa Bioengn, Rio De Janeiro, RJ, Brazil.
RP Da Poian, AT (corresponding author), Univ Fed Rio de Janeiro, CCS, Inst Bioquim Med, Bloco E,Lab E-018,Av Carlos Chagas Filho,373 Cida, Rio De Janeiro, RJ, Brazil.
EM dapoian@bioqmed.ufrj.br; arruda@micro.ufrj.br
RI Arruda, Luciana/B-5806-2014; Da Poian, Andrea T./V-1699-2019; Arruda,
   Luciana B/N-9086-2013
OI Da Poian, Andrea/0000-0002-3969-704X; Miranda Rust,
   Naiara/0000-0002-5107-5745
FU INCT-Dengue; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ); PNPD-CAPES
   fellowship
FX This work was supported by INCT-Dengue, CNPq, CAPES and FAPERJ. T.M.
   Conceicao was the recipient of a PNPD-CAPES fellowship; N.M. Rust and
   A.C.E.R. Berbel were the recipient of CNPq and CAPES fellowships,
   respectively. The authors wish to thank Dr. Dennis J. Grab (Departments
   of Pathology and Pediatrics, The Johns Hopkins University School of
   Medicine) and Dr. Julio Scharfstein (Instituto de Biofisica Carlos
   Chagas Filho, Universidade Federal do Rio de Janeiro, Brazil) for kindly
   providing the HBMECs; and Dr. Jose Mauro Granjeiro (INMETRO, Rio de
   Janeiro, Brazil) for kindly providing the HUVECs. We acknowledge Sidney
   Gomes da Costa and Joao Baltazar for technical support.
CR Anderson R, 1997, J VIROL, V71, P4226, DOI 10.1128/JVI.71.6.4226-4232.1997
   Arevalo MT, 2009, J MED VIROL, V81, P519, DOI 10.1002/jmv.21408
   Arnold R, 2005, J IMMUNOL, V174, P7359, DOI 10.4049/jimmunol.174.11.7359
   Asdonk T, 2012, BIOCHEM BIOPH RES CO, V420, P66, DOI 10.1016/j.bbrc.2012.02.116
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Avirutnan P, 1998, J IMMUNOL, V161, P6338
   Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Azizan A, 2006, J VIROL METHODS, V138, P211, DOI 10.1016/j.jviromet.2006.08.010
   Balsitis SJ, 2009, AM J TROP MED HYG, V80, P416, DOI 10.4269/ajtmh.2009.80.416
   Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P287, DOI 10.1111/j.1574-695X.2008.00420.x
   Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807
   Bonner SM, 1998, J VIROL METHODS, V71, P159, DOI 10.1016/S0166-0934(97)00211-5
   Bosch I, 2002, J VIROL, V76, P5588, DOI 10.1128/JVI.76.11.5588-5597.2002
   Bustos-Arriaga J, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001420
   Cardier JE, 2005, CYTOKINE, V30, P359, DOI 10.1016/j.cyto.2005.01.021
   Cardier JE, 2006, ENDOTHELIUM-J ENDOTH, V13, P335, DOI 10.1080/10623320600972135
   Chaturvedi UC, 1999, J MED VIROL, V59, P335, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;335::AID-JMV13&gt;3.0.CO;2-E
   Chen HC, 2007, J VIROL, V81, P5518, DOI 10.1128/JVI.02575-06
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   Conceicao TM, 2010, J VIROL METHODS, V163, P1, DOI 10.1016/j.jviromet.2009.10.001
   Conceicao TM, 2010, J INFECTION, V60, P65, DOI 10.1016/j.jinf.2009.10.003
   Dai JF, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-468
   Dalrymple N, 2011, J VIROL, V85, P9478, DOI 10.1128/JVI.05008-11
   Diamond MS, 2000, J VIROL, V74, P4957, DOI 10.1128/JVI.74.11.4957-4966.2000
   DiStasi MR, 2009, TRENDS IMMUNOL, V30, P539, DOI 10.1016/j.it.2009.07.012
   Furr SR, 2010, GLIA, V58, P1620, DOI 10.1002/glia.21034
   Gandini M, 2011, MEM I OSWALDO CRUZ, V106, P594, DOI 10.1590/S0074-02762011000500012
   German AC, 2006, T ROY SOC TROP MED H, V100, P1135, DOI 10.1016/j.trstmh.2006.02.008
   Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103
   Guabiraba R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015680
   Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460
   Hagele H, 2009, NEPHROL DIAL TRANSPL, V24, P3312, DOI 10.1093/ndt/gfp339
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P261
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Huang YH, 2000, AM J TROP MED HYG, V63, P71, DOI 10.4269/ajtmh.2000.63.71
   Imaizumi T, 2005, ENDOTHELIUM-J ENDOTH, V12, P133, DOI 10.1080/10623320500191885
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004
   Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734
   Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243
   Kelley JF, 2012, VIROLOGY, V422, P326, DOI 10.1016/j.virol.2011.10.030
   Le Goffic R, 2007, J IMMUNOL, V178, P3368, DOI 10.4049/jimmunol.178.6.3368
   Liao HW, 2010, J MED VIROL, V82, P1392, DOI 10.1002/jmv.21815
   Liao S, 2008, J GEN VIROL, V89, P1978, DOI 10.1099/vir.0.2008/000778-0
   Limonta D, 2007, J CLIN VIROL, V40, P50, DOI 10.1016/j.jcv.2007.04.024
   Lin YW, 2002, J VIROL, V76, P12242, DOI 10.1128/JVI.76.23.12242-12249.2002
   Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07
   Martinez-Gutierrez M, 2011, INTERVIROLOGY, V54, P202, DOI 10.1159/000321892
   Munoz-Jordan JL, 2005, J VIROL, V79, P8004, DOI 10.1128/JVI.79.13.8004-8013.2005
   Munoz-Jordan JL, 2010, CURR TOP MICROBIOL, V338, P35, DOI 10.1007/978-3-642-02215-9_3
   Nasirudeen AMA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000926
   Nazmi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021761
   Nikolskaia OV, 2006, J CLIN INVEST, V116, P2739, DOI [10.1172/JC127798, 10.1172/JCI27798.]
   Opitz B, 2009, THROMB HAEMOSTASIS, V102, P1103, DOI 10.1160/TH09-05-0323
   Pang T, 2007, IMMUNOL CELL BIOL, V85, P43, DOI 10.1038/sj.icb.7100008
   Perry ST, 2009, J VIROL, V83, P8276, DOI 10.1128/JVI.00365-09
   Peyrefitte CN, 2006, J MED VIROL, V78, P229, DOI 10.1002/jmv.20532
   Qin CF, 2011, MOL BIOL REP, V38, P3867, DOI 10.1007/s11033-010-0502-7
   Ramos C, 1998, J NEUROVIROL, V4, P465, DOI 10.3109/13550289809114548
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104
   Shresta S, 2004, J VIROL, V78, P2701, DOI 10.1128/JVI.78.6.2701-2710.2004
   St John AL, 2011, P NATL ACAD SCI USA, V108, P9190, DOI 10.1073/pnas.1105079108
   Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005
   Takeuchi O, 2009, IMMUNOL REV, V227, P75, DOI 10.1111/j.1600-065X.2008.00737.x
   Talavera D, 2004, J GEN VIROL, V85, P1801, DOI 10.1099/vir.0.19652-0
   [TDR WHO], 2006, 08 TDRWHO SWG
   [TDR WHO], 2009, WHOHTMNTDDEN20091
   Triantafilou K, 2011, VIRULENCE, V2, P22, DOI 10.4161/viru.2.1.13807
   Ochoa MV, 2009, ARCH VIROL, V154, P919, DOI 10.1007/s00705-009-0396-7
   Verma S, 2009, VIROLOGY, V385, P425, DOI 10.1016/j.virol.2008.11.047
   Wang Q, 2009, J IMMUNOL, V183, P6989, DOI 10.4049/jimmunol.0901386
   Yang L, 2005, BLOOD, V106, P584, DOI 10.1182/blood-2004-12-4942
   Yen YT, 2008, J VIROL, V82, P12312, DOI 10.1128/JVI.00968-08
   Yu M, 2011, CYTOKINE GROWTH F R, V22, P63, DOI 10.1016/j.cytogfr.2011.02.001
   Zamudio-Meza H, 2009, J GEN VIROL, V90, P2902, DOI 10.1099/vir.0.014159-0
   Zellweger RM, 2010, CELL HOST MICROBE, V7, P128, DOI 10.1016/j.chom.2010.01.004
NR 77
TC 34
Z9 34
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN 20
PY 2013
VL 435
IS 2
BP 281
EP 292
DI 10.1016/j.virol.2012.09.038
PG 12
WC Virology
SC Virology
GA 069TE
UT WOS:000313459200010
PM 23089253
OA Bronze
DA 2020-12-08
ER

PT J
AU Rust, NM
   Papa, MP
   Scovino, AM
   da Silva, MMC
   Calzavara-Silva, CE
   Marques, ETD
   Pecanha, LMT
   Scharfstein, J
   Arruda, LB
AF Rust, Naiara Miranda
   Papa, Michelle Premazzi
   Scovino, Aline Miranda
   Carneiro da Silva, Mayara Marques
   Calzavara-Silva, Carlos Eduardo
   de Azevedo Marques, Ernesto Torres, Jr.
   Torres Pecanha, Ligia Maria
   Scharfstein, Julio
   Arruda, Luciana B.
TI Bradykinin enhances Sindbis virus infection in human brain microvascular
   endothelial cells
SO VIROLOGY
LA English
DT Article
DE Sindbis; Bradykinin; Endothelial cells; Apoptosis
ID RESPIRATORY SYNCYTIAL VIRUS; GLYCOGEN-SYNTHASE KINASE-3; AGE-DEPENDENT
   RESISTANCE; HUMAN IMMUNE CELLS; SUBSTANCE-P; KALLIKREIN/KININ PROTECTS;
   INHIBITING APOPTOSIS; VIRAL ENCEPHALITIS; SIGNALING PATHWAY; RHINOVIRUS
   COLDS
AB Sindbis virus (SINV) induces inflammatory and vasoactive responses that are associated with rash and arthritis in human infections. The mechanisms underlying infection-associated microvasculopathy are still unknown. We investigated whether endothelial cells infected by SINV are differentially responsive to bradykinin (BK), a potent inducer of inflammatory edema in a broad range of infectious diseases. Human endothelial cells (HBMECs) infected with SINV presented an upregulation of bradykinin B2 receptors (BK2R) expression. Also, BK reduced SINV-induced apoptosis and enhanced virus replication in HBMECs in a way dependent on BK2R, PI3 kinase and ERK signaling. Strikingly, intracerebral infection of mice in the presence of a BK2R antagonist reduced the local viral load. Our data suggest that SINV infection renders human endothelial cells hypersensitive to BK, which increases host cell survival and viral replication. Ongoing studies may clarify if the deregulation of the kinin pathway contributes to infection-associated vasculopathies in life-threatening arbovirus infections. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Arruda, Luciana B.] Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Prof Paulo de Goes, CCS, BR-21941902 Rio De Janeiro, Brazil.
   [Scovino, Aline Miranda; Scharfstein, Julio] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941902 Rio De Janeiro, Brazil.
   [Carneiro da Silva, Mayara Marques; de Azevedo Marques, Ernesto Torres, Jr.] Fiocruz MS, Lab Virol & Terapia Expt, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil.
   [Torres Pecanha, Ligia Maria] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, BR-21941902 Rio De Janeiro, Brazil.
RP Arruda, LB (corresponding author), Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Prof Paulo de Goes, CCS, Bloco 1,Av Carlos Chagas Filho,373 Cidade Univ, BR-21941902 Rio De Janeiro, Brazil.
EM arruda@micro.ufrj.br
RI Arruda, Luciana/B-5806-2014; Arruda, Luciana B/N-9086-2013; Marques,
   Ernesto T. A/L-4967-2013; Publica, Inct Saude/J-9544-2013; Marques,
   Ernesto/L-4514-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; CALZAVARA-SILVA,
   CARLOS/0000-0002-1406-6401; Miranda Rust, Naiara/0000-0002-5107-5745
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERJCarlos Chagas Filho Foundation for Research Support of the
   State of Rio de Janeiro (FAPERJ)
FX This work was supported by CNPq and FAPERJ. N.M.Rust was the recipient
   of a CNPq fellowship; M.P.Papa was the recipient of a FAPERJ fellowship.
CR Aksamitiene E, 2011, CELL SIGNAL, V23, P1794, DOI 10.1016/j.cellsig.2011.06.014
   Aliberti J, 2003, J IMMUNOL, V170, P5349, DOI 10.4049/jimmunol.170.11.5349
   Assuncao-Miranda I, 2010, J MED VIROL, V82, P164, DOI 10.1002/jmv.21649
   Austin CE, 1997, J BIOL CHEM, V272, P11420
   BARNETT JKC, 1990, AM REV RESPIR DIS, V142, P162, DOI 10.1164/ajrccm/142.1.162
   Bengtson SH, 2007, INT IMMUNOPHARMACOL, V7, P1880, DOI 10.1016/j.intimp.2007.07.002
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   Bledsoe G, 2006, NEPHROL DIAL TRANSPL, V21, P624, DOI 10.1093/ndt/gfi225
   Bovenzi V, 2010, J CELL PHYSIOL, V222, P168, DOI 10.1002/jcp.21933
   Calabrese LH, 2005, INFECT DIS CLIN N AM, V19, P963, DOI 10.1016/j.idc.2005.09.002
   CHAI KX, 1993, J BIOL CHEM, V268, P24498
   CHATURVEDI UC, 1991, J GEN VIROL, V72, P859, DOI 10.1099/0022-1317-72-4-859
   Christiansen SC, 2008, INT ARCH ALLERGY IMM, V147, P299, DOI 10.1159/000144037
   Dhanushkodi NR, 2011, VIRAL IMMUNOL, V24, P237, DOI 10.1089/vim.2010.0120
   Folkerts G, 2000, AM J RESP CRIT CARE, V161, P1666, DOI 10.1164/ajrccm.161.5.9710002
   FRASER JRE, 1986, CLIN RHEUM DIS, V12, P369
   Greco S, 2006, J ENDOCRINOL, V188, P79, DOI 10.1677/joe.1.06433
   Griffin DE, 2005, CURR TOP MICROBIOL, V289, P57
   GRIFFIN DE, 1994, ARCH VIROL, P31
   Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200
   Heitsch H, 2000, DRUG NEWS PERSPECT, V13, P213
   Ho WZ, 2002, FASEB J, V16, P616, DOI 10.1096/fj.01-0655fje
   Irani DN, 1996, J IMMUNOL, V156, P3850
   Irusta PM, 2004, PROG MOL SUBCELL BIO, V36, P71
   Jaffar-Bandjee MC, 2009, MICROBES INFECT, V11, P1206, DOI 10.1016/j.micinf.2009.10.001
   JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257
   Kaman WE, 2009, MED MICROBIOL IMMUN, V198, P39, DOI 10.1007/s00430-008-0103-4
   Kerr DA, 2002, J VIROL, V76, P10393, DOI 10.1128/JVI.76.20.10393-10400.2002
   Kim JV, 2009, NATURE, V457, P191, DOI 10.1038/nature07591
   Krieg T, 2004, AM J PHYSIOL-HEART C, V287, pH2606, DOI 10.1152/ajpheart.00600.2004
   Labrada L, 2002, J VIROL, V76, P11688, DOI 10.1128/JVI.76.22.11688-11703.2002
   Laine M, 2004, J INTERN MED, V256, P457, DOI 10.1111/j.1365-2796.2004.01413.x
   Lee CJ, 2005, J VIROL, V79, P8388, DOI 10.1128/JVI.79.13.8388-8399.2005
   Levine B, 2002, CURR TOP MICROBIOL, V265, P95
   Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556
   Li Y, 2001, J NEUROIMMUNOL, V121, P67, DOI 10.1016/S0165-5728(01)00439-8
   LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988
   MENKE JG, 1994, J BIOL CHEM, V269, P21583
   Monteiro AC, 2009, J IMMUNOL, V183, P3700, DOI 10.4049/jimmunol.0900895
   Monteiro AC, 2007, PLOS PATHOG, V3, P1730, DOI 10.1371/journal.ppat.0030185
   NACLERIO RM, 1988, J INFECT DIS, V157, P133, DOI 10.1093/infdis/157.1.133
   Nikolskaia OV, 2006, J CLIN INVEST, V116, P2739, DOI [10.1172/JC127798, 10.1172/JCI27798.]
   Penna C, 2008, J CELL MOL MED, V12, P435, DOI 10.1111/j.1582-4934.2007.00210.x
   Prado GN, 2002, J CELL PHYSIOL, V193, P275, DOI 10.1002/jcp.10175
   PROUD D, 1990, J INFECT DIS, V161, P120, DOI 10.1093/infdis/161.1.120
   REGOLI D, 1990, TRENDS PHARMACOL SCI, V11, P156, DOI 10.1016/0165-6147(90)90067-I
   Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004
   Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577
   Ryman KD, 2007, J GEN VIROL, V88, P518, DOI 10.1099/vir.0.82359-0
   Sammels LM, 1999, J GEN VIROL, V80, P739, DOI 10.1099/0022-1317-80-3-739
   Sarid R, 2001, CELL DEATH DIFFER, V8, P1224, DOI 10.1038/sj.cdd.4400926
   Stins MF, 1997, IN VITRO CELL DEV-AN, V33, P243
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997
   Trgovcich J, 1999, VIROLOGY, V263, P339, DOI 10.1006/viro.1999.9913
   Tripp RA, 2000, J VIROL, V74, P1614, DOI 10.1128/JVI.74.4.1614-1622.2000
   Tseng JC, 2004, NAT BIOTECHNOL, V22, P70, DOI 10.1038/nbt917
   Valarcher JF, 2006, J GEN VIROL, V87, P1659, DOI 10.1099/vir.0.81755-0
   Valenti C, 2010, BRIT J PHARMACOL, V161, P1616, DOI 10.1111/j.1476-5381.2010.00995.x
   VANDERMEIJDEN PE, 2010, CELL, V139, P1143
   Wang CR, 2005, ARTHRITIS RHEUM-US, V52, P1319, DOI 10.1002/art.20991
   Wang H, 2008, J GEN VIROL, V89, P2651, DOI 10.1099/vir.0.2008/005314-0
   Wang S, 2008, BRAIN, V131, P1241, DOI 10.1093/brain/awn060
   Wollmann G, 2005, J VIROL, V79, P6005, DOI 10.1128/JVI.79.10.6005-6022.2005
   Xia CF, 2004, HYPERTENSION, V43, P452, DOI 10.1161/01.HYP.0000110905.29389.e5
   Yao YY, 2008, CARDIOVASC RES, V80, P354, DOI 10.1093/cvr/cvn223
   Yin H, 2005, J BIOL CHEM, V280, P8022, DOI 10.1074/jbc.M407179200
   Zhang WJ, 2011, J IMMUNOL, V187, P1764, DOI 10.4049/jimmunol.1002315
   Zimmer G, 2003, J BIOL CHEM, V278, P46854, DOI 10.1074/jbc.M306949200
NR 69
TC 10
Z9 11
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JAN 5
PY 2012
VL 422
IS 1
BP 81
EP 91
DI 10.1016/j.virol.2011.10.003
PG 11
WC Virology
SC Virology
GA 859UW
UT WOS:000297902300009
PM 22047990
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Rocha, JDB
   Decote-Ricardo, D
   Redner, P
   Lopes, UG
   Barbosa, JM
   Piuvezam, MR
   Arruda, LB
   Pecanha, LMT
AF Rocha, Juliana D. B.
   Decote-Ricardo, Debora
   Redner, Paulo
   Lopes, Ulisses G.
   Barbosa-Filho, Jose M.
   Piuvezam, Marcia R.
   Arruda, Luciana B.
   Pecanha, Ligia Maria Torres
TI Inhibitory Effect of the Alkaloid Warifteine Purified from Cissampelos
   sympodialis on B Lymphocyte Function In Vitro and In Vivo
SO PLANTA MEDICA
LA English
DT Article
DE B lymphocyte; Cissampelos sympodialis; Menispermaceae; warifteine;
   immunoglobulin; signal transduction; Toll-like receptors
ID AQUEOUS FRACTION; CELL ACTIVATION; ETHANOL EXTRACT; CAMP; INDUCTION;
   EICHL; MODULATION; MECHANISM; RESPONSES; ANTIGENS
AB The aqueous fraction of the ethanolic extract of the plant Cissampelos sympodialis (Menispermaceae) was previously described to inhibit B cell function. The alkaloid warifteine is the major component of this extract. In the present study we investigated the effect of warifteine on B lymphocyte function and characterized its mechanism of action. Purified splenic murine B lymphocytes were stimulated with either Toll-like receptor (TLR) ligands (LPS, Pam(3)Cys and CpG oligodeoxynucleotides) or anti-IgM antibody and the effect of warifteine on B cell response was investigated. Warifteine inhibited both the proliferative response and immunoglobulin (Ig) secretion induced by these stimuli. Kinetics studies demonstrated that warifteine blocked B cell function even when added after 24 h of a 72 h culture. The inhibitory effect of warifteine was also detected in cultures activated by phorbol myristate acetate and calcium ionophore. We investigated the signal transduction pathways blocked by warifteine. It did not modify the total protein phosphorylation pattern in LPS and anti-IgM-stimulated B cell cultures. It did, however, decrease the rise in intracellular calcium levels, the phosphorylation of the mitogen activated protein kinase (MAPK) ERK and the intranuclear levels of the transcription factor NF kappa B. Warifteine also induced an increase in cAMP and its effect on LPS-induced proliferation was mimicked by the control adenyl cyclase activator forskolin. In vivo Ig production induced by the TI-2 antigen TNP-ficoll was also inhibited by warifteine. Taking together, our data suggest that warifteine is a potent inhibitor of B cell response both in vitro and in vivo and that this effect may be due to the induction of increased intracellular cAMP levels, suggesting that this substance may be useful as a modulator of B cell function.
C1 [Pecanha, Ligia Maria Torres] Univ Fed Rio de Janeiro, CCS, Dept Imunol, Inst Microbiol Prof Paulo de Goes,Ilha Fundao, BR-21944570 Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944570 Rio De Janeiro, Brazil.
   Univ Fed Paraiba, Dept Fisiol & Patol, BR-58059900 Joao Pessoa, Paraiba, Brazil.
   Univ Fed Paraiba, Lab Tecnol Farmaceut, BR-58059900 Joao Pessoa, Paraiba, Brazil.
   Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Prof Paulo de Goes, BR-21944570 Rio De Janeiro, Brazil.
RP Pecanha, LMT (corresponding author), Univ Fed Rio de Janeiro, CCS, Dept Imunol, Inst Microbiol Prof Paulo de Goes,Ilha Fundao, Bloco 1,Sala I2-062, BR-21944570 Rio De Janeiro, Brazil.
EM lpecanha@micro.ufrj.br
RI Filho, Jose Maria Barbosa/B-3951-2010; Decote-Ricardo,
   Debora/O-6480-2019; Arruda, Luciana/B-5806-2014; Arruda, Luciana
   B/N-9086-2013; Lopes, Ulisses Gazos/T-6634-2019; Redner,
   Paulo/A-1870-2013; Lopes, Ulisses/N-4416-2013
OI Filho, Jose Maria Barbosa/0000-0002-9567-4096; Redner,
   Paulo/0000-0003-2844-9769; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); PRONEX - MCT; PUC/PETROBRAS; FAPERJCarlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   CAPES/MECCAPES
FX Research supported by CNPq, PRONEX - MCT, PUC/PETROBRAS and FAPERJ.
   J.D.B. Rocha and D. Decote-Ricardo were recipients of CNPq and CAPES/MEC
   fellowships, respectively, and both contributed equally in the
   development of the study. We thank Dr. John Cambier for helpful
   discussion and for supplying reagents for the biochemical studies. The
   authors are indebt with Mr. Sidney Gomes da Costa for the technical
   support, with Ilka Abreu and Dr. Julio Scharfstein for the collaboration
   in the calcium studies, and with Simone Cotta for the collaboration in
   the initial experiments.
CR Agra Maria de Fátima, 2007, Rev. bras. farmacogn., V17, P114, DOI 10.1590/S0102-695X2007000100021
   Alexandre-Moreira MS, 2003, BRAZ J MED BIOL RES, V36, P1511, DOI 10.1590/S0100-879X2003001100010
   Benschop RJ, 2001, IMMUNITY, V14, P33, DOI 10.1016/S1074-7613(01)00087-5
   Bento CAM, 1996, J IMMUNOL, V157, P4996
   BRUNSWICK M, 1988, J IMMUNOL, V140, P3364
   Cortes SF, 1995, PHYTOTHER RES, V9, P579
   Costa HF, 2008, INT IMMUNOPHARMACOL, V8, P519, DOI 10.1016/j.intimp.2007.11.009
   de Lira GA, 2002, FITOTERAPIA, V73, P356, DOI 10.1016/S0367-326X(02)00089-8
   DeFreitas MR, 1996, J PHARM PHARMACOL, V48, P332, DOI 10.1111/j.2042-7158.1996.tb05928.x
   Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   IGAZ LM, 2000, BIOCHIM BIOPHYS ACTA, V1542, P139
   Irvin BJ, 2001, EXP CELL RES, V265, P73, DOI 10.1006/excr.2001.5157
   KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118
   Melo PS, 2003, TOXICOL LETT, V142, P143, DOI 10.1016/S0378-4274(03)00064-X
   Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524
   MOND JJ, 1989, IMMUNOPHARMACOLOGY, V18, P205, DOI 10.1016/0162-3109(89)90018-0
   MOND JJ, 1995, CURR OPIN IMMUNOL, V7, P349, DOI 10.1016/0952-7915(95)80109-X
   MURAGUCHI A, 1984, J IMMUNOL, V133, P1283
   Natarajan C, 2002, J IMMUNOL, V168, P6506, DOI 10.4049/jimmunol.168.12.6506
   Peng SL, 2005, CURR OPIN IMMUNOL, V17, P230, DOI 10.1016/j.coi.2005.03.003
   Pereira RMS, 2005, BIOCHEM BIOPH RES CO, V335, P20, DOI 10.1016/j.bbrc.2005.07.061
   ROPER RL, 1994, CELL IMMUNOL, V154, P296, DOI 10.1006/cimm.1994.1079
   Smith PG, 2005, BLOOD, V105, P308, DOI 10.1182/blood-2004-01-0240
   Snapper CM, 1996, J IMMUNOL, V157, P2229
   SNAPPER CM, 1987, J IMMUNOL, V139, P10
   Thomas G, 1997, PHYTOMEDICINE, V4, P233, DOI 10.1016/S0944-7113(97)80073-6
   Venkataraman C, 1998, MOL IMMUNOL, V35, P997, DOI 10.1016/S0161-5890(98)00068-6
   Vos Q, 2000, IMMUNOL REV, V176, P154
   WHISLER RL, 1992, CELL IMMUNOL, V142, P398, DOI 10.1016/0008-8749(92)90300-E
   YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613
NR 31
TC 12
Z9 12
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0032-0943
EI 1439-0221
J9 PLANTA MED
JI Planta Med.
PD MAR
PY 2010
VL 76
IS 4
BP 325
EP 330
DI 10.1055/s-0029-1186165
PG 6
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 562ET
UT WOS:000275033200003
PM 19787569
DA 2020-12-08
ER

PT J
AU Decote-Ricardo, D
   Chagas, KKF
   Rocha, JDB
   Redner, P
   Lopes, UG
   Cambier, JC
   de Arruda, LB
   Pecanha, LMT
AF Decote-Ricardo, D.
   Chagas, K. K. F.
   Rocha, J. D. B.
   Redner, P.
   Lopes, U. G.
   Cambier, J. C.
   de Arruda, L. Barros
   Pecanha, L. M. T.
TI Modulation of in vitro murine B-lymphocyte response by curcumin
SO PHYTOMEDICINE
LA English
DT Article
DE Curcuma longa (tumeric); Immunoglobulin; Signal transduction; Toll like
   receptors; T-independent antigen
ID NF-KAPPA-B; CELLS; STIMULATION; ACTIVATION; RECEPTORS; CANCER
AB Curcumin is a phenolic natural product isolated from the rhizome of Curcuma longa (tumeric). It was previously described that curcumin had a potent anti-inflammatory effect and inhibited the proliferation of a variety of tumor cells. In the present study, we investigated the inhibitory effects of curcumin on the response of normal murine splenic B cells. Curcumin inhibited the proliferative response of purified splenic B cells from BALB/c mice stimulated with the Toll-like receptor ligands LPS and CpG oligodeoxynucleotides. LPS-induced IgM secretion was also inhibited by curcumin. The proliferative response induced by either the T-independent type 2 stimuli anti-delta-dextran or anti-IgM antibodies was relatively resistant to the effect of curcumin. We investigated the intracellular signaling events involved in the inhibitory effects of curcumin on murine B cells. Curcumin did not inhibit the increase in calcium levels induced by anti-IgM antibody. Western blotting analysis showed that curcumin inhibited TLR ligands and anti-IgM-induced phosphorylation of ERK, I kappa B and p38. Curcumin also decreased the nuclear levels of NF kappa B. Our results suggested that curcumin is an important inhibitor of signaling pathways activated upon B cell stimulation by TLR ligands. These data indicate that curcumin could be a potent pharmacological inhibitor of B cell activation. (C) 2009 Elsevier GmbH. All rights reserved.
C1 [Decote-Ricardo, D.; Chagas, K. K. F.; Rocha, J. D. B.; Pecanha, L. M. T.] Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, CCS, BR-21944570 Rio De Janeiro, Brazil.
   [Redner, P.; Lopes, U. G.] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21944570 Rio De Janeiro, Brazil.
   [Cambier, J. C.] Univ Colorado, Hlth Sci Ctr, Integrated Dept Immunol, Denver, CO USA.
   [Cambier, J. C.] Natl Jewish Med & Res Ctr, Denver, CO USA.
   [de Arruda, L. Barros] Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Prof Paulo de Goes, BR-21944570 Rio De Janeiro, Brazil.
RP Pecanha, LMT (corresponding author), Univ Fed Rio de Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, CCS, Bloco 1,Sala I2-062, BR-21944570 Rio De Janeiro, Brazil.
EM lpecanha@micro.ufrj.br
RI Lopes, Ulisses/N-4416-2013; Arruda, Luciana B/N-9086-2013; Redner,
   Paulo/A-1870-2013; Arruda, Luciana/B-5806-2014; Lopes, Ulisses
   Gazos/T-6634-2019; Decote-Ricardo, Debora/O-6480-2019; da Rocha, Joao
   Batista Teixeira/S-6813-2016
OI Redner, Paulo/0000-0003-2844-9769; da Rocha, Joao Batista
   Teixeira/0000-0003-3829-0595; Cambier, John/0000-0002-7803-242X
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295, P01AI022295, P01AI022295, P01AI022295,
   P01AI022295, P01AI022295] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P01 AI022295-200014, P01 AI022295] Funding
   Source: Medline
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Benschop RJ, 2001, IMMUNITY, V14, P33, DOI 10.1016/S1074-7613(01)00087-5
   BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5
   BRUNSWICK M, 1988, J IMMUNOL, V140, P3364
   Churchill M, 2000, J SURG RES, V89, P169, DOI 10.1006/jsre.2000.5826
   Engelke M, 2007, IMMUNOL REV, V218, P235, DOI 10.1111/j.1600-065X.2007.00539.x
   Fillatreau S, 2006, EUR J IMMUNOL, V36, P798, DOI 10.1002/eji.200636040
   Groom JR, 2007, J EXP MED, V204, P1959, DOI 10.1084/jem.20062567
   Jagetia GC, 2007, J CLIN IMMUNOL, V27, P19, DOI 10.1007/s10875-006-9066-7
   Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004
   Kuramoto Y, 1996, BIOSCI BIOTECH BIOCH, V60, P1712, DOI 10.1271/bbb.60.1712
   MOND JJ, 1995, CURR OPIN IMMUNOL, V7, P349, DOI 10.1016/0952-7915(95)80109-X
   Natarajan C, 2002, J IMMUNOL, V168, P6506, DOI 10.4049/jimmunol.168.12.6506
   Pereira RMS, 2005, BIOCHEM BIOPH RES CO, V335, P20, DOI 10.1016/j.bbrc.2005.07.061
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   SNAPPER CM, 1987, J IMMUNOL, V139, P10
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Toubi E, 2004, AUTOIMMUNITY, V37, P183, DOI 10.1080/08916930410001704944
   Treml LS, 2007, J IMMUNOL, V178, P7531, DOI 10.4049/jimmunol.178.12.7531
   YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613
NR 20
TC 13
Z9 14
U1 0
U2 7
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944-7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD OCT
PY 2009
VL 16
IS 10
BP 982
EP 988
DI 10.1016/j.phymed.2009.01.004
PG 7
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA 506KL
UT WOS:000270773600013
PM 19303754
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Monteiro, AC
   Schmitz, V
   Morrot, A
   de Arruda, LB
   Nagajyothi, F
   Granato, A
   Pesquero, JB
   Muller-Esterl, W
   Tanowitz, HB
   Scharfstein, J
AF Monteiro, Ana Carolina
   Schmitz, Veronica
   Morrot, Alexandre
   de Arruda, Luciana Barros
   Nagajyothi, Fnu
   Granato, Alessandra
   Pesquero, Joao B.
   Mueller-Esterl, Werner
   Tanowitz, Herbert B.
   Scharfstein, Julio
TI Bradykinin B-2 receptors of dendritic cells, acting as sensors of Kinins
   proteolytically released by Trypanosoma cruzi, are critical for the
   development of protective type-1 responses
SO PLOS PATHOGENS
LA English
DT Article
ID CHAGAS HEART-DISEASE; CD8(+) T-CELLS; NITRIC-OXIDE PRODUCTION; TOLL-LIKE
   RECEPTOR-2; CUTTING EDGE; DANGER SIGNAL; INFECTION; MICE; RESISTANCE;
   ACTIVATION
AB Although the concept that dendritic cells (DCs) recognize pathogens through the engagement of Toll-like receptors is widely accepted, we recently suggested that immature DCs might sense kinin-releasing strains of Trypanosoma cruzi through the triggering of G-protein-coupled bradykinin B-2 receptors (B2R). Here we report that C57BL/6.B2R-/- mice infected intraperitoneally with T. cruzi display higher parasitemia and mortality rates as compared to B2R(+/+) mice. qRT-PCR revealed a 5-fold increase in T. cruzi DNA (14 d post-infection [p.i.])in B2R(-/-) heart, while spleen parasitism was negligible in both mice strains. Analysis of recall responses (14 d p.i.) showed high and comparable frequencies of IFN-gamma-producing CD4(+) and CD8(+) T cells in the spleen of B2R-/- and wild-type mice. However, production of IFN-gamma by effector T cells isolated from B2R-/- heart was significantly reduced as compared with wild- type mice. As the infection continued, wild- type mice presented IFN-gamma-producing (CD4(+)CD44(+)and CD8(+)CD44(+)) T cells both in the spleen and heart while B2R-/- mice showed negligible frequencies of such activated T cells. Furthermore, the collapse of type-1 immune responses in B2R(-/-) mice was linked to upregulated secretion of IL-17 and TNF-alpha by antigen- responsive CD4(+) T cells. In vitro analysis of tissue culture trypomastigote interaction with splenic CD11c(+) DCs indicated that DC maturation (IL-12, CD40, and CD86) is controlled by the kinin/B2R pathway. Further, systemic injection of trypomastigotes induced IL- 12 production by CD11c(+) DCs isolated from B2R+/+ spleen, but not by DCs from B2R(-/-) mice. Notably, adoptive transfer of B2R(+-/+-) CD11c(+) DCs (intravenously) into B2R-/- mice rendered them resistant to acute challenge, rescued development of type-1 immunity, and repressed T(H)17 responses. Collectively, our results demonstrate that activation of B2R, a DC sensor of endogenous maturation signals, is critically required for development of acquired resistance to T. cruzi infection.
C1 Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil.
   NIAID, Intracellular Parasite Biol Sect, Parasit Dis Lab, Bethesda, MD 20892 USA.
   Univ Fed Rio de Janeiro, Inst Microbiol Paulo de Goes, Rio De Janeiro, Brazil.
   Albert Einstein Coll Med, Bronx, NY 10467 USA.
   Univ Sao Paulo, Dept Biofis, Sao Paulo, Brazil.
   Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, Frankfurt, Germany.
RP Scharfstein, J (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil.
EM scharf@biof.ufrj.br
RI Schmitz, Veronica P/D-2458-2013; Arruda, Luciana/B-5806-2014; Arruda,
   Luciana B/N-9086-2013; Pesquero, Joao/C-1470-2012; Morrot,
   Alexandre/J-8727-2012
OI Schmitz, Veronica P/0000-0002-0865-133X; Pesquero,
   Joao/0000-0002-4507-632X; Morrot, Alexandre/0000-0001-9432-9701
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI 052739, R01 AI052739] Funding Source:
   Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI052739, R01AI052739, R01AI052739, R01AI052739,
   R01AI052739] Funding Source: NIH RePORTER
CR Albareda MC, 2006, INT IMMUNOL, V18, P465, DOI 10.1093/intimm/dxh387
   Aliberti J, 2003, J IMMUNOL, V170, P5349, DOI 10.4049/jimmunol.170.11.5349
   Bafica A, 2006, J IMMUNOL, V177, P3515, DOI 10.4049/jimmunol.177.6.3515
   Batten M, 2006, NAT IMMUNOL, V7, P929, DOI 10.1038/ni1375
   Bellotti G, 1996, AM HEART J, V131, P301, DOI 10.1016/S0002-8703(96)90358-0
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   Bouzahzah B, 2006, CELL CYCLE, V5, P2396, DOI 10.4161/cc.5.20.3380
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Claser C, 2007, MICROBES INFECT, V9, P1011, DOI 10.1016/j.micinf.2007.04.006
   Costa VMA, 2006, J IMMUNOL, V177, P3193, DOI 10.4049/jimmunol.177.5.3193
   Cummings KL, 2003, MOL BIOCHEM PARASIT, V129, P53, DOI 10.1016/S0166-6851(03)00093-8
   Da Silva APG, 2003, IMMUNOLOGY, V108, P230, DOI 10.1046/j.1365-2567.2003.01571.x
   DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713
   Duthie MS, 2005, INFECT IMMUN, V73, P1890, DOI 10.1128/IAI.73.3.1890-1894.2005
   FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   Freitas HFG, 2005, INT J CARDIOL, V102, P239, DOI 10.1016/j.ijcard.2004.05.025
   Gomes JAS, 2005, INFECT IMMUN, V73, P7960, DOI 10.1128/IAI.73.12.7960-7966.2005
   Grisotto MG, 2001, IMMUNOLOGY, V102, P209, DOI 10.1046/j.1365-2567.2001.01170.x
   Hamano S, 2003, IMMUNITY, V19, P657, DOI 10.1016/S1074-7613(03)00298-X
   Hardison JL, 2006, INFECT IMMUN, V74, P135, DOI 10.1128/IAI.74.1.135-143.2006
   Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254
   Higuchi MD, 1997, AM J TROP MED HYG, V56, P485
   IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330
   Koga R, 2006, J IMMUNOL, V177, P7059, DOI 10.4049/jimmunol.177.10.7059
   Kumar S, 1998, PARASITE IMMUNOL, V20, P207, DOI 10.1046/j.1365-3024.1998.00154.x
   Laucella SA, 2004, J INFECT DIS, V189, P909, DOI 10.1086/381682
   Leavey JK, 2003, J IMMUNOL, V170, P2264, DOI 10.4049/jimmunol.170.5.2264
   Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   Lima APCA, 2002, J BIOL CHEM, V277, P5875, DOI 10.1074/jbc.M108518200
   Machado FS, 2005, J INFECT DIS, V191, P627, DOI 10.1086/427515
   Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754
   Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   Martin DL, 2006, PLOS PATHOG, V2, P731, DOI 10.1371/journal.ppat.0020077
   Martin DL, 2005, J IMMUNOL, V174, P1594, DOI 10.4049/jimmunol.174.3.1594
   Monteiro AC, 2006, J IMMUNOL, V177, P6325, DOI 10.4049/jimmunol.177.9.6325
   Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688
   Ouaissi A, 2002, J IMMUNOL, V168, P6366, DOI 10.4049/jimmunol.168.12.6366
   Padilla A, 2007, INFECT IMMUN, V75, P231, DOI 10.1128/IAI.01245-06
   Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261
   Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997
   ROPERT C, 2007, PROTOZOANS MACROPHAG, P49
   Scharfstein J, 2000, J EXP MED, V192, P1289, DOI 10.1084/jem.192.9.1289
   Scharfstein J, 2007, SCAND J IMMUNOL, V66, P128, DOI 10.1111/j.1365-3083.2007.01983.x
   Scharfstein J, 2003, MED INTELL UNIT, P111
   SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862-4867.1995
   Tarleton RL, 2003, TRENDS PARASITOL, V19, P447, DOI 10.1016/j.pt.2003.08.008
   Tarleton RL, 1996, INT IMMUNOL, V8, P13, DOI 10.1093/intimm/8.1.13
   Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038
   Tzelepis F, 2006, INFECT IMMUN, V74, P2477, DOI 10.1128/IAI.74.4.2477-2481.2006
   Van Overtvelt L, 1999, INFECT IMMUN, V67, P4033, DOI 10.1128/IAI.67.8.4033-4040.1999
   Zhang L, 1999, J INFECT DIS, V180, P480, DOI 10.1086/314889
NR 54
TC 59
Z9 60
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-7366
J9 PLOS PATHOG
JI PLoS Pathog.
PD NOV
PY 2007
VL 3
IS 11
BP 1730
EP 1744
AR e185
DI 10.1371/journal.ppat.0030185
PG 15
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 236NS
UT WOS:000251310300017
PM 18052532
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Chikhlikar, P
   de Arruda, LB
   Maciel, M
   Silvera, P
   Lewis, MG
   August, JT
   Marques, ETA
AF Chikhlikar, Priya
   de Arruda, Luciana Barros
   Maciel, Milton
   Silvera, Peter
   Lewis, Mark G.
   August, J. Thomas
   Marques, Ernesto T. A.
TI DNA Encoding an HIV-1 Gag/Human Lysosome-Associated Membrane Protein-1
   Chimera Elicits a Broad Cellular and Humoral Immune Response in Rhesus
   Macaques
SO PLOS ONE
LA English
DT Article
AB Previous studies of HIV-1 p55Gag immunization of mice have demonstrated the usefulness of targeting antigens to the cellular compartment containing the major histocompatibility complex type II (MHC II) complex molecules by use of a DNA antigen formulation encoding Gag as a chimera with the mouse lysosome-associated membrane protein (mLAMP/gag). In the present study, we have analyzed the magnitude and breadth of Gag-specific T-lymphocyte and antibody responses elicited in Rhesus macaques after immunization with DNA encoding a human LAMP/gag(hLAMP/gag) chimera. ELISPOT analyses indicated that the average Gag-specific IFN-gamma response elicited by the hLAMP/gag chimera was detectable after only two or three naked DNA immunizations in all five immunized macaques and reached an average of 1000 spot-forming cells (SFC)/10(6) PBMCs. High IFN-gamma ELISPOT responses were detected in CD8(+)-depleted cells, indicating that CD4(+) T-cells play a major role in these responses. The T-cell responses of four of the macaques were also tested by use of ELISPOT to 12 overlapping 15-amino acids (aa) peptide pools containing ten peptides each, encompassing the complete Gag protein sequence. The two Mamu 08 immunized macaques responded to eight and twelve of the pools, the Mamu B01 to six, and the other macaque to five pools indicating that the hLAMP/gag DNA antigen formulation elicits a broad T-cell response against Gag. Additionally, there was a strong HIV-1-specific IgG response. The IgG antibody titers increased after each DNA injection, indicating a strong amnestic B-cell response, and were highly elevated in all the macaques after three immunizations. Moreover, the serum of each macaque recognized 13 of the 49 peptides of a 20-aa peptide library covering the complete Gag amino acid sequence. In addition, HIV-1-specific IgA antibodies were present in the plasma and external secretions, including nasal washes. These data support the findings of increased immunogenicity of genetic vaccines encoded as LAMP chimeras, including the response to DNA vaccines by non-human primates.
C1 [Chikhlikar, Priya; Maciel, Milton; August, J. Thomas; Marques, Ernesto T. A.] Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
   [de Arruda, Luciana Barros] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, Rio De Janeiro, Brazil.
   [Silvera, Peter; Lewis, Mark G.] So Res Inst, Frederick, MD USA.
   [Marques, Ernesto T. A.] Fundacao Oswaldo Cruz, FIOCRUZ, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
   [Marques, Ernesto T. A.] Johns Hopkins Sch Med, Div Infect Dis, Dept Med, Baltimore, MD USA.
RP Marques, ETA (corresponding author), Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21218 USA.
EM emarques@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Marques, Ernesto/L-4514-2013; Arruda,
   Luciana/B-5806-2014; Arruda, Luciana B/N-9086-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU National Institute of Allergy and Infectious Disease, National
   Institutes of Health, USAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R37-AI41908, R21-AI44317,
   N01-AI-15429]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI015429, R01AI015429, R37AI041908,
   R01AI015429, R21AI044317, R01AI015429, R01AI015429, R01AI015429,
   R01AI015429, R37AI041908, R01AI015429, R37AI041908, R37AI041908,
   R01AI015429, R01AI015429, R01AI015429, R01AI015429, R37AI041908,
   R01AI015429, R01AI015429, R37AI041908, R01AI015429, R01AI015429,
   R37AI041908, R01AI015429, R01AI015429, R37AI041908, R01AI015429,
   R01AI015429, R01AI015429, R01AI015429, R37AI041908, R01AI015429,
   R37AI041908, R01AI015429, R01AI015429, R21AI044317] Funding Source: NIH
   RePORTER
FX Supported by Grants R37-AI41908, R21-AI44317 and N01-AI-15429 "Simian
   Vaccine Evaluation Unit'' contract from the National Institute of
   Allergy and Infectious Disease, National Institutes of Health, USA
CR Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Anwar A, 2005, VIROLOGY, V332, P66, DOI 10.1016/j.virol.2004.11.022
   Arruda LB, 2006, J IMMUNOL, V177, P2265, DOI 10.4049/jimmunol.177.4.2265
   BEAGLEY KW, 1989, J EXP MED, V169, P2133, DOI 10.1084/jem.169.6.2133
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   CARPIO E, 1991, AIDS RES HUM RETROV, V7, P97, DOI 10.1089/aid.1991.7.97
   Casimiro DR, 2003, J VIROL, V77, P7663, DOI 10.1128/JVI.77.13.7663-7668.2003
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   Douek DC, 2006, CELL, V124, P677, DOI 10.1016/j.cell.2006.02.005
   Drake JR, 1999, J IMMUNOL, V162, P1150
   DUBEY C, 1995, J IMMUNOL, V155, P45
   FUJIHASHI K, 1991, J CLIN INVEST, V88, P248, DOI 10.1172/JCI115284
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   GUPTA V, 2005, VIROLOGY
   Hanke T, 1999, J VIROL, V73, P7524, DOI 10.1128/JVI.73.9.7524-7532.1999
   Kavanagh DG, 2006, BLOOD, V107, P1963, DOI 10.1182/blood-2005-04-1513
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   MATHIESEN T, 1989, IMMUNOLOGY, V67, P453
   MATSUO K, 1992, J GEN VIROL, V73, P2445, DOI 10.1099/0022-1317-73-9-2445
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   MAZANEC MB, 1992, VIRUS RES, V23, P1, DOI 10.1016/0168-1702(92)90063-F
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   NIEDRIG M, 1991, J VIROL, V65, P4529, DOI 10.1128/JVI.65.8.4529-4533.1991
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Robinson HL, 1995, ANN NY ACAD SCI, V772, P209, DOI 10.1111/j.1749-6632.1995.tb44746.x
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397
   Sedegah M, 1998, P NATL ACAD SCI USA, V95, P7648, DOI 10.1073/pnas.95.13.7648
   Su Z, 2002, CANCER RES, V62, P5041
   Su Z, 2005, J IMMUNOL, V174, P3798, DOI 10.4049/jimmunol.174.6.3798
   SUNDQVIST VA, 1989, J MED VIROL, V29, P170, DOI 10.1002/jmv.1890290305
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   Wu L, 2005, J VIROL, V79, P8024, DOI 10.1128/JVI.79.13.8024-8031.2005
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
NR 44
TC 24
Z9 25
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 27
PY 2006
VL 1
IS 2
AR e135
DI 10.1371/journal.pone.0000135
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V10DC
UT WOS:000207443700029
PM 17205139
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Monteiro, AC
   Schmitz, V
   Svensjo, E
   Gazzinelli, RT
   Almeida, IC
   Todorov, A
   de Arruda, LB
   Torrecilhas, ACT
   Pesquero, JB
   Morrot, A
   Bouskela, E
   Bonomo, A
   Lima, APCA
   Muller-Esterl, W
   Scharfstein, J
AF Monteiro, Ana Carolina
   Schmitz, Veronica
   Svensjo, Erik
   Gazzinelli, Ricardo T.
   Almeida, Igor C.
   Todorov, Alex
   de Arruda, Luciana B.
   Torrecilhas, Ana Claudia T.
   Pesquero, Joao B.
   Morrot, Alexandre
   Bouskela, Eliete
   Bonomo, Adriana
   Lima, Ana Paula C. A.
   Mueller-Esterl, Werner
   Scharfstein, Julio
TI Cooperative activation of TLR2 and bradykinin B-2 receptor is required
   for induction of type 1 immunity in a mouse model of subcutaneous
   infection by Trypanosoma cruzi
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTOR-2; DENDRITIC CELLS; GLYCOSYLPHOSPHATIDYLINOSITOL
   ANCHORS; DANGER SIGNAL; KININ; PARASITE; MECHANISMS; RESISTANCE;
   INHIBITORS; EXPRESSION
AB We have previously reported that exogenous bradykinin activates immature dendritic cells (DCs) via the bradykinin B-2 receptor (B2R), thereby stimulating adaptive immunity. In this study, we show that these premises are met in a model of s.c. infection by Trypanosoma cruzi, a protozoan that liberates kinins from kininogens through its major protease, cruzipain. Intensity of B2R-dependent paw edema evoked by trypomastigotes correlated with levels of IL-12 produced by CD11c(+) dendritic cells isolated from draining lymph nodes. The IL-12 response induced by endogenously released kinins was vigorously increased in infected mice pretreated with inhibitors of angiotensin converting enzyme (ACE), a kinin-degrading metallopeptidase. Furthermore, these innate stimulatory effects were linked to B2R-dependent up-regulation of IFN-gamma production by Ag-specific T cells. Strikingly, the trypomastigotes failed to up-regulate type 1 immunity in TLR2(-/-) mice, irrespective of ACE inhibitor treatment. Analysis of the dynamics of inflammation revealed that TLR2 triggering by glycosylphosphatidylinositol-anchored mucins induces plasma extravasaiion, thereby favoring peripheral accumulation of kininogens in sites of infection. Further downstream, the parasites generate high levels of innate kinin signals in peripheral tissues through the activity of cruzipain. The demonstration that the deficient type I immune responses of TLR2(-/-) mice are rescued upon s.c. injection of exogenous kininogens, along with trypomastigotes, supports the notion that generation of kinin "danger" signals is intensified through cooperative activation of TLR2 and B2R. In summary, we have described a s.c. infection model where type I immunity is vigorously up-regulated by bradykinin, an innate signal whose levels in peripheral tissues are controlled by an intricate interplay of TLR2, B2R, and ACE.
C1 Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Lab Imunol Mol, Rio De Janeiro, Brazil.
   Ctr Pesquisas Rene Rachou Fiocruz, Lab Imunopatol, Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   Univ Texas, Dept Biol Sci, El Paso, TX 79968 USA.
   Univ Fed Rio de Janeiro, Inst Microbiol, Rio de Janeiro, Brazil.
   Univ Sao Paulo, Dept Bioquim, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Biofis, Sao Paulo, Brazil.
   Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA.
   Univ Estado Rio de Janeiro, Lab Microcirculacao, Rio De Janeiro, Brazil.
   Goethe Univ Frankfurt, Inst Biochem 2, Sch Med, D-6000 Frankfurt, Germany.
RP Scharfstein, J (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Biofis Carlos Chagas Filho, Lab Imunol Mol, Bloco D,Sala D 007, Rio De Janeiro, Brazil.
EM scharf@biof.ufrj.br
RI Lima, Ana Paula CA/G-4122-2012; Schmitz, Veronica P/D-2458-2013;
   Pesquero, Joao/C-1470-2012; Almeida, Igor C./AAF-9409-2019;
   /W-6163-2019; Arruda, Luciana B/N-9086-2013; Svensjo, Erik/B-5026-2008;
   Arruda, Luciana/B-5806-2014; Morrot, Alexandre/J-8727-2012
OI Schmitz, Veronica P/0000-0002-0865-133X; Pesquero,
   Joao/0000-0002-4507-632X; Almeida, Igor C./0000-0002-2443-8213; Svensjo,
   Erik/0000-0002-7356-1787; Gazzinelli, Ricardo/0000-0003-2427-7699; LIMA,
   ANA PAULA C. A./0000-0003-4631-2694; Morrot,
   Alexandre/0000-0001-9432-9701
FU NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124, G12RR008124, G12RR008124, G12RR008124,
   G12RR008124, G12RR008124] Funding Source: NIH RePORTER; NCRR NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [5G12 RR 008124] Funding Source: Medline; Wellcome
   TrustWellcome Trust [072349/Z/03/Z] Funding Source: Medline
CR Aliberti J, 2003, J IMMUNOL, V170, P5349, DOI 10.4049/jimmunol.170.11.5349
   Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467
   Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476
   Basu S, 2005, P NATL ACAD SCI USA, V102, P5120, DOI 10.1073/pnas.0407780102
   BHOOLA KD, 1992, PHARMACOL REV, V44, P1
   Blaukat A, 2003, AM J PHYSIOL-HEART C, V284, pH1909, DOI 10.1152/ajpheart.00034.2003
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Coelho PS, 2002, J LEUKOCYTE BIOL, V71, P837
   Danilov SM, 2003, EXP HEMATOL, V31, P1301, DOI 10.1016/j.exphem.2003.08.018
   DelNery E, 1997, J BIOL CHEM, V272, P25713, DOI 10.1074/jbc.272.41.25713
   Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725
   Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696
   Ferreira J, 2004, BRIT J PHARMACOL, V141, P787, DOI 10.1038/sj.bjp.0705546
   Gautam N, 2001, NAT MED, V7, P1123, DOI 10.1038/nm1001-1123
   Herwald H, 1996, J EXP MED, V184, P665, DOI 10.1084/jem.184.2.665
   Imamura T, 2005, J EXP MED, V201, P1669, DOI 10.1084/jem.20042041
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   Lima APCA, 2002, J BIOL CHEM, V277, P5875, DOI 10.1074/jbc.M108518200
   Lima APCA, 2001, MOL BIOCHEM PARASIT, V114, P41, DOI 10.1016/S0166-6851(01)00236-5
   Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658
   Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460
   Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059
   Oliveira AC, 2004, J IMMUNOL, V173, P5688, DOI 10.4049/jimmunol.173.9.5688
   Ouaissi A, 2002, J IMMUNOL, V168, P6366, DOI 10.4049/jimmunol.168.12.6366
   Riedemann NC, 2003, FASEB J, V17, P370, DOI 10.1096/fj.03-0708fje
   Scharfstein J, 2000, J EXP MED, V192, P1289, DOI 10.1084/jem.192.9.1289
   Scharfstein J, 2006, IMMUNOBIOLOGY, V211, P117, DOI 10.1016/j.imbio.2005.10.014
   Scharfstein J, 2003, MED INTELL UNIT, P111
   Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704
   Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991
   Shigematsu S, 2002, AM J PHYSIOL-HEART C, V283, pH2676, DOI 10.1152/ajpheart.00538.2002
   Shigematsu S, 2001, AM J PHYSIOL-HEART C, V280, pH441
   Skidgel RA, 2004, PEPTIDES, V25, P521, DOI 10.1016/j.peptides.2003.12.010
   Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162
   Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749
   Svensjo E, 2006, MICROBES INFECT, V8, P206, DOI 10.1016/j.micinf.2005.06.016
   Tarleton RL, 2003, TRENDS PARASITOL, V19, P447, DOI 10.1016/j.pt.2003.08.008
   Todorov AG, 2002, FASEB J, V16, P73, DOI 10.1096/fj.02-0477fje
NR 40
TC 64
Z9 65
U1 0
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2006
VL 177
IS 9
BP 6325
EP 6335
DI 10.4049/jimmunol.177.9.6325
PG 11
WC Immunology
SC Immunology
GA 097VN
UT WOS:000241477400067
PM 17056563
OA Bronze
DA 2020-12-08
ER

PT J
AU Arruda, LB
   Sim, D
   Chikhlikar, PR
   Maciel, M
   Akasaki, K
   August, JT
   Marques, ETA
AF Arruda, Luciana B.
   Sim, Del
   Chikhlikar, Priya R.
   Maciel, Milton, Jr.
   Akasaki, Kenji
   August, J. Thomas
   Marques, Ernesto T. A.
TI Dendritic cell-lysosomal-associated membrane protein (LAMP) and
   LAMP-1-HIV-1 Gag chimeras have distinct cellular trafficking pathways
   and prime T and B cell responses to a diverse repertoire of epitopes
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CLASS-II COMPARTMENT; COMPLEX CLASS-II; ANTIGEN-PRESENTING CELLS;
   EXOGENOUS ANTIGENS; DNA VACCINE; CROSS-PRESENTATION; IMMUNE-RESPONSE;
   ENDOCYTIC COMPARTMENTS; CATHEPSIN ACTIVITY; PLASMA-MEMBRANE
AB Ag processing is a critical step in defining the repertoire of epitope-specific immune responses. In the present study, HIV-1 p55Gag Ag was synthesized as a DNA plasmid with either lysosomal-associated membrane protein-1 (LAMP/gag) or human dendritic cell-LAMP (DC-LAMP/gag) and used to immunize mice. Analysis of the cellular trafficking of these two chimeras demonstrated that both molecules colocalized with MHC class II molecules but differed in their overall trafficking to endosomal/lysosomal compartments. Following DNA immunization, both chimeras elicited potent Gag-specific T and B cell immune responses in mice but differ markedly in their IL-4 and IgG1/IgG2a responses. The DC-LAMP chimera induced a stronger Th type 1 response. ELISPOT analysis of T cell responses to 122 individual peptides encompassing the entire p55gag sequence (15-aa peptides overlapping by 11 residues) showed that DNA immunization with native gag, LAMP/gag, or DC-LAMP/gag induced responses to identical immunodominant CD4(+) and CD8(+) peptides. However, LAMP/gag and DC-LAMP/gag plasmids also elicited significant responses to 23 additional cryptic epitopes that were not recognized after immunization with native gag DNA. The three plasmids induced T cell responses to a total of 39 distinct peptide sequences, 13 of which were induced by all three DNA constructs. Individually, DC-LAMP/gag elicited the most diverse response, with a specific T cell response against 35 peptides. In addition, immunization with LAMP/gag and DC-LAMP/gag chimeras also promoted Ab secretion to an increased number of epitopes. These data indicate that LAMP-1 and DC-LAMP Ag chimeras follow different trafficking pathways, induce distinct modulatory immune responses, and are able to present cryptic epitopes.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA.
   Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Rio De Janeiro, Brazil.
   Div John Hopkins Singapore, Singapore, Singapore.
   Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Hiroshima, Japan.
   Fdn Oswaldo Cruz, Aggeu Magalhaes Res Ctr, Virol & Expt Therapy Lab, Recife, PE, Brazil.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Biophys 307,725 N Wolfe St, Baltimore, MD 21205 USA.
EM emarques@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana B/N-9086-2013;
   Marques, Ernesto/L-4514-2013; Arruda, Luciana/B-5806-2014
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI041908, R21AI044317, R37AI041908, R21AI044317, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21 AI 44317, R37 AI 41908] Funding Source:
   Medline
CR Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082
   Akasaki K, 2004, ARCH BIOCHEM BIOPHYS, V425, P147, DOI 10.1016/j.abb.2004.02.042
   AKASAKI K, 1995, EXP CELL RES, V220, P464, DOI 10.1006/excr.1995.1338
   Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124
   Allen TM, 2004, J VIROL, V78, P7069, DOI 10.1128/JVI.78.13.7069-7078.2004
   Barois N, 2002, TRAFFIC, V3, P894, DOI 10.1034/j.1600-0854.2002.31205.x
   Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a
   Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004
   Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Chang MHY, 2004, BIOCHEM J, V382, P481, DOI 10.1042/BJ20031752
   CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Chen L, 2004, SCAND J IMMUNOL, V59, P545, DOI 10.1111/j.1365-3083.2004.01426.x
   Chen LY, 2004, EUR J IMMUNOL, V34, P952, DOI 10.1002/eji.200324359
   Chikhlikar P, 2004, VIROLOGY, V323, P220, DOI 10.1016/j.virol.2004.02.025
   Chouquet C, 2002, AIDS, V16, P2399, DOI 10.1097/00002030-200212060-00004
   Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006
   Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842
   De Arruda LB, 2004, IMMUNOLOGY, V112, P126, DOI 10.1111/j.1365-2567.2004.01823.x
   de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9
   Delvig AA, 2002, J LEUKOCYTE BIOL, V72, P163
   Delvig AA, 1998, J BIOL CHEM, V273, P3291, DOI 10.1074/jbc.273.6.3291
   DeStafanis D, 1997, CELL TISSUE RES, V289, P109
   Eisen HN, 2001, ANNU REV IMMUNOL, V19, P1, DOI 10.1146/annurev.immunol.19.1.1
   Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Harding CV, 2003, CURR OPIN IMMUNOL, V15, P112, DOI 10.1016/S0952-7915(02)00008-0
   Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512
   Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1
   Kavanagh DG, 2006, BLOOD, V107, P1963, DOI 10.1182/blood-2005-04-1513
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 2001, TRAFFIC, V2, P124, DOI 10.1034/j.1600-0854.2001.020207.x
   Kloetzel PM, 2004, CURR OPIN IMMUNOL, V16, P76, DOI 10.1016/j.coi.2003.11.004
   Lautwein A, 2004, J LEUKOCYTE BIOL, V75, P844, DOI 10.1189/jlb.0803367
   Lautwein A, 2002, EUR J IMMUNOL, V32, P3348, DOI 10.1002/1521-4141(200212)32:12<3348::AID-IMMU3348>3.0.CO;2-S
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Lewis PJ, 1999, J VIROL, V73, P10214, DOI 10.1128/JVI.73.12.10214-10223.1999
   LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673
   MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3
   Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mata M, 1998, J IMMUNOL, V161, P2985
   Meikle PJ, 1999, MOL GENET METAB, V66, P179, DOI 10.1006/mgme.1998.2800
   Murk JL, 2002, SEMIN CELL DEV BIOL, V13, P303, DOI 10.1016/S1084952102000605
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200
   Perrin-Cocon LA, 2004, J IMMUNOL, V172, P3564, DOI 10.4049/jimmunol.172.6.3564
   Potter NS, 2001, J IMMUNOL, V167, P2538, DOI 10.4049/jimmunol.167.5.2538
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rock KL, 2004, NAT IMMUNOL, V5, P670, DOI 10.1038/ni1089
   Rodriguez F, 2001, J VIROL, V75, P7399, DOI 10.1128/JVI.75.16.7399-7409.2001
   Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Salaun B, 2004, AM J PATHOL, V164, P861, DOI 10.1016/S0002-9440(10)63174-4
   Santra S, 2002, J VIROL, V76, P6376, DOI 10.1128/JVI.76.12.6376-6381.2002
   Schirmbeck R, 2002, MOL IMMUNOL, V39, P249, DOI 10.1016/S0161-5890(02)00105-0
   Su Z, 2002, CANCER RES, V62, P5041
   Surman S, 2001, P NATL ACAD SCI USA, V98, P4587, DOI 10.1073/pnas.071063898
   Tobian AAR, 2004, J IMMUNOL, V172, P5277, DOI 10.4049/jimmunol.172.9.5277
   Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744
   Watts C, 2004, NAT IMMUNOL, V5, P685, DOI 10.1038/ni1088
   Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821
   Wu JM, 2000, J NEUROIMMUNOL, V106, P145, DOI 10.1016/S0165-5728(00)00201-0
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
NR 69
TC 39
Z9 39
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD AUG 15
PY 2006
VL 177
IS 4
BP 2265
EP 2275
DI 10.4049/jimmunol.177.4.2265
PG 11
WC Immunology
SC Immunology
GA 073LU
UT WOS:000239745300034
PM 16887987
OA Bronze
DA 2020-12-08
ER

PT J
AU Alexandre-Moreira, MS
   Takiya, CM
   de Arruda, LB
   Pascarelli, B
   Gomes, RN
   Faria Neto, HCC
   Lima, LM
   Barreiro, EJ
AF Alexandre-Moreira, MS
   Takiya, CM
   de Arruda, LB
   Pascarelli, B
   Gomes, RN
   Faria Neto, HCC
   Lima, LM
   Barreiro, EJ
TI LASSBio-468: a new achiral thalidomide analogue which modulates
   TNF-alpha and NO production and inhibits endotoxic shock and arthritis
   in an animal model
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE endotoxic shock; TNF-alpha; NO; LPS; LASSBio-468
ID TUMOR-NECROSIS-FACTOR; PULMONARY GRANULOMA-FORMATION; NITRIC-OXIDE
   PRODUCTION; RESPONSES; MICE; MYCOBACTERIAL; IL-10; MONOCYTOGENES;
   DEFICIENT; MECHANISM
AB As part of a program researching the synthesis and immunopharmacological evaluation of novel synthetic compounds, we have described the immune modulatory profile of the new achiral thalidomide analogue LASSBio-468 in the present work. This compound was planned as an N-substituted phthalimide derivate, structurally designed as a hybrid of thalidomide and aryl sulfonamides, which were previously described as tumor necrosis factor-alpha (TNF-alpha) and PDE4 inhibitors. LASSBio-468 was recently demonstrated to inhibit the TNF-alpha production induced by lipopolysaccharide (LPS), in vivo. Here, we investigated whether this compound would affect chronic inflammation processes associated with the production of this pro-inflammatory cytokine. Treatment with LASSBio-468 before a lethal dose injection of LPS in animals greatly inhibited endotoxic shock. This effect seems to be mediated by a specific down regulation of TNF-alpha and nitric oxide production, regulated mainly at the RNA level. In another model, histopathological analysis indicated that this compound also inhibited adjuvant-induced arthritis in rats. Taken together, our data demonstrated a potent anti-inflammatory effect of LASSBio-468, suggesting its use as a potential drug against chronic inflammatory diseases. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Fed Rio de Janeiro, Fac Farm, Dept Farmacos, LASSBio, BR-21944910 Rio De Janeiro, Brazil.
   Univ Fed Alagoas, Dept Fisiol, Alagoas, Brazil.
   Univ Fed Rio de Janeiro, Dept Histol & Embriol ICB, Rio De Janeiro, Brazil.
   Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, Rio De Janeiro, Brazil.
   Fiocruz MS, IOC, Dept Farmacodinam, BR-21045900 Rio De Janeiro, Brazil.
RP Barreiro, EJ (corresponding author), Univ Fed Rio de Janeiro, Fac Farm, Dept Farmacos, LASSBio, CP 68-006, BR-21944910 Rio De Janeiro, Brazil.
EM ejb@pharma.ufrj.br
RI Alexandre-Moreira, Magna S/C-3618-2013; Arruda, Luciana B/N-9086-2013;
   Arruda, Luciana/B-5806-2014; Gomes, Rachel N/I-7643-2013; Barreiro,
   Eliezer J/B-1131-2011
OI Alexandre-Moreira, Magna S/0000-0002-9979-1994; Moreira Lima,
   Lidia/0000-0002-8625-6351
CR BADGER AM, 1989, CIRC SHOCK, V27, P51
   Barbara JAJ, 1996, IMMUNOL CELL BIOL, V74, P434, DOI 10.1038/icb.1996.73
   BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437
   Calabrese L, 2000, AM J MED, V108, P487, DOI 10.1016/S0002-9343(99)00408-8
   CHENSUE SW, 1994, AM J PATHOL, V145, P1105
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Eigler A, 1998, J LEUKOCYTE BIOL, V63, P101
   GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X
   Hasko G, 1998, BRIT J PHARMACOL, V124, P1099, DOI 10.1038/sj.bjp.0701934
   Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292
   Klausner JD, 1996, CLIN IMMUNOL IMMUNOP, V81, P219, DOI 10.1006/clin.1996.0181
   Kunkel SL, 1996, SARCOIDOSIS VASC DIF, V13, P120
   Lanzavecchia A, 2001, NAT IMMUNOL, V2, P487, DOI 10.1038/88678
   LENZ W, 1962, LANCET, P1
   Lima LM, 2002, BIOORGAN MED CHEM, V10, P3067, DOI 10.1016/S0968-0896(02)00152-9
   Marchant A, 1996, CLIN EXP IMMUNOL, V106, P91, DOI 10.1046/j.1365-2249.1996.d01-799.x
   MORIERA AL, 1993, J EXP MED, V177, P1675
   Nemeth ZH, 1998, SHOCK, V10, P49, DOI 10.1097/00024382-199807000-00009
   NEWBOULD BB, 1963, BRIT J PHARM CHEMOTH, V21, P127, DOI 10.1111/j.1476-5381.1963.tb01508.x
   Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397
   PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C
   Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428
   Qiu BQ, 2001, AM J PATHOL, V158, P1503, DOI 10.1016/S0002-9440(10)64101-6
   REDDY MP, 1994, INT J IMMUNOPHARMACO, V16, P795, DOI 10.1016/0192-0561(94)90053-1
   REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F
   ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0
   SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699
   SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125
   Stirling DI, 2000, SEMIN HEMATOL, V37, P5, DOI 10.1016/S0037-1963(00)90077-5
   TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491
   TRACEY KJ, 1995, LANCET, V345, P75, DOI 10.1016/S0140-6736(95)90055-1
   Tseng S, 1996, J AM ACAD DERMATOL, V35, P969, DOI 10.1016/S0190-9622(96)90122-X
   TURK BE, 1996, P NATL ACAD SCI USA, V93, P7226
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 34
TC 15
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAR
PY 2005
VL 5
IS 3
BP 485
EP 494
DI 10.1016/j.intimp.2004.10.017
PG 10
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA 899JQ
UT WOS:000227141100003
PM 15683845
DA 2020-12-08
ER

PT J
AU Oliveira, AC
   Peixoto, JR
   de Arruda, LB
   Campos, MA
   Gazzinelli, RT
   Golenbock, DT
   Akira, S
   Previato, JO
   Mendonca-Previato, L
   Nobrega, A
   Bellio, M
AF Oliveira, AC
   Peixoto, JR
   de Arruda, LB
   Campos, MA
   Gazzinelli, RT
   Golenbock, DT
   Akira, S
   Previato, JO
   Mendonca-Previato, L
   Nobrega, A
   Bellio, M
TI Expression of functional TLR4 confers proinflammatory responsiveness to
   Trypanosama cruzi glycoinositolphospholipids and higher resistance to
   infection with T-cruzi
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTOR-4; MACROPHAGE INFLAMMATORY PROTEIN-2;
   TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; PATTERN-RECOGNITION;
   CHAGAS-DISEASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORS; BACTERIAL
   LIPOPOLYSACCHARIDE; IL-12 UNRESPONSIVENESS; TRYPOMASTIGOTE FORMS
AB TLRs function as pattern recognition receptors in mammals and play an essential role in the recognition of microbial components. We found that the injection of glycoinositolphospholipids (GIPLs) from Trypanosoma cruzi into the peritoneal cavity of mice induced neutrophil recruitment in a TLR4-dependent manner: the injection of GIPL in the TLR4-deficient strain of mice (C57BL/10ScCr) caused no inflammatory response. In contrast, in TLR2 knockout mice, neutrophil chemoattraction did not differ significantly from that seen in wild-type controls. GIPL-induced neutrophil attraction and MIP-2 production were also severely affected in TLR4-mutant C3H/HeJ mice. The role of TLR4 was confirmed in vitro by testing genetically engineered mutants derived from TLR2-deficient Chinese hamster ovary (CHO)-K1 fibroblasts that were transfected with CD14 (CHO/CD14). Wildtype CHO/CD14 cells express the hamster TLR4 molecule and the mutant line, in addition, expresses a nonfunctional form of MD-2. In comparison to wild-type cells, mutant CHO/CD14 cells failed to respond to GIPLs, indicating a necessity for a functional TLR4/MD-2 complex in GIPL-induced NF-kappaB activation. Finally, we found that TLR4-mutant mice were hypersusceptible to T. cruzi infection, as evidenced by a higher parasitemia and earlier mortality. These results demonstrate that natural resistance to T. cruzi is TLR4 dependent, most likely due to TLR4 recognition of their GIPLs.
C1 Fed Univ Rio De Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil.
   Fed Univ Rio De Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil.
   Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   Fdn Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01655 USA.
   Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Osaka, Japan.
RP Bellio, M (corresponding author), Fed Univ Rio De Janeiro, Dept Imunol, Inst Microbiol Prof Paulo de Goes, Ctr Ciencias Saude, Bloco 1-2 Andar Sala 12-051,Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.
EM belliom@acd.ufrj.br
RI Oliveira, Ana Carolina/O-6791-2014; Akira, Shizuo/C-3134-2009; Arruda,
   Luciana B/N-9086-2013; Arruda, Luciana/B-5806-2014; Campos, Marco
   A/C-4000-2013; Nobrega, Alberto/U-1161-2019; BELLIO, MARIA/N-8525-2018
OI Oliveira, Ana Carolina/0000-0002-0036-3720; Campos, Marco
   A/0000-0003-4683-0176; Previato, Jose Osvaldo/0000-0002-9233-9954;
   Gazzinelli, Ricardo/0000-0003-2427-7699; Mendonca Previato,
   Lucia/0000-0003-3927-3244; Nobrega, Alberto/0000-0002-9840-0103; BELLIO,
   MARIA/0000-0002-3360-2740
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI52455] Funding Source: Medline; NIGMS
   NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM54060] Funding Source: Medline; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI052455, R01AI052455, R01AI052455, R01AI052455, R01AI052455,
   R01AI052455, R01AI052455, R01AI052455, R01AI052455, R01AI052455] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM054060, R01GM054060, R01GM054060,
   R01GM054060, R01GM054060, R01GM054060, R01GM054060, R01GM054060,
   R01GM054060, R01GM054060, R01GM054060, R01GM054060] Funding Source: NIH
   RePORTER
CR Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467
   BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97
   BARBER SA, 1995, J IMMUNOL, V155, P2303
   Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6
   Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C
   Bellio M, 1999, FASEB J, V13, P1627
   Call DR, 2001, AM J PATHOL, V158, P715, DOI 10.1016/S0002-9440(10)64014-X
   Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711
   Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416
   Carreira JC, 1996, GLYCOCONJUGATE J, V13, P955, DOI 10.1007/BF01053191
   DA SILVA L. H. P., 1953, Folia Clinica et Biologica, V20, P191
   Delude RL, 1998, J IMMUNOL, V161, P3001
   Deng C, 2003, J IMMUNOL, V170, P2833, DOI 10.4049/jimmunol.170.6.2833
   DESCOTEAUX A, 1991, J IMMUNOL, V146, P2747
   DosReis GA, 2002, MICROBES INFECT, V4, P1007, DOI 10.1016/S1286-4579(02)01616-7
   Fairweather D, 2003, J IMMUNOL, V170, P4731, DOI 10.4049/jimmunol.170.9.4731
   Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200
   Girones N, 2003, TRENDS PARASITOL, V19, P19, DOI 10.1016/S1471-4922(02)00006-5
   GOLGHER DB, 1993, MOL BIOCHEM PARASIT, V60, P249, DOI 10.1016/0166-6851(93)90136-L
   Gomes NA, 1996, J IMMUNOL, V156, P628
   Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Hirano S, 1996, AM J PHYSIOL-LUNG C, V270, pL836
   JOSEPH CK, 1994, J BIOL CHEM, V269, P17606
   Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251
   Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833
   Lagasse E, 1996, J IMMUNOL METHODS, V197, P139, DOI 10.1016/0022-1759(96)00138-X
   Lawton JA, 2003, CURR OPIN CHEM BIOL, V7, P446, DOI 10.1016/S1367-5931(03)00077-2
   Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419
   MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305
   Merlin T, 2001, J IMMUNOL, V166, P566, DOI 10.4049/jimmunol.166.1.566
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558
   Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Poltorak A, 2001, J IMMUNOL, V167, P2106, DOI 10.4049/jimmunol.167.4.2106
   Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085
   Previato JO, 2004, ADV PARASIT, V56, P1, DOI 10.1016/S0065-308X(03)56001-8
   PREVIATO JO, 1990, J BIOL CHEM, V265, P2518
   Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615
   Ropert C, 2002, MICROBES INFECT, V4, P1015, DOI 10.1016/S1286-4579(02)01609-X
   Sasu S, 2001, CIRC RES, V89, P244, DOI 10.1161/hh1501.094184
   Schmal H, 1996, J IMMUNOL, V156, P1963
   SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145
   Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79
   Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406
   SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244
   Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777
   Soares MBP, 2001, AN ACAD BRAS CIENC, V73, P547, DOI 10.1590/S0001-37652001000400008
   STANDIFORD TJ, 1995, J IMMUNOL, V155, P2222
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Tarleton RL, 2003, TRENDS PARASITOL, V19, P447, DOI 10.1016/j.pt.2003.08.008
   Teixeira MM, 2002, TRENDS PARASITOL, V18, P262, DOI 10.1016/S1471-4922(02)02283-3
   Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858
   Thieblemont N, 1997, J EXP MED, V185, P2095, DOI 10.1084/jem.185.12.2095
   Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774
   TRISCHMANN TM, 1982, INFECT IMMUN, V35, P546, DOI 10.1128/IAI.35.2.546-551.1982
   Viriyakosol S, 2001, J BIOL CHEM, V276, P38044
   Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200
   WRIGHTSMAN R, 1982, INFECT IMMUN, V36, P637, DOI 10.1128/IAI.36.2.637-644.1982
   XAVIER MT, 1991, J BRAZ ASS ADV SCI, V43, P49
NR 63
TC 152
Z9 161
U1 0
U2 14
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2004
VL 173
IS 9
BP 5688
EP 5696
DI 10.4049/jimmunol.173.9.5688
PG 9
WC Immunology
SC Immunology
GA 864XH
UT WOS:000224665900044
PM 15494520
OA Bronze
DA 2020-12-08
ER

PT J
AU Chikhlikar, P
   de Arruda, LB
   Agrawal, S
   Byrne, B
   Guggino, W
   August, JT
   Marques, ETA
AF Chikhlikar, P
   de Arruda, LB
   Agrawal, S
   Byrne, B
   Guggino, W
   August, JT
   Marques, ETA
TI Inverted terminal repeat sequences of adeno-associated virus enhance the
   antibody and CD8(+) responses to a HIV-1 p55Gag/LAMP DNA vaccine chimera
SO VIROLOGY
LA English
DT Article
DE LAMP; MHC II; inverted terminal repeat; AAV; rAAV; DNA vaccine; HIV-1
   Gag; CD4; CD8
ID GENETIC IMMUNIZATION; EXPRESSION; GAG; VECTORS; IMMUNITY;
   IMMUNOGENICITY; INTEGRATION; INDUCTION; CELLS
AB The immune responses to an HIV-1 p55Gag vaccine encoded as a DNA chimera with the lysosomal associated membrane protein-1 (LAMP) have been examined for the effect of the addition of the inverted terminal repeat (ITR) sequences of the adeno-associated virus (AAV) to the DNA plasmid construct, and of packaging the LAMP/gag gene as a recombinant AAV vector (rAAV). DNA plasmids encoding Gag and the LAMP/Gag protein chimera were constructed in two vectors, the pcDNA3.1 and a corresponding plasmid containing the ITR sequences (pITR) flanking the expression elements of the plasmid, and the pITR LAMP/gag DNA plasmid was encapsidated in the rAAV vector. Human 293 cells transfected in vitro with LAMP/gag plasmids either in pcDNA3.1 or pITR produced much Gag protein in cell extracts (1.6 and 2.2 ng of Gag/mg of protein, respectively). The immune responses of mice to immunization with these constructs were examined under three protocols: DNA prime/DNA boost, DNA prime/rAAV boost, and a single rAAV immunization. The results demonstrated that under DNA prime/DNA boost protocol, the "naked" DNA vaccines encoding the LAMP/gag chimera, either as pcDNA3.1 or pITR DNA plasmid constructs, elicited strong CD4(+) T cell responses. In contrast, significantly higher levels of CD8(+) and antibody responses were observed with the pITR-DNA constructs. Immunization with the rAAV vector under the DNA prime/rAAV boost protocol resulted in sustained T cell responses and a markedly increased antibody response, predominantly of the IgG(1) isotype resulting from the activation of the Th2 subset of CD4(+) T cells, that was sustained for at least 5 months after immunization. (C) 2004 Elsevier Inc. All rights reserved.
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
   Univ Florida, Gainesville, FL 32610 USA.
RP August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Biophys 309,725 N Wolfe St, Baltimore, MD 21205 USA.
EM taugust@jhmi.edu
RI Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana/B-5806-2014; Marques,
   Ernesto/L-4514-2013; Arruda, Luciana B/N-9086-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI044317, R37AI041908, R21AI044317, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37-AI41908, R21-AI44317] Funding Source:
   Medline
CR Chen ZY, 2001, MOL THER, V3, P403, DOI 10.1006/mthe.2001.0278
   Chirmule N, 2000, J VIROL, V74, P2420, DOI 10.1128/JVI.74.5.2420-2425.2000
   Chou CY, 2001, TRANSGENIC RES, V10, P303, DOI 10.1023/A:1016671513425
   Deml L, 2001, J VIROL, V75, P10991, DOI 10.1128/JVI.75.22.10991-11001.2001
   Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578
   Duan DS, 1998, J VIROL, V72, P8568, DOI 10.1128/JVI.72.11.8568-8577.1998
   Duan DS, 1999, VIROLOGY, V261, P8, DOI 10.1006/viro.1999.9821
   Fu YC, 1999, METH MOL B, V127, P167, DOI 10.1385/1-59259-678-9:167
   Hsiao CD, 2001, DEV DYNAM, V220, P323, DOI 10.1002/dvdy.1113
   Hu H, 2001, NAT IMMUNOL, V2, P705, DOI 10.1038/90643
   Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   KOTIN RM, 1991, GENOMICS, V10, P831, DOI 10.1016/0888-7543(91)90470-Y
   Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000
   MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991
   Manning WC, 1997, J VIROL, V71, P7960, DOI 10.1128/JVI.71.10.7960-7962.1997
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Marques ETA, 1998, MOL BIOCHEM PARASIT, V93, P237, DOI 10.1016/S0166-6851(98)00033-4
   Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179
   Nakai H, 2003, HUM GENE THER, V14, P871, DOI 10.1089/104303403765701169
   Nakai H, 2003, MOL THER, V7, P101, DOI 10.1016/S1525-0016(02)00023-0
   NAKAI H, 2003, MOL THER, V7, P11221
   NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994
   Qiu JT, 1999, J VIROL, V73, P9145, DOI 10.1128/JVI.73.11.9145-9152.1999
   REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   Song SH, 2001, P NATL ACAD SCI USA, V98, P4084, DOI 10.1073/pnas.061014598
   Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889
   Xiao WD, 1999, J VIROL, V73, P3994, DOI 10.1128/JVI.73.5.3994-4003.1999
   Xiao X, 1997, J VIROL, V71, P941, DOI 10.1128/JVI.71.2.941-948.1997
   Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996
   Xin KQ, 2003, J GENE MED, V5, P438, DOI 10.1002/jgm.356
   Xin KQ, 2001, HUM GENE THER, V12, P1047, DOI 10.1089/104303401750214276
   Yang JS, 1999, J VIROL, V73, P9468, DOI 10.1128/JVI.73.11.9468-9477.1999
   Yue YP, 2003, VIROLOGY, V313, P1, DOI 10.1016/S0042-6822(03)00432-X
   zur Megede J, 2000, J VIROL, V74, P2628, DOI 10.1128/JVI.74.6.2628-2635.2000
NR 37
TC 24
Z9 25
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN 1
PY 2004
VL 323
IS 2
BP 220
EP 232
DI 10.1016/j.virol.2004.02.025
PG 13
WC Virology
SC Virology
GA 830RL
UT WOS:000222140500006
PM 15193918
DA 2020-12-08
ER

PT J
AU De Arruda, LB
   Chikhlikar, PR
   August, JT
   Marques, ETA
AF De Arruda, LB
   Chikhlikar, PR
   August, JT
   Marques, ETA
TI DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the
   major histocompatibility complex II compartment by lysosomal-associated
   membrane protein, elicits enhanced long-term memory response
SO IMMUNOLOGY
LA English
DT Article
DE vaccines : DNA LAMP/Gag, prime/boost immunizations; immunological
   memory; T-cell memory; MHC II : trafficking
ID MHC CLASS-II; T-CELL RESPONSES; CHIMERIC GENE-PRODUCT; DENDRITIC CELLS;
   EXOGENOUS ANTIGENS; CROSS-PRESENTATION; PROCESSING PATHWAYS; CD8-T-CELL
   MEMORY; TYPE-1 INFECTION; IMMUNE-RESPONSES
AB Antigen presentation by major histocompatibility complex type II (MHC II) molecules and activation of CD4(+) helper T cells are critical for the generation of immunological memory. We previously described a DNA vaccine encoding human immunodeficiency virus-1 p55Gag as a chimera with the lysosome-associated membrane protein (LAMP/gag). The LAMP/gag chimera protein traffics to the MHC II compartment of transfected cells and elicits enhanced immune responses as compared to a DNA vaccine encoding native gag not targeted to the MHC II compartment. We have now investigated the long-term responses of immunized mice and show that the LAMP/gag DNA vaccine promotes long-lasting B cell- and CD4(+) and CD8(+) T-cell memory responses and elicits a potent Gag-specific CD8(+) recall response to challenge with vaccinia virus encoding gag, even II months after immunization. In contrast, the immune responses induced by DNA encoding non-targeted Gag decay rapidly and elicit very low or undetectable levels of Gag-specific CD4(+) and CD8(+) memory cells. A single priming immunization with LAMP/ gag DNA is sufficient to generate T-cell memory. Following this initial priming immunization with LAMP/gag DNA, booster immunizations with native gag DNA or the LAMP/gag chimera are equally efficient in eliciting B- and T-cell secondary responses, results in accordance with observations that secondary expansion of CD8(+) cells in the boost phase does not require additional CD4(+) help. These findings underscore the significance of targeting DNA-encoded vaccine antigens to the MHC II processing compartments for induction of long-term immunological memory.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
   Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941 Rio De Janeiro, Brazil.
RP Marques, ETA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.
EM emarques@jhmi.edu
RI Arruda, Luciana/B-5806-2014; Marques, Ernesto/L-4514-2013; Arruda,
   Luciana B/N-9086-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto/0000-0003-3826-9358; Marques, Ernesto T.
   A/0000-0003-3826-9358
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI041908, R21AI044317, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R21AI044317, R37AI041908,
   R37AI041908, R37AI041908] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37 AI041908, R37-AI41908, R21 AI44317]
   Funding Source: Medline
CR Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Appay V, 2000, J EXP MED, V192, P63, DOI 10.1084/jem.192.1.63
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   Bradley LM, 2003, TRENDS MOL MED, V9, P186, DOI 10.1016/S1471-4914(03)00053-4
   Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2
   Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957
   Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061
   Delamarre L, 2003, J EXP MED, V198, P111, DOI 10.1084/jem.20021542
   Drake JR, 1999, J IMMUNOL, V162, P1150
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   Gromme M, 1999, P NATL ACAD SCI USA, V96, P10326, DOI 10.1073/pnas.96.18.10326
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47
   Heath WR, 2001, NAT REV IMMUNOL, V1, P126, DOI 10.1038/35100512
   Heath WR, 1999, CURR OPIN IMMUNOL, V11, P314, DOI 10.1016/S0952-7915(99)80050-8
   Iwasaki A, 1997, J IMMUNOL, V159, P11
   Jaleco S, 2003, J IMMUNOL, V171, P61, DOI 10.4049/jimmunol.171.1.61
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Langlade-Demoyen P, 2003, EUR J IMMUNOL, V33, P720, DOI 10.1002/eji.200323287
   Lin F., 1996, DISCRETE CONTINUOUS, V2, P1, DOI DOI 10.3934/DCDS.1996.2.1
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Mata M, 1998, J IMMUNOL, V161, P2985
   Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141
   Oehen S, 2000, IMMUNOLOGY, V99, P163, DOI 10.1046/j.1365-2567.2000.00950.x
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   Rowland-Jones S, 1999, J INFECTION, V38, P67, DOI 10.1016/S0163-4453(99)90070-1
   Rowland-Jones SL, 1999, IMMUNOL LETT, V66, P9, DOI 10.1016/S0165-2478(98)00179-5
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Rush C, 2002, J IMMUNOL, V169, P4951, DOI 10.4049/jimmunol.169.9.4951
   Schirmbeck R, 2002, MOL IMMUNOL, V39, P249, DOI 10.1016/S0161-5890(02)00105-0
   Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Shedlock DJ, 2003, J IMMUNOL, V170, P2053, DOI 10.4049/jimmunol.170.4.2053
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Su Z, 2002, CANCER RES, V62, P5041
   Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J
   Zhong GM, 1996, J EXP MED, V184, P2061, DOI 10.1084/jem.184.5.2061
   Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045
NR 62
TC 47
Z9 47
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD MAY
PY 2004
VL 112
IS 1
BP 126
EP 135
DI 10.1111/j.1365-2567.2004.01823.x
PG 10
WC Immunology
SC Immunology
GA 813CW
UT WOS:000220886200015
PM 15129672
OA Green Published, Bronze
DA 2020-12-08
ER

PT B
AU Arruda, LB
   Sim, D
   Maciel, M
   Chikhlikar, P
   August, JT
   Marques, ETA
AF Arruda, LB
   Sim, D
   Maciel, M
   Chikhlikar, P
   August, JT
   Marques, ETA
GP MEDIMOND
TI Different HIV-Gag cellular trafficking mediated by LAMP/gag and
   DC-LAMP/gag DNA chimeras influences the repertoire of activated T and B
   cells
SO IMMUNOLOGY 2004: IMMUNODEFICIENCY, INFECTIOUS DISEASES,
   IMMUNOMODULATION, AND VACCINES
LA English
DT Proceedings Paper
CT 12th Annual International Congress of Immunology/4th Annual Conference
   of the Federation-of-Clinical-Immunology-Societies (FOCIS)
CY JUL 18-23, 2004
CL Montreal, CANADA
SP Federat Clin Immunol Soc
ID INFECTION; RESPONSES; VIRUS; ESCAPE; CD4(+); LYMPHOCYTES; VACCINATION;
   ANTIGEN; VIREMIA
AB In this study, we evaluated the processing pathways, and the repertoire of T- and B- cell epitopes elicited after immunization with HIV-1 p55Gag antigen synthesized, as a DNA vaccine chimera, with lysosomal associated membrane protein-1 (LAMP- 1) or dendritic cell-LAMP (DC-LAMP). We observed that while native Gag localized in the cytoplasm, LAMP/Gag and DC-LAMP/Gag chimeras traffic through the endolysosomal compartments and colocalized with MHC II, but they differ in their overall intracellular trafficking. ELISPOT analysis of T cell specific response showed that immunization with each construct induced a different pattern of epitopes eliciting IFN-gamma response. Moreover, immunization with LAMP chimeras induced antibody secretion to a higher number of peptides than immunization with native gag. These data suggest that differential cellular trafficking of Gag protein can change and amplify the repertoire of responding T and B cells, which can be an important strategy for HIV vaccine design.
C1 Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RP Arruda, LB (corresponding author), Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RI Arruda, Luciana B/N-9086-2013; Marques, Ernesto T. A/L-4967-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358
CR Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
   Boyle JS, 1997, INT IMMUNOL, V9, P1897, DOI 10.1093/intimm/9.12.1897
   Caulfield MJ, 2002, J VIROL, V76, P10038, DOI 10.1128/JVI.76.19.10038-10043.2002
   Gloster SE, 2004, AIDS, V18, P749, DOI 10.1097/00002030-200403260-00005
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Marques ETA, 2003, J BIOL CHEM, V278, P37926, DOI 10.1074/jbc.M303336200
   Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   Rush C, 2002, J IMMUNOL, V169, P4951, DOI 10.4049/jimmunol.169.9.4951
   Schirmbeck R, 2002, MOL IMMUNOL, V39, P249, DOI 10.1016/S0161-5890(02)00105-0
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
NR 13
TC 0
Z9 0
U1 0
U2 0
PU MEDIMOND PUBLISHING CO
PI BOLOGNA
PA VIA RUBBIANI 6/2, 40124 BOLOGNA, ITALY
BN 88-7587-075-6
PY 2004
BP 165
EP 169
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA BBQ60
UT WOS:000227165600030
DA 2020-12-08
ER

PT J
AU Marques, ETA
   Chikhlikar, P
   de Arruda, LB
   Leao, IC
   Lu, Y
   Wong, J
   Chen, JS
   Byrne, B
   August, JT
AF Marques, ETA
   Chikhlikar, P
   de Arruda, LB
   Leao, IC
   Lu, Y
   Wong, J
   Chen, JS
   Byrne, B
   August, JT
TI HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a
   DNA plasmid vaccine chimera is highly expressed, traffics to the major
   histocompatibility class II compartment, and elicits enhanced immune
   responses
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MHC CLASS-II; T-LYMPHOCYTE RESPONSES; VIRUS TYPE-1 GAG; DENDRITIC CELLS;
   ANTIGEN PRESENTATION; ENDOCYTIC COMPARTMENTS; LONGITUDINAL ANALYSIS;
   GENE-PRODUCT; CD4(+); IMMUNIZATION
AB Several genetic vaccines encoding antigen chimeras containing the lysosome-associated membrane protein ( LAMP) translocon, transmembrane, and cytoplasmic domain sequences have elicited strong mouse antigen-specific immune responses. The increased immune response is attributed to trafficking of the antigen chimera to the major histocompatibility class II (MHC II) compartment where LAMP is colocalized with MHC II. In this report, we describe a new form of an HIV-1 p55gag DNA vaccine, with the gag sequence incorporated into the complete LAMP cDNA sequence. Gag encoded with the translocon, transmembrane and cytoplasmic lysosomal membrane targeting sequences of LAMP, without the luminal domain, was poorly expressed, did not traffic to lysosomes or MHC II compartments of transfected cells, and elicited a limited immune response from DNA immunized mice. In contrast, addition of the LAMP luminal domain sequence to the construct resulted in a high level of expression of the LAMP/ Gag protein chimera in transfected cells that was further increased by including the inverted terminal repeat sequences of the adeno-associated virus to the plasmid vector. This LAMP/ Gag chimera with the complete LAMP protein colocalized with endogenous MHC II of transfected cells and elicited strong cellular and humoral immune responses of immunized mice as compared with the response to DNA-encoding native Gag, with a 10-fold increase in CD4(+) responses, a 4- to 5-fold increase in CD8(+) T-cell responses, and antibody titers of > 100,000. These results reveal novel roles of the LAMP luminal domain as a determinant of Gag protein expression, lysosomal trafficking, and possibly of the immune response to Gag.
C1 Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.
RP August, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St,Biophys Rm 309, Baltimore, MD 21205 USA.
RI Marques, Ernesto T. A/L-4967-2013; Arruda, Luciana/B-5806-2014; Marques,
   Ernesto/L-4514-2013; Arruda, Luciana B/N-9086-2013
OI Marques, Ernesto T. A/0000-0003-3826-9358; Marques,
   Ernesto/0000-0003-3826-9358; 
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R37AI041908, R37AI041908, R37AI041908, R37AI041908, R37AI041908,
   R37AI041908, R37AI041908, R37AI041908, R21AI044317, R37AI041908,
   R37AI041908, R21AI044317] Funding Source: NIH RePORTER; NIAID NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R21-AI44317, R37-AI41908] Funding Source:
   Medline
CR Agarraberes FA, 2001, J CELL SCI, V114, P2491
   Akbari O, 1999, J EXP MED, V189, P169, DOI 10.1084/jem.189.1.169
   Andrews NW, 2002, J CELL BIOL, V158, P389, DOI 10.1083/jcb.200205110
   ARTERBURN LM, 1990, J BIOL CHEM, V265, P7419
   Bear J, 1999, MOL CELL BIOL, V19, P6306
   Bertoletti A, 1998, J VIROL, V72, P2439, DOI 10.1128/JVI.72.3.2439-2448.1998
   Betts MR, 1997, J VIROL, V71, P8908, DOI 10.1128/JVI.71.11.8908-8911.1997
   Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923
   Bonini C, 2001, J IMMUNOL, V166, P5250, DOI 10.4049/jimmunol.166.8.5250
   BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994
   CALINLAURENS V, 1992, INT IMMUNOL, V4, P1113, DOI 10.1093/intimm/4.10.1113
   Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481
   Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061
   CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85
   Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122
   de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9
   Deml L, 2001, J VIROL, V75, P10991, DOI 10.1128/JVI.75.22.10991-11001.2001
   Drake JR, 1999, J IMMUNOL, V162, P1150
   DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5
   DUBEY C, 1995, J IMMUNOL, V155, P45
   Durali D, 1998, J VIROL, V72, P3547, DOI 10.1128/JVI.72.5.3547-3553.1998
   Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121
   Fernandes DM, 2000, EUR J IMMUNOL, V30, P2333, DOI 10.1002/1521-4141(2000)30:8<2333::AID-IMMU2333>3.0.CO;2-F
   Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9
   GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227
   GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828
   Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001
   HUGHES EN, 1981, J BIOL CHEM, V256, P664
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   Ji HX, 1999, HUM GENE THER, V10, P2727, DOI 10.1089/10430349950016474
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082
   Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639
   KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365
   Kotsopoulou E, 2000, J VIROL, V74, P4839, DOI 10.1128/JVI.74.10.4839-4852.2000
   KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994
   Lem L, 1999, J IMMUNOL, V162, P523
   LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839
   Lin KY, 1996, CANCER RES, V56, P21
   LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593
   LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5
   Lu Y, 2003, VACCINE, V21, P2178, DOI 10.1016/S0264-410X(03)00009-4
   Maecker HT, 1998, J IMMUNOL, V161, P6532
   MALDARELLI F, 1991, J VIROL, V65, P5732, DOI 10.1128/JVI.65.11.5732-5743.1991
   MANE SM, 1989, ARCH BIOCHEM BIOPHYS, V268, P360, DOI 10.1016/0003-9861(89)90597-3
   Marques ETA, 1998, MOL BIOCHEM PARASIT, V93, P237, DOI 10.1016/S0166-6851(98)00033-4
   McAdam S, 1998, AIDS, V12, P571, DOI 10.1097/00002030-199806000-00005
   MORENO J, 1991, J IMMUNOL, V147, P3306
   MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773
   Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364
   NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994
   Norris PJ, 2001, J VIROL, V75, P9771, DOI 10.1128/JVI.75.20.9771-9779.2001
   Obermuller S, 2002, J CELL SCI, V115, P185
   PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0
   Pontesilli O, 1998, J INFECT DIS, V178, P1008, DOI 10.1086/515659
   Porgador A, 1998, J EXP MED, V188, P1075, DOI 10.1084/jem.188.6.1075
   Prasad DVR, 2002, J IMMUNOL, V169, P1801, DOI 10.4049/jimmunol.169.4.1801
   Qiu JT, 2000, J VIROL, V74, P5997, DOI 10.1128/JVI.74.13.5997-6005.2000
   Qiu JT, 1999, J VIROL, V73, P9145, DOI 10.1128/JVI.73.11.9145-9152.1999
   Raviprakash K, 2001, VIROLOGY, V290, P74, DOI 10.1006/viro.2001.1136
   RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519
   REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F
   Robinson JH, 2002, IMMUNOLOGY, V105, P252, DOI 10.1046/j.0019-2805.2001.01358.x
   Rodriguez F, 2001, J VIROL, V75, P10421, DOI 10.1128/JVI.75.21.10421-10430.2001
   Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565
   Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   ROWELL JF, 1995, J IMMUNOL, V155, P1818
   ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59
   Ruff AL, 1997, J BIOL CHEM, V272, P8671, DOI 10.1074/jbc.272.13.8671
   Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997
   Su Z, 2002, CANCER RES, V62, P5041
   Thery C, 2001, CURR OPIN IMMUNOL, V13, P45, DOI 10.1016/S0952-7915(00)00180-1
   Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106
   Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522
   WILLINGHAM MC, 1985, ATLAS IMMUNOFLUORESC
   WU TC, 1995, P NATL ACAD SCI USA, V92, P11671, DOI 10.1073/pnas.92.25.11671
   zur Megede J, 2000, J VIROL, V74, P2628, DOI 10.1128/JVI.74.6.2628-2635.2000
NR 79
TC 63
Z9 63
U1 0
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 26
PY 2003
VL 278
IS 39
BP 37926
EP 37936
DI 10.1074/jbc.M303336200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 723MY
UT WOS:000185437200115
PM 12824194
OA Bronze
DA 2020-12-08
ER

EF